[go: up one dir, main page]

US20090324580A1 - Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases - Google Patents

Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases Download PDF

Info

Publication number
US20090324580A1
US20090324580A1 US12/281,438 US28143807A US2009324580A1 US 20090324580 A1 US20090324580 A1 US 20090324580A1 US 28143807 A US28143807 A US 28143807A US 2009324580 A1 US2009324580 A1 US 2009324580A1
Authority
US
United States
Prior art keywords
alkyl
alkenyl
optionally substituted
hydrogen
mit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/281,438
Inventor
Michael Hannus
Cecilie Martin
Maria M. Mota
Miguel Prudencio
Christina Dias Rodrigues
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenix BioScience GmbH
Instituto de Medicina Molecular Joao Lobo Antunes
Original Assignee
Cenix BioScience GmbH
Instituto de Medicina Molecular Joao Lobo Antunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06004854A external-priority patent/EP1832283A1/en
Application filed by Cenix BioScience GmbH, Instituto de Medicina Molecular Joao Lobo Antunes filed Critical Cenix BioScience GmbH
Priority to US12/281,438 priority Critical patent/US20090324580A1/en
Assigned to CENIX BIOSCIENCE GMBH reassignment CENIX BIOSCIENCE GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HANNUS, MICHAEL, MARTIN, CECILIE
Assigned to INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA reassignment INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOTA, MARIA M., RODRIGUES, CHRISTINA DIAS, PRUDENCIO, MIGUEL
Publication of US20090324580A1 publication Critical patent/US20090324580A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for therapy of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
  • Malaria is a major health problem, mainly in Sub-Saharan Africa and in some parts of Asia and South America. Each year there are about 600 million new clinical cases and at least one million individuals, mostly children, die from malaria. This reality is even more depressing realising that a death from malaria occurs every 30 seconds. Over 90% of the deaths occur in Africa. Within the last 10 to 15 years the burden of malaria has been increasing mainly because of the emergence of Plasmodium falciparum and P. vivax variants that are resistant to cheap drugs such as chloroquine, mefloquine, and pyrimethamine. In the light of the failure of the development of a malaria vaccine, despite intensive efforts, the development of novel anti-malarial drugs is crucial.
  • the infected hepatocytes burst, releasing the parasites into the bloodstream, where they will target and invade the red blood cells (RBCs).
  • RBCs red blood cells
  • the blood or erythrocytic stage of Plasmodium' s life cycle corresponds to the symptomatic phase of a malaria infection.
  • the parasites invade and multiply within the RBCs and, upon rupturing the erythrocytic membrane, are released into the blood where they target new erythrocytes.
  • Plasmodium sporozoites only develop in a very restricted type of cell, such as hepatocytes or hepatoma cell lines, strongly suggesting a crucial role of the host cell in sustaining the growth and development of this parasite.
  • Plasmodium berghei ANKA a mouse-pathogenic close relative of the human-pathogenic Plasmodium falciparum strain, in cultured human hepatoma cells.
  • RNA interference RNA interference
  • ScarB1 binds LDL, modified LDL, negatively charged phospholipid, and HDL.
  • Direct binding studies show that ScarB1 expressed in mammalian cells (for example, a variant of CHO cells) binds HDL, without cellular degradation of the HDL-apoprotein, and lipid is accumulated within cells expressing the receptor. These studies indicated that ScarB1 might play a major role in transfer of cholesterol from peripheral tissues, via HDL, into the liver and steroidogenic tissues, and that increased or decreased expression in the liver or other tissues may be useful in regulating uptake of cholesterol by cells expressing ScarB1. Subsequent studies confirmed that ScarB1 not only binds to lipid, but also transfers cholesterol into and out of cells, (see, e.g. U.S.
  • the present invention provides the use of inhibitors of a scavenger receptor class protein for the production of a medicament for the therapy of and/or prophylaxis against infections involving liver cells and/or hematopoietic cells, in particular protozoal infections, e.g. malaria.
  • the inhibitor of the scavenger receptor class protein has a structure according to formula (I):
  • the inhibitor of the scavenger receptor class protein has a structure according to formula (XXXII):
  • the inhibitor of the scavenger receptor class protein has a structure according to formula (IL):
  • the inhibitor of the scavenger receptor class protein has a structure according to formula (LIII):
  • R 29 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted or is a pharmaceutically acceptable salt thereof.
  • the inhibitor of the scavenger receptor class protein is a compound selected from Table I.
  • the inhibitor of the scavenger receptor class protein is an antibody specifically binding to said scavenger receptor class protein.
  • the inhibitor of the scavenger receptor class protein is a small interfering RNA (siRNA) capable of inhibiting expression of said scavenger receptor class protein.
  • siRNA small interfering RNA
  • the scavenger receptor class protein is scavenger receptor class B 1 (ScarB1) or scavenger receptor class B 2 (ScarBII).
  • the infectious disease is a protozoal infection.
  • the protozoa is a member of the family of plasmodiidae.
  • the plasmodiida is selected from the group consisting of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi.
  • infectious disease is malaria.
  • the present invention relates to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
  • the present invention relates to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
  • the present invention relates to the use of test compound selected in step (v) of the method of the present invention for the production of a medicament for the therapy and/or prophylaxis of infectious diseases, which involve infection of liver and/or hematopoietic cells.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound usable according to the present invention and one or more of a compound selected from the group consisting of a chinine alkaloid, chloroquine-phosphate, hydroxychloroquinesulfate, mefloquine, proguanil, di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine and pharmaceutically acceptable additives and/or auxiliary substances.
  • the present invention relates to a method for the identification of molecules of pathogens, which are involved in the infection of liver and/or hematopoietic cells, comprising the following steps:
  • the terms used herein are defined as described in “A multilingual glossary of biotechnological terms: (IUPAC Recommendations)”, Leuenberger, H. G. W, Nagel, B. and Klbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
  • These terms will in each instance of its use in the remainder of the specification have the respectively defined meaning and preferred meanings. Nevertheless in some instances of their use throughout the specification further or particular preferred meanings of these terms are indicated.
  • alkyl refers to a saturated straight or branched carbon chain.
  • the chain comprises from 1 to 16 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl, heptyl, or octyl.
  • Alkyl groups are optionally substituted.
  • heteroalkyl refers to a saturated straight or branched carbon chain.
  • the chain comprises from 1 to 16 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms.
  • the heteroatoms are selected from O, S, and N.
  • Heteroalkyl groups are optionally substituted.
  • cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl etc.
  • cycloalkyl and “heterocycloalkyl” are also meant to include bicyclic, tricyclic and polycyclic versions thereof.
  • bicyclic, tricyclic or polycyclic rings are formed it is preferred that the respective rings are connected to each other at two adjacent carbon atoms, however, alternatively the two rings are connected via the same carbon atom, i.e. they form a spiro ring system or they form “bridged” ring systems.
  • heterocycloalkyl preferably refers to a saturated ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N; a saturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a saturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms. “Cycloalkyl” and “heterocycloalkyl” groups are optionally substituted.
  • a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
  • preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro-[3,3]-heptyl, spiro-[3,4]-octyl, spiro-[4,3]-octyl, spiro-[3,5]-nonyl, spiro-[5,3]-nonyl, spiro-[3,6]-decyl, spiro-[6,3]-decyl, spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, or adamantyl.
  • heterocycloalkyl groups examples include 1,2,5,6-tetrahydropyridyl, e.g. 1-(1,2,5,6-tetrahydropyridyl), 2-(1,2,5,6-tetrahydropyridyl); piperidinyl, e.g. piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl; 1,2-diazacyclohexyl, 1,2-diazacyclohex-1-yl; 1,3-diazacyclohexyl; piperazinyl, e.g.
  • tetrahydrofuran-2-yl tetrahydrofuran-3-yl
  • tetrahydrothiophenyl e.g. tetrahydrothiophen-2-yl, or tetrahydrothiophen-3-yl
  • pyrrolidinyl e.g. pyrrolidin-1-yl, pyrrolidin-2-yl, or pyrrolidin-3-yl
  • 2-diazacyclopentyl e.g. 1,2-diazacyclopent-1-yl, or 1,2-diazacyclopent-3-yl
  • 1,3-diazacyclopentyl e.g.
  • 1-thio-2-azacyclopentyl e.g. 1-thio-2-azacyclopent-2-yl, 1-thio-2-azacyclopent-3-yl, 1-thio-2-azacyclopent-4-yl or 1-thio-2-azacyclopent-5-yl;
  • 1-thio-3-azacyclopentyl e.g. 1-thio-3-azacyclopent-2-yl, 1-thio-3-azacyclopent-3-yl, 1-thio-3-azacyclopent-4-yl or 1-thio-3-azacyclopent-5-yl.
  • alicyclic system refers to mono, bicyclic, tricyclic or polycyclic version of a cycloalkyl or heterocycloalkyl comprising at least one double and/or triple bond.
  • an alicyclic system is not aromatic or heteroaromatic, i.e. does not have a system of conjugated double bonds/free electron pairs.
  • the number of double and/or triple bonds maximally allowed in an alicyclic system is determined by the number of ring atoms, e.g. in a ring system with up to 5 ring atoms an alicyclic system comprises up to one double bond, in a ring system with 6 ring atoms the alicyclic system comprises up to two double bonds.
  • the “cycloalkenyle” as defined below is a preferred embodiment of an alicyclic ring system.
  • Alicyclic systems are optionally substituted.
  • aryl preferably refers to an aromatic monocyclic ring containing 6 carbon atoms, an aromatic bicyclic ring system containing 10 carbon atoms or an aromatic tricyclic ring system containing 14 carbon atoms. Examples are phenyl, naphthalenyl or anthracenyl. The aryl group is optionally substituted.
  • aralkyl refers to an alkyl moiety, which is substituted by aryl, wherein alkyl and aryl have the meaning as outlined above.
  • An example is the benzyl radical.
  • the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butenyl, tert-butyl, pentyl, hexyl, heptyl, or octyl.
  • the aralkyl group is optionally substituted at the alkyl and/or aryl part of the group.
  • the aryl attached to the alkyl has the meaning phenyl, naphtalenyl or anthracenyl.
  • heteroaryl preferably refers to a five or six-membered aromatic monocyclic ring wherein at least one of the carbon atoms are replaced by 1, 2, 3, or 4 (for the five membered ring) or 1, 2, 3, 4, or 5 (for the six membered ring) of the same or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 8, 9, 10, 11 or 12 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 13, 14, 15, or 16 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S.
  • heteroarylkyl refers to an alkyl moiety, which is substituted by heteroaryl, wherein alkyl and heteroaryl have the meaning as outlined above.
  • An example is the 2-alklypyridinyl, 3-alkylpyridinyl, or 2-methylpyridinyl.
  • the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butenyl, tert-butyl, pentyl, hexyl, heptyl, octyl.
  • the heteroaralkyl group is optionally substituted at the alkyl and/or heteroaryl part of the group.
  • the heteroaryl attached to the alkyl has the meaning oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzo
  • aralkenyl refers to an alkenyl or alkynyl moiety as defined above, which is substituted by an aryl and heteroaryl moiety, respectively, as defined above.
  • alkenyl refers to olefinic unsaturated carbon atoms containing chains with one or more double bonds.
  • the alkenyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethenyl, 1-propenyl, 2-propenyl, iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, iso-butenyl, sec-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, pentenyl, octenyl.
  • heteroalkenyl refers to olefinic unsaturated carbon atoms containing chains with one or more double bonds, which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms.
  • the chain comprises from 2 to 12 carbon atoms, e.g. the alkenyl chain comprises from 2 to 12 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 e.g.
  • heteroatoms are selected from O, S, and N.
  • cycloalkenyl and “heterocycloalkenyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkenyl” and “heteroalkenyl”, respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. 1-cyclopropenyl, 2-cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, cyclohexenyl, cyclopentenyl, cyclooctenyl etc.
  • cycloalkenyl and “heterocycloalkenyl” are also meant to include bicyclic, tricyclic and polycyclic versions thereof. If bicyclic, tricyclic or polycyclic rings are formed it is preferred that the respective rings are connected to each other at two adjacent carbon atoms, however, alternatively the two rings are connected via the same carbon atom, i.e. they form a spiro ring system or they form “bridged” ring systems.
  • heterocycloalkenyl preferably monounsaturated ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N; a mono-unsaturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a mono or diunsaturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms.
  • cycloalkenyl examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclopentenyl, and cyclooctenyl.
  • Preferred examples of heterocycloalkenyl include 1,2,5,6-tetrahydropyridyl, e.g. 1-(1,2,5,6-tetrahydropyridyl), or 2-(1,2,5,6-tetrahydropyridyl).
  • alkynyl refers to unsaturated carbon atoms containing chains or rings with one or more triple bonds.
  • the alkynyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, hexynyl, pentynyl, octynyl.
  • carbon atoms or hydrogen atoms in alkyl, cycloalkyl, aryl, aralkyl, alkenyl, cycloalkenyl, alkynyl radicals may be substituted independently from each other with one or more elements selected from the group consisting of O, S, N or with groups containing one ore more elements, i.e. 1, 2, 3, 4, 5, 6, or more selected from the group consisting of O, S, and N.
  • Embodiments include alkoxy, alkyl-alkoxy, cycloalkoxy, aralkoxy, alkenyloxy, cycloalkenyloxy, alkynyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, alkenylthio, cycloalkenylthio, alkynylthio, alkylamino, cycloalkylamino, arylamino, aralkylamino, alkenylamino, cycloalkenylamino, alkynylamino radicals.
  • one or more hydrogen atoms e.g. 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms in alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkenyl, heteroalkenyl cycloalkenyl, heterocycloalkenyl alkynyl radicals may be substituted independently from each other with one ore more halogen atoms, e.g. Cl, F, or Br.
  • One preferred radical is the trifluoromethyl radical.
  • radicals can be selected independently from each other, then the term “independently” means that the radicals may be the same or may be different.
  • Suitable pharmaceutically acceptable salts of the compound of the present invention include acid addition salts which may, for example, be formed by mixing a solution of choline or derivative thereof with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate).
  • alkali metal salts e.g., sodium or potassium salts
  • alkaline earth metal salts e.g., calcium or magnesium salts
  • suitable organic ligands e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sul
  • Illustrative examples of pharmaceutically acceptable salts include but are not limited to: acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate
  • the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • the present invention provides compounds which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound of formula (I).
  • a prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient.
  • prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art.
  • esters for example, methyl, ethyl
  • cycloalkyl for example, cyclohexyl
  • aralkyl for example, benzyl, p-methoxybenzyl
  • alkylcarbonyloxyalkyl for example, pivaloyloxymethyl
  • Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.
  • EP 0 039 051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
  • Certain compounds of the present invention can exist in unsolvated forms as well as in solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
  • inhibitors of scavenger receptor class proteins can interfere with the proliferation and/or development of infectious agents in liver cells and hematopoietic cells
  • the invention provides in a first aspect the use of an inhibitor of a scavenger receptor class protein for the production of a medicament therapy of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
  • the term “inhibitor of scavenger receptor class proteins” within the present invention refers to compounds which can inhibit high density lipoprotein (HDL) uptake mediated by scavenger receptor class proteins, in particular ScarB1.
  • HDL high density lipoprotein
  • ScarB1 scavenger receptor class proteins
  • a compound is considered an inhibitor of scavenger receptor class proteins, if the compound has an IC 50 of ⁇ 100 ⁇ M in a cholesterol transport assay preferably the one described below.
  • the IC 50 is 90 ⁇ M, 80 ⁇ M, 70 ⁇ M, 60 ⁇ M, 50 ⁇ M, 40 ⁇ M, 30 ⁇ M, 20 ⁇ M, 10 ⁇ M, 9 ⁇ M, 8 ⁇ M, 7 ⁇ M, 6 ⁇ M, 5 ⁇ M, 4 ⁇ M, 3 ⁇ M, 2 ⁇ M, 1 ⁇ M, 0.9 ⁇ M, 0.8 ⁇ M, 0.7 ⁇ M, 0.6 ⁇ M, 0.5 ⁇ M, 0.4 ⁇ M, 0.3 ⁇ M, 0.2 ⁇ M, 0.1 ⁇ M or less.
  • the cholesterol transport assay measures the transport of cholesterol into and/or out of a given cell, preferably a hepatic cell.
  • the measurement comprises the transport of “free” cholesterol, high density lipoproteins (HDL) and low density lipoproteins (LDL).
  • Infections involving liver cells and/or hematopoietic cells are diseases wherein the pathogen in one or mores stages of its life cycle in the respective host attacks and/or enters liver cells and/or hematopoietic cells in order to, e.g. proliferate, develop or evade the immune system in those cells, in particular protozoal infections.
  • the inhibitor of the scavenger receptor class protein is a compound with the following formula (I):
  • R 3 and R 4 form a (C 3-10 )-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, (C 6-10 )-spiroalkyl, preferably spiro-[3,3]-heptyl, spiro-[3,4]-octyl, spiro-[4,3]-octyl, spiro-[3,5]-nonyl, spiro-[5,3]-nonyl, spiro-[3,6]-decyl, spiro-[6,3]-decyl, spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, or adamantyl or C 3 to C 10
  • tetrahydrofuran-2-yl tetrahydrofuran-3-yl
  • tetrahydrothiophenyl e.g. tetrahydrothiophen-2-yl, or tetrahydrothiophen-3-yl
  • pyrrolidinyl e.g. pyrrolidin-1-yl, pyrrolidin-2-yl, or pyrrolidin-3-yl
  • 1,2-diazacyclopentyl e.g. 1,2-diazacyclopent-1-yl, or 1,2-diazacyclopent-3-yl
  • 1,3-diazacyclopentyl e.g.
  • C 3 - 10 -cycloalkyl or C 3-10 -cycloheteroalkyl is substituted with one, two, three or more substituents selected from the group consisting of hydrogen, hydroxyl, halogen, oxo, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl and/or two adjacent substituents are taken together to form an aryl or heteroaryl, preferably oxazolyl, isoxazo
  • one substituent is located in cis to the imin bound to the ring system. It is preferred that one substituent is oxo, alkyl, or heteroalkyl.
  • a preferred ring system is 1-thio-3-azacyclopentyl, preferably 1-thio-3-azacyclopent-2-yl, 3-alkyl-(1-thio-3-azacyclopentyl) or 3-alkyl-(1-thio-3-azacyclopent-2yl) and pyrrolidinyl, preferably pyrrolidin-3-yl, or 2-oxo-pyrrolidin-3-yl.
  • the compound according to formula (I) has a structure according to formula (II)
  • the respective substituent is preferably substituted with hydroxyl; halogen, F, Cl, Br or I; CN; NO 2 ; alkyl, in particular (C 1-6 )alkyl, e.g. C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl; cycloalkyl, in particular (C 3-10 )-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, heteroalkyl in particular (C 1 -C 6 )heteroalkyl, e.g.
  • C 2 , C 3 , C 4 , C 5 , or C 6 alkenyl preferably ethenyl, 1-propenyl, 2-propenyl, 1-iso-propenyl, 2-iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl; cycloalkenyl, in particular (C 3-10 )-cycloalkyl; or alkynyl, in particular C 2 -C 6 alkynyl, e.g. C 2 , C 3 , C 4 , C 5 , or C 6 alkynyl; alkanoyl, preferably C 1 -C 6 alkanoyl, e.g.
  • alkenoyl in particular C 3 -C 6 alkenoyl, e.g. C 3 , C 4 , C 5 , or C 6 alkenoyl, preferably propenoyl
  • alkynoyl in particular C 3 -C 6 alkynoyl, e.g. C 3 , C 4 , C 5 , or C 6 alkynoyl, preferably propynoyl
  • alkoxy in particular C 1 -C 6 alkoxy, e.g.
  • alkoxy preferably methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, tert-butoxy, pentoxy, or hexoxy; alkoxyalkyl, in particular C 1 -C 6 alkoxy-C 1 -C 6 alkyl, e.g.
  • the compound of formula (I) has the structure according to formula (III):
  • R 6 is hydrogen, (C 1-6 )alkyl, e.g. C 1 , C 2 , C 3 , C 4 , C 5 or C 6 -alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl or (C 2-6 )alkenyl;
  • the compound according to formula (III) has a structure selected from the structures according to formulas (IV) to (VII)
  • Preferred salts comprise Na + , K + , Mg 2+ , and Ca 2+ .
  • R 7 , R 8 , R 9 , and R 10 are each independent of each other selected from the group consisting of (C 1-16 )alkyl, e.g.
  • the other substituent(s) in this case are preferably hydrogen.
  • R 7 and R 8 or R 9 and R 10 together form an oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl,
  • the compound according to formula (II) has a structure selected from the structures according to formulas (VIII) to (XXXI)
  • the inhibitor of the scavenger receptor class protein is a compound having a structure according to the following formula (XXXII):
  • the compound has a structure according to formula (XXXII) wherein
  • the compound has a structure according to formula (XXXII) wherein
  • the compound has a structure according to formula (XXXII) wherein
  • R 6 is mono or disubstituted aryl or heteroaryl, preferably phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-ind
  • the one or two substituents are preferably independently selected from the group consisting of F, Cl, Br, (C 1-6 )alkoxy, e.g. C 1 , C 2 , C 3 , C 4 , C 5 or C 6 -alkoxy, in particular methoxy, ethoxy, propxy, butoxy, pentoxy, hexoxy, (C 1-6 )alkyl, e.g.
  • C 1 , C 2 , C 3 , C 4 , C 5 or C 6 -alkyl in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, or iso-hexyl and NR 11 ′R 12 ′, wherein R 11 ′R 12 ′, wherein R 11 ′R 12 ′ are independent of each other selected from hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted.
  • R 6 is phenyl substituted with one or two (C 1-6 )alkyl, e.g. C 1 , C 2 , C 3 , C 4 , C 5 or C 6 -alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, or iso-hexyl and/or one or two NR 11 ′R 12 ′, wherein R 11 ′R 12 ′, wherein R 11 ′R 12 ′ are independent of each other selected from hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl.
  • C 1-6 alkyl
  • Preferred salts comprise Na + , K + , Mg 2+ , and Ca 2+ .
  • the compound usable according to the present invention having a structure according to formula (XXXIII) to (XLVIII) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO 2 ; NO 2 ; CN; (C 1-16 )alkyl, e.g.
  • the inhibitor of the scavenger receptor class protein is a compound with the following formula (IL):
  • R 18 is aralkyl, in particular phenylmethyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl wherein both the alkyl and the aryl, in particular the phenyl radical are substituted one or more times with a substituent independently selected from the group consisting of F, Cl, Br, hydroxyl.
  • X is O.
  • the compound according to formula (IL) has a structure according to formula (L):
  • Preferred salts comprise Na + , K + , Mg 2+ and Ca 2+ .
  • the compound usable according to the present invention having a structure according to formula (L) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO 2 ; NO 2 ; CN; (C 1-16 )alkyl, e.g.
  • the inhibitor of the scavenger receptor class protein has a structure according to formula (LI):
  • R 21 and R 22 are independent of each other phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazo
  • R 23 , R 24 , and R 25 are independent of each other hydrogen, hydroxyl, F, Cl, Br, I, CN, SO 2 , NO 2 , alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted, preferably hydrogen.
  • the compound according to formula (LI) has a structure according to formula (LII):
  • the compound usable according to the present invention having a structure according to formula (LII) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO 2 ; NO 2 ; CN; (C 1-6 )alkyl, e.g.
  • the inhibitor of the scavenger receptor class protein has a structure according to formula (LIII):
  • both R 27 and R 29 are aryl, preferably phenyl, substituted preferably with one to three substituents selected from the group consisting of F; Cl; Br; I; hydroxyl; SO 2 ; NO 2 ; CN; (C 1-6 )alkyl, e.g. C 1 , C 2 , C 3 , C 4 , C 5 , or C 6 -alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C 2-6 )alkenyl, e.g.
  • C 2 , C 3 , C 4 , C 5 , or C 6 -alkenyl in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C 1-6 )alkoxy, e.g.
  • R 29 is phenyl substituted with 1, 2, or 3 halogen radicals, preferably I.
  • R 27 is phenyl substituted with 1, 2, or 3 amino radicals or substituted amino radicals.
  • Preferred salts comprise Na + , K + , Mg 2+ , and Ca 2+ .
  • the compound usable according to the present invention having a structure according to formula (LIV) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO 2 , NO 2 ; CN; (C 1-16 )alkyl, e.g.
  • a further aspect of the present invention is directed at inhibitors of scavenger receptor type proteins the use of which has been disclosed herein, specifically at all inhibitors of scavenger receptor type proteins according to formulas (I) to (LIV) and according to all of the above indicated preferred and particularly preferred embodiments of compounds having structures according to these formulas.
  • a further aspect of the present invention is a pharmaceutical composition comprising any of the compounds usable according to the present invention.
  • WO 2004/032716 A2 describes a large number of different compounds specifically inhibiting cholesterol transport activity of ScarB1. For the purpose of this opinion it is specifically referred to these compounds, which can also be used in the uses of the present invention. Accordingly, a further aspect of the present invention is the use of one or more of the compounds selected from Table I below.
  • antibody as used herein comprises monoclonal and polyclonal antibodies and binding fragments thereof, in particular Fc-fragments as well as so called “single-chain-antibodies” (Bird R. E. et al (1988) Science 242:423-6), chimeric, humanized, in particular CDR-grafted antibodies, and dia or tetrabodies (Holliger P. et al (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6444-8). Also comprised are immunoglobulin like proteins that are selected through techniques including, for example, phage display to specifically bind to scavenger receptor class proteins.
  • RNA interference was discovered through the observation that injection of double stranded RNA (dsRNA) into the nematode C. elegans led to specific silencing of genes highly homologous in sequence to the delivered dsRNA (Fire A. et al. (1998) Nature 391: 806-811). RNAi was subsequently also observed in insects, frogs (Oelgeschlager M. et al. (2000) Nature 405: 757-763), and other animals including mice (Svoboda P. et al. (2000) Development 127: 4147-4156; Wianny F. and Zemicka-Goetz M. (2000) Nat. Cell Biol 2: 70-75).
  • dsRNA double stranded RNA
  • siRNA small interfering RNA
  • the inhibitor of the scavenger receptor class protein is a small interfering RNA (siRNA) capable of inhibiting expression of a scavenger receptor class protein.
  • each RNA strand of the siRNA has a length from 19 to 30, particularly from 19 to 23 nucleotides, wherein said RNA molecule is capable of mediating target-specific nucleic acid modifications, particularly RNA interference and/or DNA methylation. It is further preferred that at least one strand has a 3′ overhang from 1 to 5 nucleotides, more preferably from 1 to 3 nucleotides and most preferably of 2 nucleotides. The other strand may be blunt-ended or may have up to 6 nucleotides 3′ overhang.
  • the siRNA is designed to inhibit expression of scavenger receptor class B 1 (ScarB1) and ScarBII. To that end various short, e.g.
  • dsRNAs 19 to 25 nucleotides dsRNAs are designed on the basis of the sequence of either ScarB1 (SEQ ID NO: 1) or ScarBII (SEQ ID NO: 2). It is particularly preferred that the siRNA is a double stranded RNA each comprised of the RNAs according to SEQ ID NO: 3 and SEQ ID NO: 4; SEQ ID NO: 5 and SEQ ID NO: 6; and SEQ ID NO: 7 and SEQ ID NO: 8, respectively.
  • the scavenger receptor class protein is scavenger receptor class B 1 (ScarB1) or scavenger receptor class B 2 (ScarBII).
  • the pathogenic protozoa is selected from the group consisting of Entomoeba histolytica, Trichomonas tenas, Trichomonas hominis, Trichomonas vaginalis, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Toxoplasma gondii, Theileria lawrenci, Theileria parva, Plasmodium vivax, Plasmodium falciparum, and Plasmodium malaria.
  • the protozoa is a member of the family of plasmodiidae, preferably Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi.
  • the infectious disease for which treatment and/or prophylaxis is provide is malaria.
  • the present invention relates in another aspect to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
  • the term “contacting” refers to the process of allowing the compound to bind to, preferably to bind to and enter the cell and comprises mixing as well as transfecting, transducing and/or electroporating.
  • a cell “comprising” a scavenger receptor class protein, preferably ScarB1 or ScarBII may have been stably or transiently transfected with a nucleic acid encoding a scavenger receptor class protein or functional variant thereof, by e.g. viral infection, electroporation, CaCl 2 precipitation or the protein may have been directly introduced into the cell by, e.g. electroporation, or liposomal delivery etc.
  • a “functional variant” of a scavenger receptor class protein is a protein, which has been modified by N-terminal, C-terminal and/or internal deletions and/or amino acid additions and or mutations, preferably conservative mutations and which has at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70% or more of the cholesterol transport activity into or out of the cell, if compared to the respective wild type scavenger receptor class protein on which the variant is based.
  • the measuring of the cholesterol transport is preferably carried out by providing some type of labelled cholesterol to the cell, e.g. free cholesterol, LDL or HDL, which might be labelled by any art known label, in particular radioactive, or fluorescent label.
  • the selected test compound preferably inhibits the cholesterol transport into or out of the cells by at least 10%, preferably by at least 20%, preferably by at least 30%, preferably by at least 40%, preferably by at least 50%, preferably by at least 60%, preferably by at least 70%, preferably by at least 80%, preferably by at least 90% or more, if compared to an untreated cell, which is kept under otherwise similar conditions.
  • Methods of propagating/maintaining infectious agents in cell culture systems, in particular in liver and/or haematopoietic cells are known from the prior art and are also described herein.
  • the test compounds are contacted with such cellular systems, which can be in vitro or in vivo, e.g. in animal models of the infectious agent.
  • Test compounds that can be used in the context of the methods of the present invention are not particularly limited and comprise without limitation peptides, proteins, peptidomimetics, small molecules, and/or nucleic acids.
  • Peptides in this sense are chains of naturally and/or non-naturally occurring amino acids with 1 to 50 amino acids connected by peptide bonds. Chains with 50 or more naturally and/or non-naturally occurring amino acids are referred to as proteins.
  • Preferred peptides used in the methods of the present invention are peptides interfering with the interaction of the scavenger receptor class protein(s), in particular ScarB1 and/or ScarBII, with the structure on the respective pathogen, e.g.
  • peptides are fragments of scavenger receptor type proteins, in particular of ScarB1 and/or ScarBII. Particularly preferred fragments are fragments of the extracellular domain of these receptors.
  • Peptidomimetics are well known in the art and refer to compounds, which are designed based on the primary structure of a given peptide to be modelled, e.g.
  • peptidomimetics can be designed to be, e.g. more protease resistant, have a different half life, improved pharmacokinetics or pharmacodynamics etc.
  • Small molecules within the meaning of the present invention are non peptidly (no peptide bonds), non nucleic acid compounds, of a molecular weight lower than 1.000 g/mol, preferably lower than 500 g/mol. In most cases the small molecules used in the methods of the present invention are hydrocarbons or mixtures thereof, e.g. plant extracts.
  • nucleic acids comprises without limitation, DNA and RNA, e.g. siRNA etc.
  • the selecting of a test compound inhibiting proliferation or development of the infectious agent is based on its activity in inhibiting proliferation and/or development of the infectious agent. It is expected that any compound showing an activity in step (iii) will also be active in inhibiting the infectious agent. However, in some instances a compound with a high activity in step (iii) will be less active than in step (v) as another drug having the same activity in step (iii) and vice versa. Accordingly, the further step of assessing the activity of the preselected compounds in a further selection step leads to compounds more active in therapy and/or prophylaxis of infectious diseases, in particular malaria.
  • infectious agents are those, which are outlined above in particular plasmodiidae, preferably Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi.
  • the present invention also relates in another aspect to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
  • Soluble parts are fragments, which preferably do not comprise the hydrophobic membrane spanning regions of the protein.
  • a test compound is considered to specifically bind to a scavenger receptor class protein, in particular ScarB1 or ScarBII, if it has a binding constant to the respective scavenger receptor class protein of 100 ⁇ M or less, preferably 50 ⁇ M or less, preferably 30 ⁇ M or less, and preferably 20 ⁇ M or less.
  • the scavenger receptor class proteins, in particular ScarB1 or ScarBII protein, used in above assay is recombinantly expressed.
  • suitable expression systems include without limitation baculovirus systems using cells like Hi5 or Sf9, bacterial expression systems using E. coli, yeas systems using cells like P. pastori or S. cerevisiae or mammalian systems using cell like CHO, HeLa, NIH 3T3, or Swiss 3T3. It is further preferred that the proteins, the variants or parts thereof are purified prior to their use in above assay.
  • the present invention comprises the additional step of formulating the test compound selected in step (v) and (iv), respectively, of either method with pharmaceutically acceptable additives and/or auxiliary substances.
  • auxiliary substances comprise liposomes, virosomes, microsphere, niosomes, dendrimeres, stabilizers, buffers, and carriers.
  • Stabilizers are known in the art and comprise, for example, ⁇ -tocopherol and various carbohydrates.
  • the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as saline solutions in water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • a saline solution is a preferred carrier when the composition comprising the scavenger receptor class inhibitor is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, alginates, calcium carbonate, dextrose, fructose, maltose, maltodextrin, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition comprising the scavenger receptor class inhibitor if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • the composition comprising the scavenger receptor class inhibitor can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • the compounds usable according to the invention can be formulated as neutral or salt forms.
  • compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • compositions comprising the scavenger receptor class inhibitor(s) may be adapted for oral administration and can be provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions.
  • Tablets or hard gelatine capsules may comprise lactose, starch or derivatives thereof, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, stearic acid or salts thereof.
  • Soft gelatine capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars.
  • the scavenger receptor class inhibitor usable according to the present invention may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used).
  • a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
  • a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
  • glyceryl monostearate or glyceryl distearate may be used.
  • Pharmaceutical compositions for oral administration may be formulated to facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.
  • the scavenger receptor class inhibitor may be adapted for transdermal administration and can be provided as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. They may be adapted for topical administration and can be provided as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For topical administration to the skin, mouth, eye or other external tissues a topical ointment or cream is preferably used. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredient may be formulated in a cream with an oil-in-water base or a water-in-oil base.
  • Pharmaceutical compositions adapted for topical administration to the eye include eye drops.
  • the active ingredient can be dissolved or suspended in a suitable carrier, e.g., in an aqueous solvent.
  • Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouthwashes.
  • the scavenger receptor class inhibitor may be adapted for nasal administration and can comprise solid carriers such as powders (preferably having a particle size in the range of 20 to 500 microns). Powders can be administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nose from a container of powder held close to the nose.
  • compositions adopted for nasal administration may comprise liquid carriers, e.g., nasal sprays or nasal drops. These compositions may comprise aqueous or oil solutions of the active ingredient.
  • Compositions for administration by inhalation may be supplied in specially adapted devices including, but not limited to, pressurized aerosols, nebulizers or insufflators, which can be constructed so as to provide predetermined dosages of the active ingredient.
  • pharmaceutical compositions of the invention are administered via the nasal cavity to the lungs.
  • the scavenger receptor class inhibitor may be adapted for rectal administration may be provided as suppositories or enemas.
  • Pharmaceutical compositions adapted for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • the scavenger receptor class inhibitor may be adapted for parenteral administration and can include aqueous and non-aqueous sterile injectable solutions or suspensions, which may contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially isotonic with the blood of an intended recipient.
  • Other components that may be present in such compositions include water, alcohols, polyols, glycerine and vegetable oils, for example.
  • compositions adapted for parenteral administration may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, e.g., sterile saline solution for injections, immediately prior to use.
  • a sterile liquid carrier e.g., sterile saline solution for injections
  • the present invention relates to the use of a test compound selected in step (v) of the method of the present invention for the production of a medicament for the therapy and/or prophylaxis of infectious diseases, which involve infection of liver and/or hematopoietic cells.
  • the present invention in a further aspect relates to pharmaceutical compositions comprising one or more of compound usable according to the present invention and one or more of a known malaria therapeutic including in particular one or more selected from the group consisting of chinine alkaloids, chloroquine (-phosphate, hydroxychloroquinesulfate), mefloquine (Lariam), bi-guanides: proguanil (Paludrine), di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine and suitable carriers.
  • chinine alkaloids chloroquine (-phosphate, hydroxychloroquinesulfate), mefloquine (Lariam)
  • bi-guanides proguanil (Paludrine)
  • di-aminopyrimidines pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine and suitable carriers.
  • the present invention also relates to the use of the compounds usable according to the present invention and one or more malaria medicament, preferably chinine alkaloids, chloroquine (-phosphate, hydroxychloroquinesulfate), mefloquine (Lariam), bi-guanides: proguanil (Paludrine), di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine for the manufacture of a medicament for the treatment of diseases involving liver and/or hematopoeitc cells, preferably malaria.
  • the two medicaments are administered simultaneously, e.g. combined in one administration form or simultaneously or subsequently in separate administration forms.
  • the present invention in a further aspect relates to a method of identifying molecules, which are present in, in particular on the surface, of pathogens capable of infecting liver and hematopoietic cells and which interact with one or more scavenger receptor class protein, in particular ScarB1 and/or ScarBII.
  • the method preferably comprises the following steps:
  • Preferred molecules of pathogens which can be tested for their binding to scavenger receptor class proteins comprise proteins, lipids and carbohydrates, preferably proteins.
  • cell surface receptors of pathogens are involved in a specific interaction with a corresponding receptor on a host cell. Accordingly, it is particularly preferred that the molecules tested for binding to scavenger receptor class proteins are cell surface receptors of the particular pathogen.
  • pathogens outlined above can be the source for molecules tested in this method of the invention, preferably, however, the pathogens are selected from the group consisting Entomoeba histolytica, Trichomonas tenas, Trichomonas hominis, Trichomonas vaginalis, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Toxoplasma gondii, Theileria lawrenci, Theileria parva, Plasmodium vivax, Plasmodium falciparum, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi, in particular Plasmodium vivax and Plasmodium falciparum.
  • the contacting between the scavenger receptor class protein and the molecule(s) derived from the pathogen can be carried out in vivo or in vitro.
  • both the scavenger receptor class protein(s), functional variants, or soluble parts thereof and the potentially interacting molecule(s) can be present together in a cell
  • either the scavenger receptor class protein(s), functional variants, or soluble parts thereof or the potentially interacting molecule(s) can be expressed in a cell, e.g. on the surface of a cell, which is then contacted with the respective other entity in, e.g. solution or
  • both scavenger receptor class protein(s), functional variants, or soluble parts thereof and the potentially interacting molecule(s) are contacted in vitro.
  • a molecule comprised in a pathogen is considered to specifically bind to a scavenger receptor class protein, in particular ScarB1 or ScarBII, if it has a binding constant to the respective scavenger receptor class protein of 100 ⁇ M or less, preferably 50 ⁇ M or less, preferably 30 ⁇ M or less, and preferably 20 ⁇ M or less.
  • the target i.e. the scavenger receptor class protein
  • affinity purification affinity purification
  • cross-linking phage display
  • two-hybrid two-hybrid assays.
  • the target i.e. the scavenger receptor class protein
  • the target is contacted with the molecules derived from the pathogens in a homogenous system, i.e.
  • the target is bound “pulled down” by interaction with a molecule specifically binding the target, e.g. a scavenger receptor specific antibody, which has been attached to a bead or matrix.
  • a molecule specifically binding the target e.g. a scavenger receptor specific antibody
  • the specifically bound molecules are then eluted and analyzed by e.g. MS, peptide sequencing or Western blot.
  • the affinity purification is similar to co-immunoprecipitation, however, the binding is carried out by applying the molecules of the pathogens to a column loaded with a matrix to which the scavenger receptor class protein has been attached.
  • Cross-linking typically involves the labelling of the target, which may or may not be further modified to include a cross-linking moiety, the contacting of the labelled target with the molecules of the pathogen, preferably with the intact pathogen and effecting crosslinking between the target and whatever molecule the target has bound to.
  • the complex which is formed between the target and the molecule of the pathogen can then be purified away from the other molecules of the pathogen on the basis of the label and/or analyzed by art known methods, involving MS, peptide sequencing and the like.
  • Phage display is a method wherein proteins or protein fragments are fused to phage coat proteins and, thus, displayed on the surface of the resulting phage.
  • LaCount D J, et al. describe a high-throughput version of the yeast two-hybrid assay that circumvents the difficulties in expressing P. falciparum proteins in Saccharomyces cerevisiae.
  • This assay could be adapted to isolate scavenger receptor class protein, in particular ScarB1 and ScarBII, interacting proteins from the pathogens indicated above, in particular from P. falciparum
  • assays and variations thereof can be used to identify proteins of pathogens interacting with scavenger receptor class proteins present on liver and hematopoietic cells. The identification will then facilitate the isolation of compounds specifically interfering with the interaction between the molecules of the pathogens and the scavenger receptor class proteins.
  • FIG. 1 Inhibition of EEF (Exo-Erythrocytic Forms) development in Huh-7 human hepatoma cells by BLT-1. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 2 Inhibition of EEF development in Huh-7 human hepatoma cells by BLT-2. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 3 Inhibition of EEF development in Huh-7 human hepatoma cells by BLT-4. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 4 Inhibition of EEF development in Huh-7 human hepatoma cells by Ezetimibe. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 5 Ezetimibe reduces infection rate for liver in mice.
  • FIG. 6 Structures of preferred compounds usable to treat infection by plasmodiidae.
  • FIG. 7 Knock down of ScarB1 by RNAi reduces EEF development in human hepatoma cells.
  • FIG. 8 Inhibitory effect on EEF development correlates with knock down of ScarB1. Dark bars depict the remaining mRNA and light bars depict the numbers of EEF.
  • FIG. 9 siRNAs sequences targeting ScarB1 (SEQ ID NO 3 to SEQ ID NO 8)
  • FIG. 10 Nucleic acid sequence of Homo sapiens scavenger receptor class B, member 1 (SCARB1), NM — 005505.3 (SEQ ID NO: 1).
  • FIG. 11 Scavenger receptor class B, member 1 [Homo sapiens], amino acid sequence, NP — 005496.3 (SEQ ID NO: 9).
  • FIG. 12 BLT-1 reduces infection rate for liver in mice.
  • FIG. 13 Inhibitory effect on EEF development correlates with knock down of ScarB1 in living mice.
  • FIG. 14 Inhibition of EEF development in Mouse Primary Hepatocytes by BLT-1.
  • FIG. 15 Inhibition of P. Yoelii EEF development in Hepa 1-6 cells by BLT-1. The time period given indicates the length of the presence of 10 ⁇ M BLT-1 during infection.
  • FIG. 16 Infection Score for preferred compounds usable in the present invention and for comparative compounds.
  • Huh human hepatoma cells were cultivated in RPMI (Gibco/Invitrogen) medium containing 10% FBS, 1% non-essential amino acid solution (Gibco/Invitrogen), 1% penicillin/streptomycin solution (Gibco/Invitrogen), 1% glutamine (Gibco/Invitrogen) and 1% Hepes pH 8 (Gibco/Invitrogen).
  • Hepa 1-6 cells were cultured in complete DMEM medium (Gibco/Invitrogen) supplemented with 10% fetal calf serum (Gibco/Invitrogen) and 1% penicillin/streptomycin (Gibco/Invitrogen) incubated at 37° C. and 5% CO 2 .
  • Cells were split twice per week by seeding 10 6 cells in 15 ml complete medium in 75 ml culture flasks (Nunc). For passaging, cells were detached from the flask by incubation with 3 ml Trypsin solution (Gibco/Invitrogen) for 5 min at 37° C. Trypsin was inactivated by adding 10 ml of complete medium to the flask.
  • the plates were left for 30 min at RT before they were transferred to an incubator with 37° C. and 5% CO 2 .
  • Sporozoites were obtained from Anopheles stephensi mosquitoes infected with P. berghei ANKA or P. yoelii. Salivary glands were dissected and collected in RPMI medium (GIBCO) on ice. Collected tissues were gently ground in the medium to release sporozoites. Tissue fragments were removed by centrifugation at 40 ⁇ g for 3 min, and sporozoites were collected from the supernatant.
  • Blt-1, Blt-2, and Blt-4 were purchased from ChemBridge Corporation (San Diego, USA).
  • Ezetimibe (for chemical structure see FIG. 6 and structure (XXVI)) was derived from powdered Ezeterol tablets (Essex Pharma, UK). Each compound was dissolved in DMSO at a final concentration of 50 mM. 48 hours after seeding of 6000 Huh-7 cells per well, growth medium was replaced by fresh complete culture medium, containing the compounds in 4 different concentrations, generated by dilution series of the compound stock solutions in complete growth medium: 8 ⁇ M; 1.6 ⁇ M; 320 nM; 64 nM.
  • Controls media were prepared according to DMSO concentrations in the 4 compound dilutions, i.e. 0.016%; 0.0032%; 0.00064%; 0.000128%.
  • Huh-7 cells were equilibrated for 1 h with compound/DMSO-containing medium at 37° C. before infection with 10,000 sporozoites per well ( FIG. 1 to 4 ).
  • the secondary antibody solution consisting of blocking buffer, substituted with an alexa-555 labeled goat anti mouse secondary antibody (Molecular Probes/Invitrogen) in a final dilution of 1/1000, Phalloidin coupled to alexa-488 in a final dilution of 1/500 and Hoechst-33342 in a final dilution of 1:2000, was applied to the cells for 45 min at RT followed by extensive washing with PBS.
  • alexa-555 labeled goat anti mouse secondary antibody Molecular Probes/Invitrogen
  • experimental plates were sealed with each well containing 100 ⁇ l of PBS and stored at 4° C. in the dark until image acquisition.
  • An automated image analysis routine based on Metamorph was applied to the image sets from each well, consisting of 3 images, representing the channels for alexa 488, alexa 555 and Hoechst respectively, for each of the 9 fields acquired.
  • Numerical readouts comprised of cell proliferation as measured by the number of nuclei per imaged field (Hoechst staining), cell confluency as measured by the percentage of the imaged field covered by cells (actin/Phalloidin staining), and number of EEFs per imaged field. EEFs were identified as bright, round objects in the 2E6 staining. Objects in a size range of 16-150 pixels were quantified.
  • EEF numbers were normalized to the cell confluency (see above).
  • EEF numbers normalized to cell confluency, were averaged between the 9 fields imaged per well and normalized to the corresponding mean value from 3 untreated wells present on the same experimental plate.
  • Ezeterol tablets were used to prepare a 0.3 mg/ml solution of Ezetimibe in water.
  • Experimental C57B1/6 mice were treated by oral gavage with 200 ⁇ l of Ezetimibe solution (3 mg/kg) 2 hours prior to infection with sporozoites.
  • 200 ⁇ l of water were administered by oral gavage.
  • Infection with Plasmodium berghei was performed by i.v. injection of 30 000 sporozoites (see FIG. 5 ).
  • BLT-1 treatment of C57B1/6 mice male, 6-8 weeks old
  • intra-peritoneal injections of 50 mg/kg of BLT-1 in DMSO were carried out prior to infection.
  • Control mice were treated with DMSO only. Two hours later, mice were infected by intravenous injection with 3 ⁇ 10 4 P. berghei sporozoites (see FIG. 12 ).
  • P. berghei ANKA load and ScarB1 expression in the liver was quantified by Real-Time PCR using the SYBR Green Mix (Applied Biosystems) and primers designed for the 18S RNA of the parasite and primers for ScarB1.
  • the mouse hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1) gene was used as housekeeping control to account for differential efficiencies in RNA extraction between samples (see FIGS. 5 and 13 ).
  • siRNAs of a given nucleotide sequence were synthesized by Ambion, Inc. (Austin, Tex., USA), using standard methods known to the person skilled in the art of siRNA synthesis.
  • the sequences of the two respective RNAs hybridized to each other are shown in the left and right hand panel of FIG. 9 (From left to right and from top to bottom SEQ ID NO: 3, 4, 5, 6, 7, and 8).
  • RNAi experiments cells were transfected with siRNAs 24 h after cell seeding of 4000 cells per well of a 96 well plate.
  • siRNA was transfected in triplicates; the transfection mix was prepared as follows:
  • Cells were incubated at 37° C. for 4 hours and then shifted back to initial growth conditions by adding 50 ⁇ l of fresh medium, supplemented with 30% fetal calf serum and 3% Penicillin/Streptomycin.
  • Each 96 well screening plate contained 3 wells transfected with a control siRNA (sharing no complete sequence homology with any coding sequence in the human transcriptome) and 3 untreated wells. ( FIGS. 7 and 8 )
  • Real-Time qPCR with gene-specific primers was performed in the following reaction mix
  • ldlA[mSR-BI] cells are plated at 15,000 cells/well in clear bottom, black wall 384-well black assay plates (Costar) in 50 ⁇ l of medium A (Ham's F12 supplemented with 2 mM L-glutamine, 50 units/ml penicillin/50 ⁇ g/ml streptomycin, and 0.25 mg/ml G418.) supplemented with 10% fetal bovine serum (medium B).
  • medium A Ham's F12 supplemented with 2 mM L-glutamine, 50 units/ml penicillin/50 ⁇ g/ml streptomycin, and 0.25 mg/ml G418.
  • medium B fetal bovine serum
  • cells are washed once with medium C (medium A with 1% (w/v) bovine serum albumin (BSA) and 25 mM HEPES pH 7.4, but no G418) and supplied with 40 ⁇ l of medium C.
  • BSA bovine serum albumin
  • Test compounds are dissolved in 100% DMSO and are added manually or for high throughput screens robotically ‘pin’ transferred (40 nl) to each well to give a nominal concentration of 10 ⁇ M (0.01% DMSO). After a 1 hr incubation at 37° C., DiI-HDL (final concentration of 10 ⁇ g protein/ml) in 20 ⁇ l of medium C are added.
  • fluorescence is measured at room temperature (approximately 2 minutes/plate) using a Analyst plate reader (Rhodamine B dichroic filter, emission 525 nm and excitation 580 nm; LJL Biosystems), both prior to removing the incubation medium (to test for autofluorescence and quenching) and after the medium removal and four washes with 80 ⁇ l of PBS/1 mM MgCl 2 /0.1 mM CaCl 2 to determine cellular uptake of DiI.
  • a Analyst plate reader Rhodamine B dichroic filter, emission 525 nm and excitation 580 nm; LJL Biosystems
  • each screen includes ldlA-7 and ldlA[mSR-BI] cells in the presence and/or absence of a 40-fold excess of unlabeled HDL, but with no added compounds, as controls.
  • all media and buffers contain 0.5% DMSO and 0.5% bovine serum albumin to maintain compound solubility.
  • Cells are pre-incubated with BLTs for 1 hr (or 2.5 hrs for transferrin, EGF and cholera toxin uptake experiments) and all the experiments are performed at 37° C. Detailed characterization of the respective test compound and their effects is performed.
  • values are normalized so that the 100% of control represents activity in the absence of compounds and 0% represents activity determined in the presence of a 40-fold excess of unlabeled HDL or, for Y1-BS1 cells, in the presence of a 1:500 dilution of the KKB-1 blocking antibody (Gu, et al., 2000, supra).
  • the amounts of cell-associated [ 3 H]cholesteryl ether are expressed as the equivalent amount of [ 3 H]CE-HDL protein (ng) to permit direct comparison of the relative amounts of 125 I-HDL binding and [ 3 H]CE uptake.
  • the rates of HDL dissociation from cells are determined by incubation of the cells with 125 I-HDL (10 ⁇ g protein/ml, 2 hrs, 37° C.) with and without BLTs. The medium is then either replaced with the same medium in which the 125 I-HDL is substituted by a 40-fold excess of unlabeled HDL or a 40-fold excess of unlabeled HDL is added to the labelled incubation medium. The amounts of cell-associated 125 I-HDL are then determined as a function of time. Either of these methods can be used.
  • mice Male, 6-8 weeks old were treated daily for 10 days with 200 ⁇ g/kg of the control siRNA (Negative, Ambion Inc., Texas, USA) or siRNA targeting SR-BI (ID 72593 and 152100, Ambion Inc., Texas, US). Mice were infected by intravenous injection of 2 ⁇ 10 4 P. berghei sporozoites. (see FIG. 13 )
  • C57B1/6 freshly isolated mouse primary hepatocytes (1 ⁇ 10 5 cells per well) were seeded in 700 ⁇ l of Williams E medium supplemented with 1 ⁇ glutamax (Gibco/Invitrogen), 4% fetal calf serum (Gibco/Invitrogen) and 1% penicillin/streptomycin (Gibco/Invitrogen) in 24 well plates incubated at 37° C. 5% CO 2 .
  • Huh-7 human hepatoma cells were treated as described in examples 3 and 4. Incubation with the compounds was performed at final concentrations of 1, 2, 5, and 10 ⁇ M.
  • Influence of the compounds on proliferation and infection with plasmodium sporozoites was calculated as % of the plate mean for all samples, with the mean set to 100%. To assess its performance, each compound was assigned a score between 0 and 4 for inhibition of infection. A compound would score at 4, if at all 4 tested concentrations it would reduce the number of EEFs by at least 50% (corresponding to an IC 50 of 1 ⁇ M or lower), it would score at 3, if this was true for the 3 highest concentrations (IC 50 between 1 and 2 ⁇ M), and so on. (see FIG. 16 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.

Description

  • The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for therapy of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
  • Malaria is a major health problem, mainly in Sub-Saharan Africa and in some parts of Asia and South America. Each year there are about 600 million new clinical cases and at least one million individuals, mostly children, die from malaria. This reality is even more depressing realising that a death from malaria occurs every 30 seconds. Over 90% of the deaths occur in Africa. Within the last 10 to 15 years the burden of malaria has been increasing mainly because of the emergence of Plasmodium falciparum and P. vivax variants that are resistant to cheap drugs such as chloroquine, mefloquine, and pyrimethamine. In the light of the failure of the development of a malaria vaccine, despite intensive efforts, the development of novel anti-malarial drugs is crucial.
  • Death by malaria is almost exclusively caused by P. falciparum, transmitted by the vector Anopheles gambiae, which preferentially feeds on humans. As the mosquito bites, sporozoites are injected into the skin. After finding of a blood vessel, they travel directly to the liver. Once there, they migrate through several hepatocytes before they infect a final one, surrounded by a parasitophorous vacuole where the intrahepatic form of the parasite grows and multiplies. This asymptomatic phase is known as the liver or hepatic stage of disease. During this period there is an amazing parasite multiplication (each parasite gives rise to 10-30 thousand new parasites in 2-7 days depending on the parasite species). Eventually, the infected hepatocytes burst, releasing the parasites into the bloodstream, where they will target and invade the red blood cells (RBCs). The blood or erythrocytic stage of Plasmodium's life cycle corresponds to the symptomatic phase of a malaria infection. The parasites invade and multiply within the RBCs and, upon rupturing the erythrocytic membrane, are released into the blood where they target new erythrocytes.
  • The hepatic stage of a Plasmodium infection constitutes an appealing target for the development of anti-malarial drugs since these would act before the onset of pathology. Despite the importance of such knowledge, little is known about the parasite's requirements and the strategies it developed in order to successfully invade and develop inside the liver cells.
  • Plasmodium sporozoites only develop in a very restricted type of cell, such as hepatocytes or hepatoma cell lines, strongly suggesting a crucial role of the host cell in sustaining the growth and development of this parasite.
  • To model this infection, the inventors have developed an assay monitoring infection and maturation of Plasmodium berghei ANKA, a mouse-pathogenic close relative of the human-pathogenic Plasmodium falciparum strain, in cultured human hepatoma cells.
  • This assay has also been used for the identification of new host factors required for sporozoit development by RNA interference (RNAi) screening. Surprisingly, it was found that a family of receptors termed “scavenger receptors” is required for development/proliferation of sporozoits in hepatic cells. The function of scavenger receptors B1 (ScarB1) was characterized in WO 96/00288, U.S. Pat. No. 6,359,859 and U.S. Pat. No. 6,429,289. It was reported by that ScarB1 is expressed principally in steroidogenic tissues and liver and appears to mediate HDL-transfer and uptake of cholesterol. Competitive binding studies showed that ScarB1 binds LDL, modified LDL, negatively charged phospholipid, and HDL. Direct binding studies show that ScarB1 expressed in mammalian cells (for example, a variant of CHO cells) binds HDL, without cellular degradation of the HDL-apoprotein, and lipid is accumulated within cells expressing the receptor. These studies indicated that ScarB1 might play a major role in transfer of cholesterol from peripheral tissues, via HDL, into the liver and steroidogenic tissues, and that increased or decreased expression in the liver or other tissues may be useful in regulating uptake of cholesterol by cells expressing ScarB1. Subsequent studies confirmed that ScarB1 not only binds to lipid, but also transfers cholesterol into and out of cells, (see, e.g. U.S. Pat. Nos. 5,962,322 and 5,925,333). Furthermore this receptor has been shown to affect female fertility, as described in WO 99/11288. Research on the role of scavenger family proteins, in particular on the role of ScarB1 have led to the identification of a large number of modulators of ScarB1 function (see, e.g. WO 2004/032716 A2). The function of ScarB1 first observed by the present inventors, which is entirely unrelated to the hitherto described functions of ScarB1 created the opportunity to test known inhibitors of ScarB1 function for their effect on infectious diseases, involving liver cells. It was observed that inhibitors of ScarB1 function inhibit the growth of protozoa in liver cells, thus, that inhibitors of ScarB1 can be used to treat infectious diseases involving liver cells and since the ScarB1 is expressed in erythrocytes, in hematopoietic cells, in particular malaria.
    • SUMMARY OF THE INVENTION
  • Accordingly, in a first aspect the present invention provides the use of inhibitors of a scavenger receptor class protein for the production of a medicament for the therapy of and/or prophylaxis against infections involving liver cells and/or hematopoietic cells, in particular protozoal infections, e.g. malaria.
  • In a preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein has a structure according to formula (I):
  • Figure US20090324580A1-20091231-C00001
  • wherein,
    • R1 is NR5R6;
    • R2 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R3 and R4 together form a cycloalkyl, heterocycloalkyl, cycloalkenyl or heterocycloalkenyl, optionally substituted;
    • R5 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R6 hydrogen, hydroxyl, halogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, alkynyl, alkanoyl, alkoxyalkyl; or —CO—R′; optionally substituted, preferably hydrogen, aryl or —CO—R′, wherein
      • R′ is hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; aryl; aralkyl; heteroalkyl; cycloheteroalkyl; heteroaryl; heteroaralkyl; or alkynyl;
    • and
    • Y is S or N, preferably S;
      or is a pharmaceutically acceptable salt thereof.
  • In a further preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein has a structure according to formula (XXXII):
  • Figure US20090324580A1-20091231-C00002
  • wherein,
      • R1 is NR5R6;
      • R2 is hydrogen or alkyl, optionally substituted;
      • R5 is hydrogen, alkyl or alkenyl, optionally substituted;
    • R6 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, heteroalkenyl, cycloheteroalkenyl or alkynyl, optionally substituted, preferably cycloalkyl, cycloheteroalkyl, aryl or heteroaryl; and
    • R13, R14, R15, R16, and R17 are independent of each other hydrogen, hydroxyl, halogen, SO2, NO2, CN; alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl, or NR11R12, optionally substituted;
    • R11 is hydrogen or alkyl, optionally substituted;
    • R12 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted; and
    • X is S or O;
      or is a pharmaceutically acceptable salt thereof.
  • In a further preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein has a structure according to formula (IL):
  • Figure US20090324580A1-20091231-C00003
  • wherein
    • R18 is alkyl, alkenyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, optionally substituted;
    • R19 and R20 are independently alkyl, alkenyl, aryl or heteroaryl, optionally substituted; and
    • X is O or S
      or is a pharmaceutically acceptable salt thereof.
  • In a preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein has a structure according to formula (LI):
  • Figure US20090324580A1-20091231-C00004
  • wherein
    • R21 and R22 are independent of each other aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted; and
    • R23, R24, and R25 are independent of each other hydrogen, hydroxyl, F, Cl, Br, I, CN, SO2, NO2, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein has a structure according to formula (LIII):
  • Figure US20090324580A1-20091231-C00005
  • wherein
    • R26 is hydrogen, aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted;
    • R27 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted;
    • R28 is hydrogen or alkyl, optionally substituted; and
  • R29 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted or is a pharmaceutically acceptable salt thereof.
  • In a preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein is a compound selected from Table I.
  • In a preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein is an antibody specifically binding to said scavenger receptor class protein.
  • In a preferred embodiment of the use of the present invention the inhibitor of the scavenger receptor class protein is a small interfering RNA (siRNA) capable of inhibiting expression of said scavenger receptor class protein.
  • In a preferred embodiment of the use of the present invention the scavenger receptor class protein is scavenger receptor class B 1 (ScarB1) or scavenger receptor class B 2 (ScarBII).
  • In a preferred embodiment of the use of the present invention the infectious disease is a protozoal infection.
  • In a preferred embodiment of the use of the present invention the protozoa is a member of the family of plasmodiidae.
  • In a preferred embodiment of the use of the present invention the plasmodiida is selected from the group consisting of Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi.
  • In a preferred embodiment of the use of the present invention the infectious disease is malaria.
  • In a further aspect the present invention relates to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
    • (i) contacting a cell expressing a scavenger receptor class protein with a test compound,
    • (ii) measuring cholesterol transport into or out of said cell,
    • (iii) selecting test compound, which inhibits cholesterol transport into or out of said cells,
    • (iv) contacting liver or hematopoietic cell with selected test compound prior, during or after infection of said cell with an infectious agent, and
    • (v) selecting test compound inhibiting proliferation of the infectious agent by at least 10%.
  • In a further aspect the present invention relates to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
    • (i) contacting a scavenger receptor class protein, functional variants, or soluble parts thereof with a test compound,
    • (ii) selecting a test compound, which specifically binds to ScarB1 or ScarBII,
    • (iii) contacting liver or hematopoietic cell with the selected test compound prior, during or after infection of said cell with an infectious agent, and
    • (iv) selecting a test compound inhibiting proliferation and/or development of the infectious agent by at least 10%.
  • In a further aspect the present invention relates to the use of test compound selected in step (v) of the method of the present invention for the production of a medicament for the therapy and/or prophylaxis of infectious diseases, which involve infection of liver and/or hematopoietic cells.
  • In a further aspect the present invention relates to a pharmaceutical composition comprising a compound usable according to the present invention and one or more of a compound selected from the group consisting of a chinine alkaloid, chloroquine-phosphate, hydroxychloroquinesulfate, mefloquine, proguanil, di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine and pharmaceutically acceptable additives and/or auxiliary substances.
  • In a further aspect the present invention relates to a method for the identification of molecules of pathogens, which are involved in the infection of liver and/or hematopoietic cells, comprising the following steps:
    • (i) contacting one or more scavenger receptor class proteins, functional variants, or soluble parts thereof with one or more molecules present in pathogens, which are involved in the infection of liver and/or hematopoietic cells,
    • (ii) selecting a molecule, which specifically binds to the scavenger receptor class protein.
    Definitions
  • Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
  • Preferably, the terms used herein are defined as described in “A multilingual glossary of biotechnological terms: (IUPAC Recommendations)”, Leuenberger, H. G. W, Nagel, B. and Klbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
  • Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. In the following passages different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.
  • Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
  • In the following definitions of the terms: alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alicyclic system, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, aralkenyl, aralkynyl, heteroaralkenyl, heteroaralkynyl and alkynyl are provided. These terms will in each instance of its use in the remainder of the specification have the respectively defined meaning and preferred meanings. Nevertheless in some instances of their use throughout the specification further or particular preferred meanings of these terms are indicated.
  • The term “alkyl” refers to a saturated straight or branched carbon chain. Preferably, the chain comprises from 1 to 16 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl, heptyl, or octyl. Alkyl groups are optionally substituted.
  • The term “heteroalkyl” refers to a saturated straight or branched carbon chain. Preferably, the chain comprises from 1 to 16 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms. Preferably the heteroatoms are selected from O, S, and N. A preferred heteroalkyl has the structure —(CH2)n—X—(CH2)mCH3, with n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, m=1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 and X═S, O or NR′ with R′═H or hydrocarbon, in particular —O—CH3, —OC2H5, —CH2—O—CH3, —CH2—O—C2H5, —CH2—O—C3H7, —CH2—O—C4H9, —CH2—O—C5H11, —C2H4—O—CH3, —C2H4—O—C3H7, —C2H4—O—C4H9 etc. Heteroalkyl groups are optionally substituted.
  • The terms “cycloalkyl” and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl etc. The terms “cycloalkyl” and “heterocycloalkyl” are also meant to include bicyclic, tricyclic and polycyclic versions thereof. If bicyclic, tricyclic or polycyclic rings are formed it is preferred that the respective rings are connected to each other at two adjacent carbon atoms, however, alternatively the two rings are connected via the same carbon atom, i.e. they form a spiro ring system or they form “bridged” ring systems. The term “heterocycloalkyl” preferably refers to a saturated ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N; a saturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a saturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms. “Cycloalkyl” and “heterocycloalkyl” groups are optionally substituted. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro-[3,3]-heptyl, spiro-[3,4]-octyl, spiro-[4,3]-octyl, spiro-[3,5]-nonyl, spiro-[5,3]-nonyl, spiro-[3,6]-decyl, spiro-[6,3]-decyl, spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, or adamantyl. Examples of preferred heterocycloalkyl groups include 1,2,5,6-tetrahydropyridyl, e.g. 1-(1,2,5,6-tetrahydropyridyl), 2-(1,2,5,6-tetrahydropyridyl); piperidinyl, e.g. piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl; 1,2-diazacyclohexyl, 1,2-diazacyclohex-1-yl; 1,3-diazacyclohexyl; piperazinyl, e.g. 1-piperazinyl, 2-piperazinyl, 3-piperazinyl, or 4-piperazinyl; 1-oxo-2-azacyclohexyl; 1-oxo-3-azacyclohexyl; morpholinyl, e.g. 2-morpholinyl, 3-morpholinyl, or 4-morpholinyl; 1,8 diaza-spiro-[4,5]-decyl, 1,7 diaza-spiro-[4,5]-decyl, 1,6 diaza-spiro-[4,5]-decyl, 2,8 diaza-spiro[4,5]decyl, 2,7 diaza-spiro[4,5]-decyl, 2,6 diaza-spiro[4,5]decyl, 1,8 diaza-spiro-[5,4]decyl, 1,7 diaza-spiro-[5,4]-decyl, 2,8 diaza-spiro-[5,4]-decyl, 2,7 diaza-spiro-[5,4]-decyl, 3,8 diaza-spiro-[5,4]-decyl, 3,7 diaza-spiro-[5,4]-decyl, 1,4-diazabicyclo-[2.2.2]-oct-2-yl; tetrahydrofuranyl, e.g. tetrahydrofuran-2-yl, or tetrahydrofuran-3-yl; tetrahydrothiophenyl, e.g. tetrahydrothiophen-2-yl, or tetrahydrothiophen-3-yl; or pyrrolidinyl, e.g. pyrrolidin-1-yl, pyrrolidin-2-yl, or pyrrolidin-3-yl; 2-diazacyclopentyl, e.g. 1,2-diazacyclopent-1-yl, or 1,2-diazacyclopent-3-yl; 1,3-diazacyclopentyl, e.g. 1,3-diazacyclopent-1-yl, or 1,3-diazacyclohex-2-yl; 1-oxo-2-azacyclopentyl, e.g. 1-oxo-2-azacyclopent-2-yl, 1-oxo-2-azacyclopent-3-yl, 1-oxo-2-azacyclopent-4-yl or 1-oxo-2-azacyclopent-5-yl; 1-oxo-3-azacyclopentyl, e.g. 1-oxo-3-azacyclopent-2-yl, 1-oxo-3-azacyclopent-3-yl, 1-oxo-3-azacyclopent-4-yl or 1-oxo-3-azacyclopent-5-yl; 1-thio-2-azacyclopentyl, e.g. 1-thio-2-azacyclopent-2-yl, 1-thio-2-azacyclopent-3-yl, 1-thio-2-azacyclopent-4-yl or 1-thio-2-azacyclopent-5-yl; 1-thio-3-azacyclopentyl, e.g. 1-thio-3-azacyclopent-2-yl, 1-thio-3-azacyclopent-3-yl, 1-thio-3-azacyclopent-4-yl or 1-thio-3-azacyclopent-5-yl.
  • The term “alicyclic system” refers to mono, bicyclic, tricyclic or polycyclic version of a cycloalkyl or heterocycloalkyl comprising at least one double and/or triple bond. However, an alicyclic system is not aromatic or heteroaromatic, i.e. does not have a system of conjugated double bonds/free electron pairs. Thus, the number of double and/or triple bonds maximally allowed in an alicyclic system is determined by the number of ring atoms, e.g. in a ring system with up to 5 ring atoms an alicyclic system comprises up to one double bond, in a ring system with 6 ring atoms the alicyclic system comprises up to two double bonds. Thus, the “cycloalkenyle” as defined below is a preferred embodiment of an alicyclic ring system. Alicyclic systems are optionally substituted.
  • The term “aryl” preferably refers to an aromatic monocyclic ring containing 6 carbon atoms, an aromatic bicyclic ring system containing 10 carbon atoms or an aromatic tricyclic ring system containing 14 carbon atoms. Examples are phenyl, naphthalenyl or anthracenyl. The aryl group is optionally substituted.
  • The term “aralkyl” refers to an alkyl moiety, which is substituted by aryl, wherein alkyl and aryl have the meaning as outlined above. An example is the benzyl radical. Preferably, in this context the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butenyl, tert-butyl, pentyl, hexyl, heptyl, or octyl. The aralkyl group is optionally substituted at the alkyl and/or aryl part of the group. Preferably the aryl attached to the alkyl has the meaning phenyl, naphtalenyl or anthracenyl.
  • The term “heteroaryl” preferably refers to a five or six-membered aromatic monocyclic ring wherein at least one of the carbon atoms are replaced by 1, 2, 3, or 4 (for the five membered ring) or 1, 2, 3, 4, or 5 (for the six membered ring) of the same or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 8, 9, 10, 11 or 12 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 13, 14, 15, or 16 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S. Examples are furanyl, thiophenyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 2,3-benzodiazinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, or 1,2,4-benzotriazinyl.
  • The term “heteroaralkyl” refers to an alkyl moiety, which is substituted by heteroaryl, wherein alkyl and heteroaryl have the meaning as outlined above. An example is the 2-alklypyridinyl, 3-alkylpyridinyl, or 2-methylpyridinyl. Preferably, in this context the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butenyl, tert-butyl, pentyl, hexyl, heptyl, octyl. The heteroaralkyl group is optionally substituted at the alkyl and/or heteroaryl part of the group. Preferably the heteroaryl attached to the alkyl has the meaning oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, or 1,2,4-benzotriazinyl.
  • Similarly the terms “aralkenyl”, heteroaralkenyl”, “aralkynyl” and “heteroaralkynyl” refer to an alkenyl or alkynyl moiety as defined above, which is substituted by an aryl and heteroaryl moiety, respectively, as defined above.
  • The term “alkenyl” refers to olefinic unsaturated carbon atoms containing chains with one or more double bonds. Preferably, the alkenyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethenyl, 1-propenyl, 2-propenyl, iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, iso-butenyl, sec-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, pentenyl, octenyl.
  • The term “heteroalkenyl” refers to olefinic unsaturated carbon atoms containing chains with one or more double bonds, which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms. Preferably, the chain comprises from 2 to 12 carbon atoms, e.g. the alkenyl chain comprises from 2 to 12 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 e.g. ethenyl, 1-propenyl, 2-propenyl, iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, iso-butenyl, sec-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, pentenyl, octenyl and is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms. Preferably the heteroatoms are selected from O, S, and N. Preferred examples include —(CH 2n)—X—(CmH2m−1), with n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, m=2, 3, 4, 5, 6, 7, 8, 9, or 10 and X═S, O or NR′ with R′═H or hydrocarbon, or —(CoH2o−2)—X—(CpH2p+1), with o=3, 4, 5, 6, 7, 8, 9, 10, m=1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 and X═S, O or NR′ with R′═H or hydrocarbon, in particular —OC2H3, —CH2—O—C2H3, —CH2—O—C3H5, —CH2—O—C5H9, —C2H2—O—CH3, —C2H2—O—C2H5, —C2H5—O—C2H3, —C2H2—O—C3H7, —C2H4—O—C3H5, —C2H2—O—C4H9 , —C2H4—O—C4H7 etc. heteroalkyl groups are optionally substituted.
  • The terms “cycloalkenyl” and “heterocycloalkenyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkenyl” and “heteroalkenyl”, respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. 1-cyclopropenyl, 2-cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, cyclohexenyl, cyclopentenyl, cyclooctenyl etc. The terms “cycloalkenyl” and “heterocycloalkenyl” are also meant to include bicyclic, tricyclic and polycyclic versions thereof. If bicyclic, tricyclic or polycyclic rings are formed it is preferred that the respective rings are connected to each other at two adjacent carbon atoms, however, alternatively the two rings are connected via the same carbon atom, i.e. they form a spiro ring system or they form “bridged” ring systems. The term “heterocycloalkenyl” preferably monounsaturated ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N; a mono-unsaturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a mono or diunsaturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms. Preferred examples of cycloalkenyl include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclopentenyl, and cyclooctenyl. Preferred examples of heterocycloalkenyl include 1,2,5,6-tetrahydropyridyl, e.g. 1-(1,2,5,6-tetrahydropyridyl), or 2-(1,2,5,6-tetrahydropyridyl).
  • The term “alkynyl” refers to unsaturated carbon atoms containing chains or rings with one or more triple bonds. Preferably, the alkynyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, hexynyl, pentynyl, octynyl.
  • In preferred embodiments, carbon atoms or hydrogen atoms in alkyl, cycloalkyl, aryl, aralkyl, alkenyl, cycloalkenyl, alkynyl radicals may be substituted independently from each other with one or more elements selected from the group consisting of O, S, N or with groups containing one ore more elements, i.e. 1, 2, 3, 4, 5, 6, or more selected from the group consisting of O, S, and N.
  • Embodiments include alkoxy, alkyl-alkoxy, cycloalkoxy, aralkoxy, alkenyloxy, cycloalkenyloxy, alkynyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, alkenylthio, cycloalkenylthio, alkynylthio, alkylamino, cycloalkylamino, arylamino, aralkylamino, alkenylamino, cycloalkenylamino, alkynylamino radicals.
  • Other embodiments include hydroxyalkyl, hydroxycycloalkyl, hydroxyaryl, hydroxyaralkyl, hydroxyalkenyl, hydroxycycloalkenyl, hydroxyalinyl, mercaptoalkyl, mercaptocycloalkyl, mercaptoaryl, mercaptoaralkyl, mercaptoalkenyl, mercaptocycloalkenyl, mercaptoalkynyl, aminoalkyl, aminocycloalkyl, aminoaryl, aminoaralkyl, aminoalkenyl, aminocycloalkenyl, aminoalkynyl radicals.
  • In preferred embodiment, one or more hydrogen atoms, e.g. 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms in alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkenyl, heteroalkenyl cycloalkenyl, heterocycloalkenyl alkynyl radicals may be substituted independently from each other with one ore more halogen atoms, e.g. Cl, F, or Br. One preferred radical is the trifluoromethyl radical.
  • If two or more radicals can be selected independently from each other, then the term “independently” means that the radicals may be the same or may be different.
  • The term “pharmaceutically acceptable salt” refers to a salt of the compound of the present invention. Suitable pharmaceutically acceptable salts of the compound of the present invention include acid addition salts which may, for example, be formed by mixing a solution of choline or derivative thereof with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compound of the invention carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate). Illustrative examples of pharmaceutically acceptable salts include but are not limited to: acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate/diphosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, undecanoate, valerate, and the like (see, for example, Berge, S. M., et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound of formula (I). A prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 16.5 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 0 039 051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
  • Compounds according to the invention can be synthesized by art known methods. It should be noted that the general procedures.
  • Certain compounds of the present invention can exist in unsolvated forms as well as in solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
  • The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
    • Specific Embodiments
  • Due to the surprising discovery that inhibitors of scavenger receptor class proteins, can interfere with the proliferation and/or development of infectious agents in liver cells and hematopoietic cells the invention provides in a first aspect the use of an inhibitor of a scavenger receptor class protein for the production of a medicament therapy of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria. The term “inhibitor of scavenger receptor class proteins” within the present invention refers to compounds which can inhibit high density lipoprotein (HDL) uptake mediated by scavenger receptor class proteins, in particular ScarB1. Various assays to measure HDL uptake and its inhibition are known from the prior art. WO 2004/032716 to which specific reference is herewith made with respect to the high-throughput screening for inhibitors of ScarB1 disclosed therein. A compound is considered an inhibitor of scavenger receptor class proteins, if the compound has an IC50 of <100 μM in a cholesterol transport assay preferably the one described below. Preferably the IC50 is 90 μM, 80 μM, 70 μM, 60 μM, 50 μM, 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 0.9 μM, 0.8 μM, 0.7 μM, 0.6 μM, 0.5 μM, 0.4 μM, 0.3 μM, 0.2 μM, 0.1 μM or less. Preferably, the cholesterol transport assay measures the transport of cholesterol into and/or out of a given cell, preferably a hepatic cell. The measurement comprises the transport of “free” cholesterol, high density lipoproteins (HDL) and low density lipoproteins (LDL). Infections involving liver cells and/or hematopoietic cells are diseases wherein the pathogen in one or mores stages of its life cycle in the respective host attacks and/or enters liver cells and/or hematopoietic cells in order to, e.g. proliferate, develop or evade the immune system in those cells, in particular protozoal infections.
  • Of the various inhibitors of scavenger receptor class proteins those appear to be particular effective in the treatment of liver cell or hematopoietic cell infection, which comprise a urea or thiourea moiety. Accordingly, in a preferred use of the invention the inhibitor of the scavenger receptor class protein is a compound with the following formula (I):
  • Figure US20090324580A1-20091231-C00006
  • wherein,
    • R1 is NR5R6;
    • R2 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R3 and R4 together form a cycloalkyl, heterocycloalkyl, cycloalkenyl or heterocycloalkenyl, optionally substituted;
    • R5 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R6 hydrogen, hydroxyl, halogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, alkynyl, alkanoyl, alkoxyalkyl; or —CO—R′; optionally substituted, preferably hydrogen, aryl or —CO—R′, wherein
      • R′ is hydrogen; alkyl, in particular C1-C6 alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl; alkenyl; cycloalkenyl; aryl; aralkyl; heteroalkyl; cycloheteroalkyl; heteroaryl; heteroaralkyl; or alkynyl;
    • and
    • Y is S or N, preferably S
      or a pharmaceutically acceptable salt thereof.
  • In a further preferred use of the invention the compound according to formula (I) has a structure
  • wherein,
    • R1 is NR5R6;
    • R2 is hydrogen or alkyl, optionally substituted, preferably hydrogen; and/or
    • R3 and R4 together form a (C3-10)-cycloalkyl, i.e. C3, C4, C5, C6, C7, C8, C9, or C10-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, (C6-10)-spiroalkyl, preferably spiro-[3,3]-heptyl, spiro-[3,4]-octyl, spiro-[4,3]-octyl, spiro-[3,5]-nonyl, spiro-[5,3]-nonyl, spiro-[3,6]-decyl, spiro-[6,3]-decyl, spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, or adamantyl or C3 to C10-heterocycloalkyl i.e. C3, C4, C5, C6, C7, C8, C9, or C10-cycloalkyl or (C3-10)-cycloheteroalkenyl, i.e. C3, C4, C5, C6, C7, C8, C9, or C10-cycloheteroalkenyl, preferably piperidinyl, e.g. piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl; 1,2-diazacyclohexyl, e.g. 1,2-diazacyclohex-1-yl, 1,2-diazacyclohex-2-yl or 1,2-diazacyclohex-4-yl; 1,3-diazacyclohexyl, e.g. 1,3-diazacyclohex-1-yl, 1,3-diazacyclohex-3-yl or 1,3-diazacyclohex-4-yl; piperazinyl, e.g. piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, or piperazin-4-yl; 1-oxo-2-azacyclohexyl, e.g. 1-oxo-2-azacyclohexyl-2-yl, 1-oxo-2-azacyclohexyl-3-yl, 1-oxo-2-azacyclohexyl-4-yl, 1-oxo-2-azacyclohexyl-5-yl or 1-oxo-2-azacyclohexyl-6-yl; 1-oxo-3-azacyclohexyl, e.g. 1-oxo-3-azacyclohexyl-2-yl, 1-oxo-3-azacyclohexyl-3-yl, 1-oxo-3-azacyclohexyl-4-yl, 1-oxo-3-azacyclohexyl-5-yl, 1-oxo-3-azacyclohexyl-6-yl; morpholinyl, e.g. morpholin-2-yl, morpholin-3-yl, or morpholin-4-yl; (C6-10)-spiroheteroalkyl, e.g. 1,8 diaza-spiro-[4,5]-decyl, 1,7 diaza-spiro-[4,5]-decyl, 1,6 diaza-spiro-[4,5]-decyl, 2,8 diaza-spiro[4,5]decyl, 2,7 diaza-spiro[4,5]-decyl, 2,6 diaza-spiro[4,5]decyl, 1,8 diaza-spiro-[5,4]decyl, 1,7 diaza-spiro-[5,4]-decyl, 2,8 diaza-spiro-[5,4]-decyl, 2,7 diaza-spiro-[5,4]-decyl, 3,8 diaza-spiro-[5,4]-decyl, 3,7 diaza-spiro-[5,4]-decyl, 1,4-diazabicyclo-[2.2.2]-oct-2-yl; tetrahydrofuranyl, e.g. tetrahydrofuran-2-yl, or tetrahydrofuran-3-yl; tetrahydrothiophenyl, e.g. tetrahydrothiophen-2-yl, or tetrahydrothiophen-3-yl; or pyrrolidinyl, e.g. pyrrolidin-1-yl, pyrrolidin-2-yl, or pyrrolidin-3-yl; 1,2-diazacyclopentyl, e.g. 1,2-diazacyclopent-1-yl, or 1,2-diazacyclopent-3-yl; 1,3-diazacyclopentyl, e.g. 1,3-diazacyclopent-1-yl, or 1,3-diazacyclohex-2-yl; 1-oxo-2-azacyclopentyl, e.g. 1-oxo-2-azacyclopent-2-yl, 1-oxo-2-azacyclopent-3-yl, 1-oxo-2-azacyclopent-4-yl or 1-oxo-2-azacyclopent-5-yl; 1-oxo-3-azacyclopentyl, e.g. 1-oxo-3-azacyclopent-2-yl, 1-oxo-3-azacyclopent-3-yl, 1-oxo-3-azacyclopent-4-yl or 1-oxo-3-azacyclopent-5-yl; 1-thio-2-azacyclopentyl, e.g. 1-thio-2-azacyclopent-2-yl, 1-thio-2-azacyclopent-3-yl, 1-thio-2-azacyclopent-4-yl or 1-thio-2-azacyclopent-5-yl; 1-thio-3-azacyclopentyl, e.g. 1-thio-3-azacyclopent-2-yl, 1-thio-3-azacyclopent-3-yl, 1-thio-3-azacyclopent-4-yl or 1-thio-3-azacyclopent-5-yl; optionally substituted; and/or
    • R5 is hydrogen or alkyl, optionally substituted, preferably hydrogen; and/or
    • R6 is hydrogen, hydroxyl; halogen, F, Cl, Br or I; CN; NO2; alkyl, in particular (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, heteroalkyl in particular (C1-C6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6 heteroalkyl, cycloheteroalkyl, in partiucluar (C3-10)-cycloheteroalkyl; aryl, in particular phenyl, naphtalenyl or anthracenyl; aralkyl; heteroaryl, preferably oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, 1,2,4-benzotriazinyl; heteroaralkyl; alkenyl, in particular C2-C6 alkenyl, e.g. C2, C3, C4, C5, or C6 alkenyl, preferably ethenyl, 1-propenyl, 2-propenyl, 1-iso-propenyl, 2-iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl; cycloalkenyl, in particular (C3-10)-cycloalkyl; or alkynyl, in particular C2-C6 alkynyl, e.g. C2, C3, C4, C5, or C6 alkynyl; alkanoyl, preferably C1-C6 alkanoyl, e.g. C1, C2, C3, C4, C5, or C6 alkanoyl; alkenoyl, in particular C3-C6 alkenoyl, e.g. C3, C4, C5, or C6 alkenoyl, preferably propenoyl; alkynoyl, in particular C3-C6 alkynoyl, e.g. C3, C4, C5, or C6 alkynoyl, preferably propynoyl; alkoxy, in particular C1-C6 alkoxy, e.g. C1, C2, C3, C4, C5, or C6 alkoxy, preferably methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, tert-butoxy, pentoxy, or hexoxy; alkoxyalkyl, in particular C1-C6 alkoxy-C1-C6 alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, methoxypropyl, ethoxypropyl, or propoxypropyl; or —CO—R′; optionally substituted, preferably hydrogen, —CO—R′ or aryl; wherein
      • R′ is hydrogen; alkyl, in particular C1-C6 alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl; alkenyl; cycloalkenyl; aryl; aralkyl; heteroalkyl; cycloheteroalkyl; heteroaryl; heteroaralkyl; or alkynyl.
  • If R3 and R4 form a (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, (C6-10)-spiroalkyl, preferably spiro-[3,3]-heptyl, spiro-[3,4]-octyl, spiro-[4,3]-octyl, spiro-[3,5]-nonyl, spiro-[5,3]-nonyl, spiro-[3,6]-decyl, spiro-[6,3]-decyl, spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, or adamantyl or C3 to C10-heterocycloalkyl preferably piperidinyl, e.g. piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl; 1,2-diazacyclohexyl, e.g. 1,2-diazacyclohex-1-yl, 1,2-diazacyclohex-2-yl or 1,2-diazacyclohex-4-yl; 1,3-diazacyclohexyl, e.g. 1,3-diazacyclohex-1-yl, 1,3-diazacyclohex-3-yl or 1,3-diazacyclohex-4-yl; piperazinyl, e.g. piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, or piperazin-4-yl; 1-oxo-2-azacyclohexyl, e.g. 1-oxo-2-azacyclohexyl-2-yl, 1-oxo-2-azacyclohexyl-3-yl, 1-oxo-2-azacyclohexyl-4-yl, 1-oxo-2-azacyclohexyl-5-yl or 1-oxo-2-azacyclohexyl-6-yl; 1-oxo-3-azacyclohexyl, e.g. 1-oxo-3-azacyclohexyl-2-yl, 1-oxo-3-azacyclohexyl-3-yl, 1-oxo-3-azacyclohexyl-4-yl, 1-oxo-3-azacyclohexyl-5-yl, 1-oxo-3-azacyclohexyl-6-yl; morpholinyl, e.g. morpholin-2-yl, morpholin-3-yl, or morpholin-4-yl; (C6-10)-spiroheteroalkyl, e.g. 1,8 diaza-spiro-[4,5]-decyl, 1,7 diaza-spiro-[4,5]-decyl, 1,6 diaza-spiro-[4,5]-decyl, 2,8 diaza-spiro[4,5]decyl, 2,7 diaza-spiro[4,5]-decyl, 2,6 diaza-spiro[4,5]decyl, 1,8 diaza-spiro-[5,4]decyl, 1,7 diaza-spiro-[5,4]-decyl, 2,8 diaza-spiro-[5,4]-decyl, 2,7 diaza-spiro-[5,4]-decyl, 3,8 diaza-spiro-[5,4]-decyl, 3,7 diaza-spiro-[5,4]-decyl, 1,4-diazabicyclo-[2.2.2]-oct-2-yl; tetrahydrofuranyl, e.g. tetrahydrofuran-2-yl, or tetrahydrofuran-3-yl; tetrahydrothiophenyl, e.g. tetrahydrothiophen-2-yl, or tetrahydrothiophen-3-yl; or pyrrolidinyl, e.g. pyrrolidin-1-yl, pyrrolidin-2-yl, or pyrrolidin-3-yl; 1,2-diazacyclopentyl, e.g. 1,2-diazacyclopent-1-yl, or 1,2-diazacyclopent-3-yl; 1,3-diazacyclopentyl, e.g. 1,3-diazacyclopent-1-yl, or 1,3-diazacyclohex-2-yl; 1-oxo-2-azacyclopentyl, e.g. 1-oxo-2-azacyclopent-2-yl, 1-oxo-2-azacyclopent-3-yl, 1-oxo-2-azacyclopent-4-yl or 1-oxo-2-azacyclopent-5-yl; 1-oxo-3-azacyclopentyl, e.g. 1-oxo-3-azacyclopent-2-yl, 1-oxo-3-azacyclopent-3-yl, 1-oxo-3-azacyclopent-4-yl or 1-oxo-3-azacyclopent-5-yl; 1-thio-2-azacyclopentyl, e.g. 1-thio-2-azacyclopent-2-yl, 1-thio-2-azacyclopent-3-yl, 1-thio-2-azacyclopent-4-yl or 1-thio-2-azacyclopent-5-yl; 1-thio-3-azacyclopentyl, e.g. 1-thio-3-azacyclopent-2-yl, 1-thio-3-azacyclopent-3-yl, 1-thio-3-azacyclopent-4-yl or 1-thio-3-azacyclopent-5-yl; it is preferred that the C3-10-cycloalkyl or C3-10-cycloheteroalkyl is substituted with one, two, three or more substituents selected from the group consisting of hydrogen, hydroxyl, halogen, oxo, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl and/or two adjacent substituents are taken together to form an aryl or heteroaryl, preferably oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuiranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, 1,2,4-benzotriazinyl, phenyl, naphtalenyl or antracenyl; optionally substituted. It is particularly preferred that one substituent is located in cis to the imin bound to the ring system. It is preferred that one substituent is oxo, alkyl, or heteroalkyl. A preferred ring system is 1-thio-3-azacyclopentyl, preferably 1-thio-3-azacyclopent-2-yl, 3-alkyl-(1-thio-3-azacyclopentyl) or 3-alkyl-(1-thio-3-azacyclopent-2yl) and pyrrolidinyl, preferably pyrrolidin-3-yl, or 2-oxo-pyrrolidin-3-yl.
  • In a preferred use of the invention the compound according to formula (I) has a structure according to formula (II)
  • Figure US20090324580A1-20091231-C00007
  • wherein,
    • R1 is NR5R6;
    • R2 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R5 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R6 hydrogen, hydroxyl, halogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, alkynyl, alkanoyl, alkoxyalkyl; or —CO—R′; optionally substituted, preferably hydrogen, aryl or —CO—R′, wherein
      • R′ is hydrogen, alkyl, in particular C1-C6 alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, alkenyl, cycloalkenyl, or alkynyl;
    • R7, R8, R9, and R10 are each independent of each other selected from the group consisting of hydrogen, hydroxyl, halogen, oxo, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, heteroaralkynyl, or NR11R12, optionally substituted and/or one or both of R7 and R8 or R9 and R10 are taken together to form an aryl or heteroaryl, optionally substituted; and
    • R11 is hydrogen or alkyl, optionally substituted;
    • R12 hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted;
    • X is not present, is CH2, C2H4, N, S or O; and
    • Y is S or N, preferably S;
      or a pharmaceutically acceptable salt thereof. It is preferred that R7 and/or R8 are non-polar side chains.
  • It is preferred that in a compound according to formula (II)
    • R6 is hydrogen, hydroxyl; halogen, F, Cl, Br or I; CN; NO2; alkyl, in particular (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, heteroalkyl in particular (C1-C6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6 heteroalkyl, cycloheteroalkyl, in partiucluar (C3-10)-cycloheteroalkyl; aryl, in particular phenyl, naphtalenyl or anthracenyl; aralkyl; heteroaryl, preferably oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, 1,2,4-benzotriazinyl; heteroaralkyl; alkenyl, in particular C2-C6 alkenyl, e.g. C2, C3, C4, C5, or C6 alkenyl, preferably ethenyl, 1-propenyl, 2-propenyl, 1-iso-propenyl, 2-iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl; cycloalkenyl, in particular (C3-10)-cycloalkyl; or alkynyl, in particular C2-C6 alkynyl, e.g. C2, C3, C4, C5, or C6 alkynyl; alkanoyl, preferably C1-C6 alkanoyl, e.g. C1, C2, C3, C4, C5, or C6 alkanoyl; alkenoyl, in particular C3-C6 alkenoyl, e.g. C3, C4, C5, or C6 alkenoyl, preferably propenoyl; alkynoyl, in particular C3-C6 alkynoyl, e.g. C3, C4, C5, or C6 alkynoyl, preferably propynoyl; alkoxy, in particular C1-C6 alkoxy, e.g. C1, C2, C3, C4, C5, or C6 alkoxy, preferably methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, tert-butoxy, pentoxy, or hexoxy; alkoxyalkyl, in particular C1-C6 alkoxy-C1-C6 alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, methoxypropyl, ethoxypropyl, or propoxypropyl; and —CO—R′″; optionally substituted, preferably hydrogen, —CO—R′ or aryl; wherein
      • R′ is hydrogen, alkyl, in particular C1-C6 alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, alkenyl, cycloalkenyl; or alkynyl;
    • and/or
    • R7 is (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl, n-heptyl, n-octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy-(C1-6)alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, methoxyethyl, ethoxyethyl, propoxyethy, butoxyethyl, pentoxyethyl, hexoxyethyl, methoxypropyl, ethoxypropyl, propoxypropyl, butoxypropyl, pentoxypropyl, hexoxypropyl, methoxybutyl, ethoxybutyl, propoxybutyl, butoxybutyl, pentoxybutyl, hexoxybutyl, methoxypentyl, ethoxypentyl, propoxypentyl, butoxypentyl, pentoxypentyl, hexoxypentyl, methoxyhexyl, ethoxyhexyl, propoxyhexyl, butoxyhexyl, pentoxyhexyl, hexoxyhexyl; (C1-6)aralkyl, e.g. C1, C2, C3, C4, C5 or C6-aralkyl, wherein the aryl residue is preferably selected from phenyl or naphthalenyl; or (C1-6)heteroaralkyl, e.g. C1, C2, C3, C4, C5 or C6-heteroaralkyl, wherein the heteroaryl residue is preferably selected from the group consisting of oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, 1,2,4-benzotriazinyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl; cycloalkenyl, in particular (C3-10)-cycloalkenyl; heterocycloalkyl, in particular (C3-10)-hetercycloalkenyl; or oxo; optionally substituted; preferably R7 is a non-polar side chain;
    • R8, R9 and R10 are independent of each other selected from the group consisting of hydrogen, Cl, Br, F, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl; (C2-6)alkenyl e.g. C2, C3, C4, C5 or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy; (C1-6)alkyl-(C1-6)alkoxy; (C1-6)aralkyl; (C1-6)heteroaralkyl.
  • In above preferred embodiment of R7 the respective substituent is preferably substituted with hydroxyl; halogen, F, Cl, Br or I; CN; NO2; alkyl, in particular (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl, preferably methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, heteroalkyl in particular (C1-C6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6 heteroalkyl, cycloheteroalkyl, in partiucluar (C3-10)-cycloheteroalkyl; aryl, in particular phenyl, naphtalenyl or anthracenyl; aralkyl; heteroaryl, preferably oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, 1,2,4-benzotriazinyl; heteroaralkyl; alkenyl, in particular C2-C6 alkenyl, e.g. C2, C3, C4, C5, or C6 alkenyl, preferably ethenyl, 1-propenyl, 2-propenyl, 1-iso-propenyl, 2-iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl; cycloalkenyl, in particular (C3-10)-cycloalkyl; or alkynyl, in particular C2-C6 alkynyl, e.g. C2, C3, C4, C5, or C6 alkynyl; alkanoyl, preferably C1-C6 alkanoyl, e.g. C1, C2, C3, C4, C5, or C6 alkanoyl; alkenoyl, in particular C3-C6 alkenoyl, e.g. C3, C4, C5, or C6 alkenoyl, preferably propenoyl; alkynoyl, in particular C3-C6 alkynoyl, e.g. C3, C4, C5, or C6 alkynoyl, preferably propynoyl; alkoxy, in particular C1-C6 alkoxy, e.g. C1, C2, C3, C4, C5, or C6 alkoxy, preferably methoxy, ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, tert-butoxy, pentoxy, or hexoxy; alkoxyalkyl, in particular C1-C6 alkoxy-C1-C6 alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, methoxypropyl, ethoxypropyl, or propoxypropyl; and —CO—R′″; optionally substituted, preferably hydrogen, —CO—R″ or aryl;
      • wherein
      • R″ is hydrogen, alkyl, in particular C1-C6 alkyl, e.g. C1, C2, C3, C4, C5, or C6 alkyl; cycloalkyl, in particular (C3-10)-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, alkenyl, cycloalkenyl; or alkynyl.
  • In a preferred embodiment the compound of formula (I) has the structure according to formula (III):
  • Figure US20090324580A1-20091231-C00008
  • wherein,
    • R1 is NR5R6;
    • R2 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R5 is hydrogen or alkyl, optionally substituted, preferably hydrogen;
    • R6 hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted, preferably hydrogen; and
    • R7 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl, or NR11R12, optionally substituted, preferably R7 is alkyl or alkyl interrupted one or more times by O, S, or N;
    • R8, R9 and R10 are independent of each other hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted, preferably hydrogen;
    • R11 is hydrogen or alkyl, optionally substituted;
    • R12 hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted; and
    • Y is S or N, preferably S;
      or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+. It is preferred that R7 is a non-polar side chain.
  • In a preferred use of the embodiment of the invention wherein the compound has a structure according to formula (II) or (III)
    • R7 is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular methyl, ethyl, propyl, butyl, pentyl hexyl, heptyl, or octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, or octenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkyl-(C1-6)alkoxy; amino, optionally mono- or disubstituted by (C1-6) alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl; and/or
    • R8, R9, and R10 are each independent of each other substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; and/or
    • R2, R5, R6, R11 and R12 are each independent of each other substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy.
  • In a preferred use of this embodiment of the invention wherein the compound has a structure according to formula (II) or (III)
    • R2 is hydrogen or (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl;
    • R5 is hydrogen;
  • R6 is hydrogen, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl or (C2-6)alkenyl;
    • R7 is (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl, n-heptyl, n-octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy-(C1-6)alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, methoxyethyl, ethoxyethyl, propoxyethy, butoxyethyl, pentoxyethyl, hexoxyethyl, methoxypropyl, ethoxypropyl, propoxypropyl, butoxypropyl, pentoxypropyl, hexoxypropyl, methoxybutyl, ethoxybutyl, propoxybutyl, butoxybutyl, pentoxybutyl, hexoxybutyl, methoxypentyl, ethoxypentyl, propoxypentyl, butoxypentyl, pentoxypentyl, hexoxypentyl, methoxyhexyl, ethoxyhexyl, propoxyhexyl, butoxyhexyl, pentoxyhexyl, hexoxyhexyl; (C1-6)aralkyl, e.g. C1, C2, C3, C4, C5 or C6-aralkyl; or (C1-6)heteroaralkyl, e.g. C1, C2, C3, C4, C5 or C6-heteroaralkyl, preferably R7is a non-polar side chain;
    • R8, R9 and R10 are independent of each other selected from the group consisting of hydrogen, Cl, Br, F, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl; (C2-6)alkenyl e.g. C2, C3, C4, C5 or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy; (C1-6)alkyl-(C1-6)alkoxy; (C1-6)aralkyl; (C1-6)heteroaralkyl.
  • In a preferred use of the invention the compound according to formula (III) has a structure selected from the structures according to formulas (IV) to (VII)
  • Figure US20090324580A1-20091231-C00009
  • or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred embodiment of the use of the present invention wherein the compound has a structure according to formula (II) one, two or three of R7, R8, R9, and R10 are each independent of each other selected from the group consisting of (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl, n-heptyl, n-octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; oxo; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy-(C1-6)alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, methoxyethyl, ethoxyethyl, propoxyethy, butoxyethyl, pentoxyethyl, hexoxyethyl, methoxypropyl, ethoxypropyl, propoxypropyl, butoxypropyl, pentoxypropyl, hexoxypropyl, methoxybutyl, ethoxybutyl, propoxybutyl, butoxybutyl, pentoxybutyl, hexoxybutyl, methoxypentyl, ethoxypentyl, propoxypentyl, butoxypentyl, pentoxypentyl, hexoxypentyl, methoxyhexyl, ethoxyhexyl, propoxyhexyl, butoxyhexyl, pentoxyhexyl, hexoxyhexyl; (C1-6)aralkyl, e.g. C1, C2, C3, C4, C5 or C6-aralkyl; or (C1-6)heteroaralkyl, e.g. C1, C2, C3, C4, C5 or C6-heteroaralkyl, optionally substituted. The other substituent(s) in this case are preferably hydrogen.
  • In a preferred embodiment of the use of the present invention wherein the compound has a structure according to formula (II) one or both of R7 and R8 or R9 and R10, preferably R9 and R10, together form an oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3,-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indolyl, isoindolyl, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzisoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, 2,3-benzodiazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, 1,2,4-benzotriazinyl, phenyl, naphtalenyl or antracenyl, optionally substituted. The other substituents R7 and R8 or R9 and R10 as the case may be, are each independent of each other selected from the group consisting of hydrogen, (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl, n-heptyl, n-octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; oxo; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy-(C1-6)alkyl, e.g. methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, methoxyethyl, ethoxyethyl, propoxyethy, butoxyethyl, pentoxyethyl, hexoxyethyl, methoxypropyl, ethoxypropyl, propoxypropyl, butoxypropyl, pentoxypropyl, hexoxypropyl, methoxybutyl, ethoxybutyl, propoxybutyl, butoxybutyl, pentoxybutyl, hexoxybutyl, methoxypentyl, ethoxypentyl, propoxypentyl, butoxypentyl, pentoxypentyl, hexoxypentyl, methoxyhexyl, ethoxyhexyl, propoxyhexyl, butoxyhexyl, pentoxyhexyl, hexoxyhexyl; (C1-6)aralkyl, e.g. C1, C2, C3, C4, C5 or C6-aralkyl; or (C1-6)heteroaralkyl, e.g. C1, C2, C3, C4, C5 or C6-heteroaralkyl, optionally substituted.
  • In a preferred use of the invention the compound according to formula (II) has a structure selected from the structures according to formulas (VIII) to (XXXI)
  • Figure US20090324580A1-20091231-C00010
    Figure US20090324580A1-20091231-C00011
    Figure US20090324580A1-20091231-C00012
    Figure US20090324580A1-20091231-C00013
  • optionally substituted or a pharmaceutically acceptable salt thereof.
  • In a preferred embodiment the compound usable according to the present invention having a structure according to formula (VI) to (XXXI) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO2; NO2; CN; (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular methyl, ethyl, propyl, butyl, pentyl hexyl, heptyl, or octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, or octenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkyl-(C1-6)alkoxy; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl; (C2-6)alkenylsulphonyl; and NR11R12; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted;
      • wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl; halogen; alkyl, preferably (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; heteroalkyl, preferably (C1-6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroalkyl, wherein preferably one or two carbon atoms are replaced by a heteroatom selected from the group consisting of N, S, and O; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl, preferably (C2-6)alkenyl, (C2-6)alkenyloxy, cycloalkenyl, (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted.
  • In a preferred use of the invention the inhibitor of the scavenger receptor class protein is a compound having a structure according to the following formula (XXXII):
  • Figure US20090324580A1-20091231-C00014
  • wherein,
    • R1 is NR5R6;
    • R2 is hydrogen or alkyl, optionally substituted;
    • R5 is hydrogen, alkyl or alkenyl, optionally substituted;
    • R6 is hydrogen; hydroxyl; halogen; alkyl, preferably (C1-8)alkyl, e.g. C1, C2, C3, C4, C5, C6, C7 or C8-alkyl; heteroalkyl, preferably (C1-8)heteroalkyl, e.g. C1, C2, C3, C4, C5, C6, C7 or C8-alkyl; cycloalkyl, preferably (C3-10)-cycloalkyl, e.g. C1, C2, C3, C4, C5, C6, C7, C8, C9, or C10; cycloheteroalkyl, preferably (C3-10)-cycloheteroalkyl, e.g. C1, C2, C3, C4, C5, C6, C7, C8, C9, or C10, wherein preferably one or two carbon atoms are substituted by heteroatoms, preferably selected from the group consisting of S, N, and O; aralkyl, preferably (C1-6)-aralkyl, e.g. C1, C2, C3, C4, C5, or C6-aralkyl; heteroaryl, preferably mono or bicyclic heteroaryl, preferably comprising one, two or three heteroatoms selected from the group consisting of S, N, and O; heteroaralkyl, preferably (C1-6)-heteroaralkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroaralkyl, wherein the heteroaryl preferably is a mono or bicyclic heteroaryl, preferably comprising one, two or three heteroatoms selected from the group consisting of S, N, and O; alkenyl, preferably (C2-6)-alkenyl e.g. C2, C3, C4, C5, or C6-alkenyl, preferably ethenyl, 1-propenyl, 2-propenyl, 1-iso-propenyl, 2-iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl; cycloalkenyl, preferably C3-10-cycloalkenyl, e.g. C1, C2, C3, C4, C5, C6, C7, C8, C9, or C10-cycloalkenyl; cycloheteroalkenyl, preferably (C3-10)-cycloheteroalkenyl, e.g. C1, C2, C3, C4, C5, C6, C7, C8, C9, or C10-cycloheteroalkenyl; or alkynyl, preferably (C2-6)-alkynyl e.g. C2, C3, C4, C5, or C6-alkynyl; optionally substituted, preferably cycloalkyl, cycloheteroalykl, aryl or heteroaryl;
    • R13, R14, R15, R16, and R17 are independent of each other hydrogen, hydroxyl, halogen, SO2, NO2, CN; alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl, or NR11R12, optionally substituted;
    • R11 is hydrogen or alkyl, optionally substituted;
    • R12 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted; and
    • X is S or O;
      or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred embodiment of the use of the present invention the compound has a structure according to formula (XXXII) wherein
    • R2 and R5 are independent of each other substituted preferably 1 to 3 time with a radical selected from the group consisting of halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; and/or
    • R6 is substituted preferably 1 to 3 time with a radical selected from the group consisting of halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy-(C1-6)alkyl; NR11′R12′; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted; wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl;
      • halogen; alkyl, preferably (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; heteroalkyl, preferably (C1-6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroalkyl, wherein preferably one or two carbon atoms are replaced by a heteroatom selected from the group consisting of N, S, and O; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl, preferably (C2-6)alkenyl, (C2-6)alkenyloxy, cycloalkenyl, (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted; and/or
    • R13, R14, R15, R16, and R17 are independent of each other substituted preferably 1 to 3 time with a radical selected from the group consisting of halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, e.g. C1, C2, C3, C4, C5 or C6-alkoxy, in particular methoxy, ethoxy, propxy, butoxy, pentoxy, hexoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl.
  • In a preferred embodiment of the use of the present invention the compound has a structure according to formula (XXXII) wherein
    • R2 is hydrogen or (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl; and/or
    • R5 is hydrogen, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; and/or
    • R6 is phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3,-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; 1,2,4-benzotriazinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; spiro-[3,3]-heptyl; spiro-[3,4]-octyl; spiro-[4,3]-octyl; spiro-[3,5]-nonyl; spiro-[5,3]-nonyl; spiro-[3,6]-decyl; spiro-[6,3]-decyl; spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, adamantyl, piperidinyl; 1,2-diazacyclohexyl; 1,3-diazacyclohexyl; piperazinyl; 1-oxo-2-azacyclohexyl; 1-oxo-3-azacyclohexyl; 1,8-diaza-spiro-[4,5]-decyl; 1,7-diaza-spiro-[4,5]-decyl; 1,6-diaza-spiro-[4,5]-decyl; 2,8-diaza-spiro[4,5]decyl; 2,7-diaza-spiro[4,5]-decyl; 2,6-diaza-spiro[4,5]decyl; 1,8-diaza-spiro-[5,4]decyl; 1,7-diaza-spiro-[5,4]-decyl; 2,8-diaza-spiro-[5,4]-decyl; 2,7-diaza-spiro-[5,4]-decyl; 3,8-diaza-spiro-[5,4]-decyl; 3,7-diaza-spiro-[5,4]-decyl; 1,4-diazabicyclo-[2.2.2]-oct-2-yl morpholinyl; tetrahydrofuranyl; tetrahydrothiophenyl; pyrrolidinyl; (C1-6)aralkyl; (C1-C6)heteroaralkyl; (C1-6)alkyl or (C2-6)alkenyl; optionally substituted; and/or
    • R13 is (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkoxy(C1-6)alkyl; (C1-6)aralkyl; or (C1-6)heteroaralkyl; and/or
    • R13, R14, R15, R16, and R17 are independent of each other selected from the group consisting of hydrogen, halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy(C1-6)alkyl; (C1-6)aralkyl; (C1-6)heteroaralkyl.
  • In a preferred embodiment of the use of the present invention the compound has a structure according to formula (XXXII) wherein
    • R2 is hydrogen or (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl;
    • R5 is hydrogen, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl;
    • R6 is phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3,-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; 1,2,4-benzotriazinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; spiro-[3,3]-heptyl; spiro-[3,4]-octyl; spiro-[4,3]-octyl; spiro-[3,5]-nonyl; spiro-[5,3]-nonyl; spiro-[3,6]-decyl; spiro-[6,3]-decyl; spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, adamantyl, piperidinyl; 1,2-diazacyclohexyl; 1,3-diazacyclohexyl; piperazinyl; 1-oxo-2-azacyclohexyl; 1-oxo-3-azacyclohexyl; 1,8-diaza-spiro-[4,5]-decyl; 1,7-diaza-spiro-[4,5]-decyl; 1,6-diaza-spiro-[4,5]-decyl; 2,8-diaza-spiro[4,5]decyl; 2,7-diaza-spiro[4,5]-decyl; 2,6-diaza-spiro[4,5]decyl; 1,8-diaza-spiro-[5,4]decyl; 1,7-diaza-spiro-[5,4]-decyl; 2,8-diaza-spiro-[5,4]-decyl; 2,7-diaza-spiro-[5,4]-decyl; 3,8-diaza-spiro-[5,4]-decyl; 3,7-diaza-spiro-[5,4]-decyl; 1,4-diazabicyclo-[2.2.2]-oct-2-yl morpholinyl; tetrahydrofuranyl; tetrahydrothiophenyl; pyrrolidinyl; (C1-6)aralkyl; (C1-C6)heteroaralkyl; (C1-6)alkyl or (C2-6)alkenyl; optionally substituted and
    • R13, R14, R15, R16, and R17 are independent of each other selected from the group consisting of hydrogen, halogen, e.g. F, Cl, Br; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkoxy(C1-6)alkyl; (C1-6)aralkyl; (C1-6)heteroaralkyl.
  • In a further preferred embodiment R6 is mono or disubstituted aryl or heteroaryl, preferably phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl. In this preferred embodiment the one or two substituents are preferably independently selected from the group consisting of F, Cl, Br, (C1-6)alkoxy, e.g. C1, C2, C3, C4, C5 or C6-alkoxy, in particular methoxy, ethoxy, propxy, butoxy, pentoxy, hexoxy, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, or iso-hexyl and NR11′R12′, wherein R11′R12′, wherein R11′R12′ are independent of each other selected from hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted.
  • Preferably R6 is phenyl substituted with one or two (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, or iso-hexyl and/or one or two NR11′R12′, wherein R11′R12′, wherein R11′R12′ are independent of each other selected from hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl.
  • In a preferred use of the invention the compound according to formula (XXXII) has a structure according to formula (XXXIII) to (XLVIII):
  • Figure US20090324580A1-20091231-C00015
    Figure US20090324580A1-20091231-C00016
    Figure US20090324580A1-20091231-C00017
    Figure US20090324580A1-20091231-C00018
  • optionally substituted or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred embodiment the compound usable according to the present invention having a structure according to formula (XXXIII) to (XLVIII) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO2; NO2; CN; (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular methyl, ethyl, propyl, butyl, pentyl hexyl, heptyl, or octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, or octenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkyl-(C1-6)alkoxy; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl; (C2-6)alkenylsulphonyl; and NR11′R12′; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted;
      • wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl; halogen; alkyl, preferably (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; heteroalkyl, preferably (C1-6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroalkyl, wherein preferably one or two carbon atoms are replaced by a heteroatom selected from the group consisting of N, S, and O; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl, preferably (C2-6)alkenyl, (C2-6)alkenyloxy, cycloalkenyl, (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted.
  • In a preferred use of the invention the inhibitor of the scavenger receptor class protein is a compound with the following formula (IL):
  • Figure US20090324580A1-20091231-C00019
  • wherein,
    • R18 is alkyl, alkenyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, optionally substituted;
    • R19 and R20 are independently alkyl, alkenyl, aryl or heteroaryl, optionally substituted; and
    • X is O or S
      or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred use of the invention
    • R18 is substituted preferably 1 to 3 time with a radical selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl; (C2-6)alkenyl; (C1-6)alkoxy; in particular methoxy, (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl; and/or
    • R19 and R20 are independently substituted preferably 1 to 3 time with a radical selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 or C6-alkyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, n-hexyl, iso-hexyl; (C2-6)alkenyl; (C2-6)alkenyl; (C1-6)alkoxy, e.g. C1, C2, C3, C4, C5 or C6-alkoxy, in particular methoxy, ethoxy, propxy, butoxy, pentoxy, hexoxy;
  • In a preferred use of the invention
    • R18 is (C1-6)aralkyl, in particular (C1-6)phenylalkyl, e.g. C1, C2, C3, C4, C5, or C6-phenylalkyl, more particularly phenylmethyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl; (C1-6)heteroaralkyl, phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl; and/or
    • R19 and R20 are independently phenyl, naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl.
  • In a preferred embodiment R18 is aralkyl, in particular phenylmethyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl wherein both the alkyl and the aryl, in particular the phenyl radical are substituted one or more times with a substituent independently selected from the group consisting of F, Cl, Br, hydroxyl. In this context it is preferred that X is O.
  • In a preferred use of the invention the compound according to formula (IL) has a structure according to formula (L):
  • Figure US20090324580A1-20091231-C00020
  • optionally substituted or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+ and Ca2+.
  • In a preferred embodiment the compound usable according to the present invention having a structure according to formula (L) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO2; NO2; CN; (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular methyl, ethyl, propyl, butyl, pentyl hexyl, heptyl, or octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, or octenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkyl-(C1-6)alkoxy; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl; (C2-6)alkenylsulphonyl; and NR11′R12′; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted;
      • wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl; halogen; alkyl, preferably (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; heteroalkyl, preferably (C1-6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroalkyl, wherein preferably one or two carbon atoms are replaced by a heteroatom selected from the group consisting of N, S, and O; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl, preferably (C2-6)alkenyl, (C2-6)alkenyloxy, cycloalkenyl, (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted.
  • In a preferred use of the invention the inhibitor of the scavenger receptor class protein has a structure according to formula (LI):
  • Figure US20090324580A1-20091231-C00021
  • wherein,
    • R21 and R22 are independent of each other aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted; and
    • R23, R24, and R25 are independent of each other hydrogen, hydroxyl, F, Cl, Br, I, CN, SO2, NO2, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted, preferably hydrogen.
  • In a preferred use of the invention
    • R21 and R22 are independent of each other substituted preferably with 1 to 3 radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, (C1-6)alkoxy-(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; and/or
    • R23, R24, and R25 are independent of each substituted preferably with 1 to 3 radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy
      or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred use of the invention R21 and R22 are independent of each other phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl. If R21 and R22 have this preferred meaning it is preferred that R23, R24, and R25 are independent of each other hydrogen, hydroxyl, F, Cl, Br, I, CN, SO2, NO2, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted, preferably hydrogen.
  • In a preferred use of the invention the compound according to formula (LI) has a structure according to formula (LII):
  • Figure US20090324580A1-20091231-C00022
  • In a preferred embodiment the compound usable according to the present invention having a structure according to formula (LII) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular methyl, ethyl, propyl, butyl, pentyl hexyl, heptyl, or octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, or octenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkyl-(C1-6)alkoxy; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl; (C2-6)alkenylsulphonyl; and NR11′R12′; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted;
      • wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl; halogen; alkyl, preferably (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; heteroalkyl, preferably (C1-6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroalkyl, wherein preferably one or two carbon atoms are replaced by a heteroatom selected from the group consisting of N, S, and O; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl, preferably (C2-6)alkenyl, (C2-6)alkenyloxy, cycloalkenyl, (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted.
  • In a preferred use of the invention the inhibitor of the scavenger receptor class protein has a structure according to formula (LIII):
  • Figure US20090324580A1-20091231-C00023
  • In a preferred use of the invention
    • R26 is hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted;
    • R27 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted;
    • R28 is hydrogen or alkyl, optionally substituted; and
    • R29 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted
      or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred use of the invention
    • R27 and R29 are independent of each other substituted preferably with one to three radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C2-6)alkenyloxy, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; and/or
    • R26 and R28 are independent of each other substituted preferably with one to three radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy.
  • In a preferred use of the invention
    • R27 and R29 are independent of each other phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl; and/or
    • R26 and R28 are independent of each other hydrogen, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)aralkyl or (C1-6)heteroaralkyl.
  • In a preferred use of the invention
    • R27 and R29 are independent of each other phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl; and
    • R26 and R28 are independent of each other hydrogen, (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)aralkyl or (C1-6)heteroaralkyl.
  • It is particularly preferred that both R27 and R29 are aryl, preferably phenyl, substituted preferably with one to three substituents selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; (C2-6)alkenyl, e.g. C2, C3, C4, C5, or C6-alkenyl, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy, (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C2-6)alkenyloxy, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl. Preferably R29 is phenyl substituted with 1, 2, or 3 halogen radicals, preferably I. Preferably, R27 is phenyl substituted with 1, 2, or 3 amino radicals or substituted amino radicals.
  • In a preferred use of the invention the compound according to formula (LIII) has a structure according to formula (LIV):
  • Figure US20090324580A1-20091231-C00024
  • optionally substituted or a pharmaceutically acceptable salt thereof. Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • In a preferred embodiment the compound usable according to the present invention having a structure according to formula (LIV) is substituted, preferably 1, 2, or 3 times with a radical selected from the group consisting of halogen, e.g. F, Cl, Br, or I; hydroxyl; SO2, NO2; CN; (C1-16)alkyl, e.g. C1, C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular methyl, ethyl, propyl, butyl, pentyl hexyl, heptyl, or octyl; (C2-16)alkenyl, e.g. C2, C3, C4, C5 C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, or C16, in particular ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, or octenyl; (C1-6)alkoxy, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy; (C1-6)alkyl-(C1-6)alkoxy; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl; (C2-6)alkenylsulphonyl; and NR11′R12′; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted;
      • wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl; halogen; alkyl, preferably (C1-6)alkyl, e.g. C1, C2, C3, C4, C5, or C6-alkyl, in particular methyl, ethyl, propyl, butyl, pentyl or hexyl; heteroalkyl, preferably (C1-6)heteroalkyl, e.g. C1, C2, C3, C4, C5, or C6-heteroalkyl, wherein preferably one or two carbon atoms are replaced by a heteroatom selected from the group consisting of N, S, and O; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl, preferably (C2-6)alkenyl, (C2-6)alkenyloxy, cycloalkenyl, (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted.
  • A further aspect of the present invention is directed at inhibitors of scavenger receptor type proteins the use of which has been disclosed herein, specifically at all inhibitors of scavenger receptor type proteins according to formulas (I) to (LIV) and according to all of the above indicated preferred and particularly preferred embodiments of compounds having structures according to these formulas.
  • A further aspect of the present invention is a pharmaceutical composition comprising any of the compounds usable according to the present invention.
  • Various inhibitors of scavenger type proteins are known from the prior art. Specifically, WO 2004/032716 A2 describes a large number of different compounds specifically inhibiting cholesterol transport activity of ScarB1. For the purpose of this opinion it is specifically referred to these compounds, which can also be used in the uses of the present invention. Accordingly, a further aspect of the present invention is the use of one or more of the compounds selected from Table I below.
  • TABLE I
    Figure US20090324580A1-20091231-C00025
    MIT 9952-1
    Figure US20090324580A1-20091231-C00026
    MIT 9952-2
    Figure US20090324580A1-20091231-C00027
    MIT 9952-3
    Figure US20090324580A1-20091231-C00028
    MIT 9952-4
    Figure US20090324580A1-20091231-C00029
    MIT 9952-5
    Figure US20090324580A1-20091231-C00030
    MIT 9952-6
    Figure US20090324580A1-20091231-C00031
    MIT 9952-7
    Figure US20090324580A1-20091231-C00032
    MIT 9952-8
    Figure US20090324580A1-20091231-C00033
    MIT 9952-9
    Figure US20090324580A1-20091231-C00034
    MIT 9952-10
    Figure US20090324580A1-20091231-C00035
    MIT 9952-11
    Figure US20090324580A1-20091231-C00036
    MIT 9952-12
    Figure US20090324580A1-20091231-C00037
    MIT 9952-13
    Figure US20090324580A1-20091231-C00038
    MIT 9952-14
    Figure US20090324580A1-20091231-C00039
    MIT 9952-15
    Figure US20090324580A1-20091231-C00040
    MIT 9952-16
    Figure US20090324580A1-20091231-C00041
    MIT 9952-17
    Figure US20090324580A1-20091231-C00042
    MIT 9952-18
    Figure US20090324580A1-20091231-C00043
    MIT 9952-19
    Figure US20090324580A1-20091231-C00044
    MIT 9952-20
    Figure US20090324580A1-20091231-C00045
    MIT 9952-21
    Figure US20090324580A1-20091231-C00046
    MIT 9952-22
    Figure US20090324580A1-20091231-C00047
    MIT 9952-23
    Figure US20090324580A1-20091231-C00048
    MIT 9952-24
    Figure US20090324580A1-20091231-C00049
    MIT 9952-25
    Figure US20090324580A1-20091231-C00050
    MIT 9952-26
    Figure US20090324580A1-20091231-C00051
    MIT 9952-27
    Figure US20090324580A1-20091231-C00052
    MIT 9952-28
    Figure US20090324580A1-20091231-C00053
    MIT 9952-29
    Figure US20090324580A1-20091231-C00054
    MIT 9952-30
    Figure US20090324580A1-20091231-C00055
    MIT 9952-31
    Figure US20090324580A1-20091231-C00056
    MIT 9952-32
    Figure US20090324580A1-20091231-C00057
    MIT 9952-33
    Figure US20090324580A1-20091231-C00058
    MIT 9952-34
    Figure US20090324580A1-20091231-C00059
    MIT 9952-35
    Figure US20090324580A1-20091231-C00060
    MIT 9952-36
    Figure US20090324580A1-20091231-C00061
    MIT 9952-37
    Figure US20090324580A1-20091231-C00062
    MIT 9952-38
    Figure US20090324580A1-20091231-C00063
    MIT 9952-39
    Figure US20090324580A1-20091231-C00064
    MIT 9952-40
    Figure US20090324580A1-20091231-C00065
    MIT 9952-41
    Figure US20090324580A1-20091231-C00066
    MIT 9952-42
    Figure US20090324580A1-20091231-C00067
    MIT 9952-43
    Figure US20090324580A1-20091231-C00068
    MIT 9952-44
    Figure US20090324580A1-20091231-C00069
    MIT 9952-45
    Figure US20090324580A1-20091231-C00070
    MIT 9952-46
    Figure US20090324580A1-20091231-C00071
    MIT 9952-47
    Figure US20090324580A1-20091231-C00072
    MIT 9952-48
    Figure US20090324580A1-20091231-C00073
    MIT 9952-49
    Figure US20090324580A1-20091231-C00074
    MIT 9952-50
    Figure US20090324580A1-20091231-C00075
    MIT 9952-51
    Figure US20090324580A1-20091231-C00076
    MIT 9952-52
    Figure US20090324580A1-20091231-C00077
    MIT 9952-53
    Figure US20090324580A1-20091231-C00078
    MIT 9952-54
    Figure US20090324580A1-20091231-C00079
    MIT 9952-55
    Figure US20090324580A1-20091231-C00080
    MIT 9952-56
    Figure US20090324580A1-20091231-C00081
    MIT 9952-57
    Figure US20090324580A1-20091231-C00082
    MIT 9952-58
    Figure US20090324580A1-20091231-C00083
    MIT 9952-59
    Figure US20090324580A1-20091231-C00084
    MIT 9952-60
    Figure US20090324580A1-20091231-C00085
    MIT 9952-61
    Figure US20090324580A1-20091231-C00086
    MIT 9952-62
    Figure US20090324580A1-20091231-C00087
    MIT 9952-63
    Figure US20090324580A1-20091231-C00088
    MIT 9952-64
    Figure US20090324580A1-20091231-C00089
    MIT 9952-65
    Figure US20090324580A1-20091231-C00090
    MIT 9952-66
    Figure US20090324580A1-20091231-C00091
    MIT 9952-67
    Figure US20090324580A1-20091231-C00092
    MIT 9952-68
    Figure US20090324580A1-20091231-C00093
    MIT 9952-69
    Figure US20090324580A1-20091231-C00094
    MIT 9952-70
    Figure US20090324580A1-20091231-C00095
    MIT 9952-71
    Figure US20090324580A1-20091231-C00096
    MIT 9952-72
    Figure US20090324580A1-20091231-C00097
    MIT 9952-73
    Figure US20090324580A1-20091231-C00098
    MIT 9952-74
    Figure US20090324580A1-20091231-C00099
    MIT 9952-75
    Figure US20090324580A1-20091231-C00100
    MIT 9952-76
    Figure US20090324580A1-20091231-C00101
    MIT 9952-77
    Figure US20090324580A1-20091231-C00102
    MIT 9952-78
    Figure US20090324580A1-20091231-C00103
    MIT 9952-79
    Figure US20090324580A1-20091231-C00104
    MIT 9952-80
    Figure US20090324580A1-20091231-C00105
    MIT 9952-81
    Figure US20090324580A1-20091231-C00106
    MIT 9952-82
    Figure US20090324580A1-20091231-C00107
    MIT 9952-83
    Figure US20090324580A1-20091231-C00108
    MIT 9952-84
    Figure US20090324580A1-20091231-C00109
    MIT 9952-85
    Figure US20090324580A1-20091231-C00110
    MIT 9952-86
    Figure US20090324580A1-20091231-C00111
    MIT 9952-87
    Figure US20090324580A1-20091231-C00112
    MIT 9952-88
    Figure US20090324580A1-20091231-C00113
    MIT 9952-89
    Figure US20090324580A1-20091231-C00114
    MIT 9952-90
    Figure US20090324580A1-20091231-C00115
    MIT 9952-91
    Figure US20090324580A1-20091231-C00116
    MIT 9952-92
    Figure US20090324580A1-20091231-C00117
    MIT 9952-93
    Figure US20090324580A1-20091231-C00118
    MIT 9952-94
    Figure US20090324580A1-20091231-C00119
    MIT 9952-95
    Figure US20090324580A1-20091231-C00120
    MIT 9952-96
    Figure US20090324580A1-20091231-C00121
    MIT 9952-97
    Figure US20090324580A1-20091231-C00122
    MIT 9952-98
    Figure US20090324580A1-20091231-C00123
    MIT 9952-99
    Figure US20090324580A1-20091231-C00124
    MIT 9952-100
    Figure US20090324580A1-20091231-C00125
    MIT 9952-101
    Figure US20090324580A1-20091231-C00126
    MIT 9952-102
    Figure US20090324580A1-20091231-C00127
    MIT 9952-103
    Figure US20090324580A1-20091231-C00128
    MIT 9952-104
    Figure US20090324580A1-20091231-C00129
    MIT 9952-105
    Figure US20090324580A1-20091231-C00130
    MIT 9952-106
    Figure US20090324580A1-20091231-C00131
    MIT 9952-107
    Figure US20090324580A1-20091231-C00132
    MIT 9952-108
    Figure US20090324580A1-20091231-C00133
    MIT 9952-109
    Figure US20090324580A1-20091231-C00134
    MIT 9952-110
    Figure US20090324580A1-20091231-C00135
    MIT 9952-111
    Figure US20090324580A1-20091231-C00136
    MIT 9952-112
    Figure US20090324580A1-20091231-C00137
    MIT 9952-113
    Figure US20090324580A1-20091231-C00138
    MIT 9952-114
    Figure US20090324580A1-20091231-C00139
    MIT 9952-115
    Figure US20090324580A1-20091231-C00140
    MIT 9952-116
    Figure US20090324580A1-20091231-C00141
    MIT 9952-117
    Figure US20090324580A1-20091231-C00142
    MIT 9952-118
    Figure US20090324580A1-20091231-C00143
    MIT 9952-119
    Figure US20090324580A1-20091231-C00144
    MIT 9952-120
    Figure US20090324580A1-20091231-C00145
    MIT 9952-121
    Figure US20090324580A1-20091231-C00146
    MIT 9952-122
    Figure US20090324580A1-20091231-C00147
    MIT 9952-123
    Figure US20090324580A1-20091231-C00148
    MIT 9952-124
    Figure US20090324580A1-20091231-C00149
    MIT 9952-125
    Figure US20090324580A1-20091231-C00150
    MIT 9952-126
    Figure US20090324580A1-20091231-C00151
    MIT 9952-127
    Figure US20090324580A1-20091231-C00152
    MIT 9952-128
    Figure US20090324580A1-20091231-C00153
    MIT 9952-129
    Figure US20090324580A1-20091231-C00154
    MIT 9952-130
    Figure US20090324580A1-20091231-C00155
    MIT 9952-131
    Figure US20090324580A1-20091231-C00156
    MIT 9952-132
    Figure US20090324580A1-20091231-C00157
    MIT 9952-133
    Figure US20090324580A1-20091231-C00158
    MIT 9952-13
    Figure US20090324580A1-20091231-C00159
    MIT 9952-135
    Figure US20090324580A1-20091231-C00160
    MIT 9952-136
    Figure US20090324580A1-20091231-C00161
    MIT 9952-137
    Figure US20090324580A1-20091231-C00162
    MIT 9952-138
    Figure US20090324580A1-20091231-C00163
    MIT 9952-139
    Figure US20090324580A1-20091231-C00164
    MIT 9952-140
    Figure US20090324580A1-20091231-C00165
    MIT 9952-141
    Figure US20090324580A1-20091231-C00166
    MIT 9952-142
    Figure US20090324580A1-20091231-C00167
    MIT 9952-143
    Figure US20090324580A1-20091231-C00168
    MIT 9952-144
    Figure US20090324580A1-20091231-C00169
    MIT 9952-145
    Figure US20090324580A1-20091231-C00170
    MIT 9952-146
    Figure US20090324580A1-20091231-C00171
    MIT 9952-147
    Figure US20090324580A1-20091231-C00172
    MIT 9952-148
    Figure US20090324580A1-20091231-C00173
    MIT 9952-149
    Figure US20090324580A1-20091231-C00174
    MIT 9952-150
    Figure US20090324580A1-20091231-C00175
    MIT 9952-151
    Figure US20090324580A1-20091231-C00176
    MIT 9952-152
    Figure US20090324580A1-20091231-C00177
    MIT 9952-153
    Figure US20090324580A1-20091231-C00178
    MIT 9952-154
    Figure US20090324580A1-20091231-C00179
    MIT 9952-155
    Figure US20090324580A1-20091231-C00180
    MIT 9952-156
    Figure US20090324580A1-20091231-C00181
    MIT 9952-157
    Figure US20090324580A1-20091231-C00182
    MIT 9952-158
    Figure US20090324580A1-20091231-C00183
    MIT 9952-159
    Figure US20090324580A1-20091231-C00184
    MIT 9952-160
    Figure US20090324580A1-20091231-C00185
    MIT 9952-161
    Figure US20090324580A1-20091231-C00186
    MIT 9952-162
    Figure US20090324580A1-20091231-C00187
    MIT 9952-163
    Figure US20090324580A1-20091231-C00188
    MIT 9952-164
    Figure US20090324580A1-20091231-C00189
    MIT 9952-165
    Figure US20090324580A1-20091231-C00190
    MIT 9952-166
    Figure US20090324580A1-20091231-C00191
    MIT 9952-167
    Figure US20090324580A1-20091231-C00192
    MIT 9952-168
    Figure US20090324580A1-20091231-C00193
    MIT 9952-169
    Figure US20090324580A1-20091231-C00194
    MIT 9952-170
    Figure US20090324580A1-20091231-C00195
    MIT 9952-171
    Figure US20090324580A1-20091231-C00196
    MIT 9952-172
    Figure US20090324580A1-20091231-C00197
    MIT 9952-173
    Figure US20090324580A1-20091231-C00198
    MIT 9952-174
    Figure US20090324580A1-20091231-C00199
    MIT 9952-175
    Figure US20090324580A1-20091231-C00200
    MIT 9952-176
    Figure US20090324580A1-20091231-C00201
    MIT 9952-177
    Figure US20090324580A1-20091231-C00202
    MIT 9952-178
    Figure US20090324580A1-20091231-C00203
    MIT 9952-179
    Figure US20090324580A1-20091231-C00204
    MIT 9952-180
    Figure US20090324580A1-20091231-C00205
    MIT 9952-181
    Figure US20090324580A1-20091231-C00206
    MIT 9952-182
    Figure US20090324580A1-20091231-C00207
    MIT 9952-183
    Figure US20090324580A1-20091231-C00208
    MIT 9952-184
    Figure US20090324580A1-20091231-C00209
    MIT 9952-185
    Figure US20090324580A1-20091231-C00210
    MIT 9952-186
    Figure US20090324580A1-20091231-C00211
    MIT 9952-187
    Figure US20090324580A1-20091231-C00212
    MIT 9952-188
    Figure US20090324580A1-20091231-C00213
    MIT 9952-189
    Figure US20090324580A1-20091231-C00214
    MIT 9952-190
    Figure US20090324580A1-20091231-C00215
    MIT 9952-191
    Figure US20090324580A1-20091231-C00216
    MIT 9952-192
    Figure US20090324580A1-20091231-C00217
    MIT 9952-193
    Figure US20090324580A1-20091231-C00218
    MIT 9952-194
    Figure US20090324580A1-20091231-C00219
    MIT 9952-195
    Figure US20090324580A1-20091231-C00220
    MIT 9952-196
    Figure US20090324580A1-20091231-C00221
    MIT 9952-197
    Figure US20090324580A1-20091231-C00222
    MIT 9952-198
    Figure US20090324580A1-20091231-C00223
    MIT 9952-199
    Figure US20090324580A1-20091231-C00224
    MIT 9952-200
    Figure US20090324580A1-20091231-C00225
    MIT 9952-201
    Figure US20090324580A1-20091231-C00226
    MIT 9952-202
    Figure US20090324580A1-20091231-C00227
    MIT 9952-203
    Figure US20090324580A1-20091231-C00228
    MIT 9952-204
    Figure US20090324580A1-20091231-C00229
    MIT 9952-205
    Figure US20090324580A1-20091231-C00230
    MIT 9952-206
    Figure US20090324580A1-20091231-C00231
    MIT 9952-207
    Figure US20090324580A1-20091231-C00232
    MIT 9952-208
    Figure US20090324580A1-20091231-C00233
    MIT 9952-209
    Figure US20090324580A1-20091231-C00234
    MIT 9952-210
    Figure US20090324580A1-20091231-C00235
    MIT 9952-211
    Figure US20090324580A1-20091231-C00236
    MIT 9952-212
    Figure US20090324580A1-20091231-C00237
    MIT 9952-213
    Figure US20090324580A1-20091231-C00238
    MIT 9952-214
    Figure US20090324580A1-20091231-C00239
    MIT 9952-215
    Figure US20090324580A1-20091231-C00240
    MIT 9952-216
    Figure US20090324580A1-20091231-C00241
    MIT 9952-217
    Figure US20090324580A1-20091231-C00242
    MIT 9952-218
    Figure US20090324580A1-20091231-C00243
    MIT 9952-219
    Figure US20090324580A1-20091231-C00244
    MIT 9952-220
    Figure US20090324580A1-20091231-C00245
    MIT 9952-221
    Figure US20090324580A1-20091231-C00246
    MIT 9952-222
    Figure US20090324580A1-20091231-C00247
    MIT 9952-223
    Figure US20090324580A1-20091231-C00248
    MIT 9952-224
    Figure US20090324580A1-20091231-C00249
    MIT 9952-225
    Figure US20090324580A1-20091231-C00250
    MIT 9952-226
    Figure US20090324580A1-20091231-C00251
    MIT 9952-227
    Figure US20090324580A1-20091231-C00252
    MIT 9952-228
    Figure US20090324580A1-20091231-C00253
    MIT 9952-229
    Figure US20090324580A1-20091231-C00254
    MIT 9952-230
    Figure US20090324580A1-20091231-C00255
    MIT 9952-231
    Figure US20090324580A1-20091231-C00256
    MIT 9952-232
    Figure US20090324580A1-20091231-C00257
    MIT 9952-233
    Figure US20090324580A1-20091231-C00258
    MIT 9952-234
    Figure US20090324580A1-20091231-C00259
    MIT 9952-235
    Figure US20090324580A1-20091231-C00260
    MIT 9952-236
    Figure US20090324580A1-20091231-C00261
    MIT 9952-237
    Figure US20090324580A1-20091231-C00262
    MIT 9952-238
    Figure US20090324580A1-20091231-C00263
    MIT 9952-239
    Figure US20090324580A1-20091231-C00264
    MIT 9952-240
    Figure US20090324580A1-20091231-C00265
    MIT 9952-241
    Figure US20090324580A1-20091231-C00266
    MIT 9952-242
    Figure US20090324580A1-20091231-C00267
    MIT 9952-243
    Figure US20090324580A1-20091231-C00268
    MIT 9952-244
    Figure US20090324580A1-20091231-C00269
    MIT 9952-245
    Figure US20090324580A1-20091231-C00270
    MIT 9952-246
    Figure US20090324580A1-20091231-C00271
    MIT 9952-247
    Figure US20090324580A1-20091231-C00272
    MIT 9952-248
    Figure US20090324580A1-20091231-C00273
    MIT 9952-249
    Figure US20090324580A1-20091231-C00274
    MIT 9952-250
    Figure US20090324580A1-20091231-C00275
    MIT 9952-251
    Figure US20090324580A1-20091231-C00276
    MIT 9952-252
    Figure US20090324580A1-20091231-C00277
    MIT 9952-253
    Figure US20090324580A1-20091231-C00278
    MIT 9952-254
    Figure US20090324580A1-20091231-C00279
    MIT 9952-255
    Figure US20090324580A1-20091231-C00280
    MIT 9952-256
    Figure US20090324580A1-20091231-C00281
    MIT 9952-257
    Figure US20090324580A1-20091231-C00282
    MIT 9952-258
    Figure US20090324580A1-20091231-C00283
    MIT 9952-259
    Figure US20090324580A1-20091231-C00284
    MIT 9952-260
    Figure US20090324580A1-20091231-C00285
    MIT 9952-261
    Figure US20090324580A1-20091231-C00286
    MIT 9952-262
    Figure US20090324580A1-20091231-C00287
    MIT 9952-263
    Figure US20090324580A1-20091231-C00288
    MIT 9952-264
    Figure US20090324580A1-20091231-C00289
    MIT 9952-265
    Figure US20090324580A1-20091231-C00290
    MIT 9952-266
    Figure US20090324580A1-20091231-C00291
    MIT 9952-267
    Figure US20090324580A1-20091231-C00292
    MIT 9952-268
    Figure US20090324580A1-20091231-C00293
    MIT 9952-269
    Figure US20090324580A1-20091231-C00294
    MIT 9952-270
    Figure US20090324580A1-20091231-C00295
    MIT 9952-271
    Figure US20090324580A1-20091231-C00296
    MIT 9952-272
    Figure US20090324580A1-20091231-C00297
    MIT 9952-273
    Figure US20090324580A1-20091231-C00298
    MIT 9952-274
    Figure US20090324580A1-20091231-C00299
    MIT 9952-275
    Figure US20090324580A1-20091231-C00300
    MIT 9952-276
    Figure US20090324580A1-20091231-C00301
    MIT 9952-277
    Figure US20090324580A1-20091231-C00302
    MIT 9952-278
    Figure US20090324580A1-20091231-C00303
    MIT 9952-279
    Figure US20090324580A1-20091231-C00304
    MIT 9952-280
    Figure US20090324580A1-20091231-C00305
    MIT 9952-281
    Figure US20090324580A1-20091231-C00306
    MIT 9952-282
    Figure US20090324580A1-20091231-C00307
    MIT 9952-283
    Figure US20090324580A1-20091231-C00308
    MIT 9952-284
    Figure US20090324580A1-20091231-C00309
    MIT 9952-285
    Figure US20090324580A1-20091231-C00310
    MIT 9952-286
    Figure US20090324580A1-20091231-C00311
    MIT 9952-287
    Figure US20090324580A1-20091231-C00312
    MIT 9952-288
    Figure US20090324580A1-20091231-C00313
    MIT 9952-289
    Figure US20090324580A1-20091231-C00314
    MIT 9952-290
    Figure US20090324580A1-20091231-C00315
    MIT 9952-291
    Figure US20090324580A1-20091231-C00316
    MIT 9952-292
    Figure US20090324580A1-20091231-C00317
    MIT 9952-293
    Figure US20090324580A1-20091231-C00318
    MIT 9952-294
    Figure US20090324580A1-20091231-C00319
    MIT 9952-295
    Figure US20090324580A1-20091231-C00320
    MIT 9952-296
    Figure US20090324580A1-20091231-C00321
    MIT 9952-297
    Figure US20090324580A1-20091231-C00322
    MIT 9952-298
    Figure US20090324580A1-20091231-C00323
    MIT 9952-299
    Figure US20090324580A1-20091231-C00324
    MIT 9952-300
    Figure US20090324580A1-20091231-C00325
    MIT 9952-301
    Figure US20090324580A1-20091231-C00326
    MIT 9952-302
    Figure US20090324580A1-20091231-C00327
    MIT 9952-303
    Figure US20090324580A1-20091231-C00328
    MIT 9952-304
    Figure US20090324580A1-20091231-C00329
    MIT 9952-305
    Figure US20090324580A1-20091231-C00330
    MIT 9952-306
    Figure US20090324580A1-20091231-C00331
    MIT 9952-307
    Figure US20090324580A1-20091231-C00332
    MIT 9952-308
    Figure US20090324580A1-20091231-C00333
    MIT 9952-309
    Figure US20090324580A1-20091231-C00334
    MIT 9952-310
    Figure US20090324580A1-20091231-C00335
    MIT 9952-311
    Figure US20090324580A1-20091231-C00336
    MIT 9952-312
    Figure US20090324580A1-20091231-C00337
    MIT 9952-313
    Figure US20090324580A1-20091231-C00338
    MIT 9952-314
    Figure US20090324580A1-20091231-C00339
    MIT 9952-315
    Figure US20090324580A1-20091231-C00340
    MIT 9952-316
    Figure US20090324580A1-20091231-C00341
    MIT 9952-317
    Figure US20090324580A1-20091231-C00342
    MIT 9952-318
    Figure US20090324580A1-20091231-C00343
    MIT 9952-319
    Figure US20090324580A1-20091231-C00344
    MIT 9952-320
    Figure US20090324580A1-20091231-C00345
    MIT 9952-321
    Figure US20090324580A1-20091231-C00346
    MIT 9952-322
    Figure US20090324580A1-20091231-C00347
    MIT 9952-323
    Figure US20090324580A1-20091231-C00348
    MIT 9952-324
    Figure US20090324580A1-20091231-C00349
    MIT 9952-325
    Figure US20090324580A1-20091231-C00350
    MIT 9952-326
    Figure US20090324580A1-20091231-C00351
    MIT 9952-327
    Figure US20090324580A1-20091231-C00352
    MIT 9952-328
    Figure US20090324580A1-20091231-C00353
    MIT 9952-329
    Figure US20090324580A1-20091231-C00354
    MIT 9952-330
    Figure US20090324580A1-20091231-C00355
    MIT 9952-331
    Figure US20090324580A1-20091231-C00356
    MIT 9952-332
    Figure US20090324580A1-20091231-C00357
    MIT 9952-333
    Figure US20090324580A1-20091231-C00358
    MIT 9952-334
    Figure US20090324580A1-20091231-C00359
    MIT 9952-335
    Figure US20090324580A1-20091231-C00360
    MIT 9952-336
    Figure US20090324580A1-20091231-C00361
    MIT 9952-337
    Figure US20090324580A1-20091231-C00362
    MIT 9952-338
    Figure US20090324580A1-20091231-C00363
    MIT 9952-339
    Figure US20090324580A1-20091231-C00364
    MIT 9952-340
    Figure US20090324580A1-20091231-C00365
    MIT 9952-341
    Figure US20090324580A1-20091231-C00366
    MIT 9952-342

    optionally substituted or pharmaceutically acceptable salts thereof Preferred salts comprise Na+, K+, Mg2+, and Ca2+.
  • Since the present inventors have surprisingly found that scavenger receptor class proteins, in particular ScarB1, have a role in the life cycle of pathogens, which proliferate, develop and/or hide in liver or haematopoietic cells another preferred use of the present invention relates to the use of one or more antibodies specifically binding to said scavenger receptor class protein for the treatment and/or prophylaxis of infections involving liver and/or haematopoietic cells. Preferably, the antibody binds to the extracellular part of the scavenger receptor class protein thereby interfering with the interaction of the pathogen with the receptor. The term “antibody” as used herein comprises monoclonal and polyclonal antibodies and binding fragments thereof, in particular Fc-fragments as well as so called “single-chain-antibodies” (Bird R. E. et al (1988) Science 242:423-6), chimeric, humanized, in particular CDR-grafted antibodies, and dia or tetrabodies (Holliger P. et al (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6444-8). Also comprised are immunoglobulin like proteins that are selected through techniques including, for example, phage display to specifically bind to scavenger receptor class proteins.
  • A mechanism termed “RNA interference” (RNAi) was discovered through the observation that injection of double stranded RNA (dsRNA) into the nematode C. elegans led to specific silencing of genes highly homologous in sequence to the delivered dsRNA (Fire A. et al. (1998) Nature 391: 806-811). RNAi was subsequently also observed in insects, frogs (Oelgeschlager M. et al. (2000) Nature 405: 757-763), and other animals including mice (Svoboda P. et al. (2000) Development 127: 4147-4156; Wianny F. and Zemicka-Goetz M. (2000) Nat. Cell Biol 2: 70-75). It was then described that this effect could also be obtained with short RNA doublexes termed “small interfering RNA” (siRNA) (Elbashir S. M. et al. (2001) Nature 411: 428-9 and WO02/044321). As set out below siRNAs were also used to identify scavenger receptor class proteins as a potential target to interfere with the proliferation and/or development of pathogens, in particular malaria. Accordingly, in a further preferred use of the present invention the inhibitor of the scavenger receptor class protein is a small interfering RNA (siRNA) capable of inhibiting expression of a scavenger receptor class protein. It is preferred that each RNA strand of the siRNA has a length from 19 to 30, particularly from 19 to 23 nucleotides, wherein said RNA molecule is capable of mediating target-specific nucleic acid modifications, particularly RNA interference and/or DNA methylation. It is further preferred that at least one strand has a 3′ overhang from 1 to 5 nucleotides, more preferably from 1 to 3 nucleotides and most preferably of 2 nucleotides. The other strand may be blunt-ended or may have up to 6 nucleotides 3′ overhang. Preferably the siRNA is designed to inhibit expression of scavenger receptor class B 1 (ScarB1) and ScarBII. To that end various short, e.g. 19 to 25 nucleotides dsRNAs are designed on the basis of the sequence of either ScarB1 (SEQ ID NO: 1) or ScarBII (SEQ ID NO: 2). It is particularly preferred that the siRNA is a double stranded RNA each comprised of the RNAs according to SEQ ID NO: 3 and SEQ ID NO: 4; SEQ ID NO: 5 and SEQ ID NO: 6; and SEQ ID NO: 7 and SEQ ID NO: 8, respectively.
  • In a preferred use of the invention the scavenger receptor class protein is scavenger receptor class B 1 (ScarB1) or scavenger receptor class B 2 (ScarBII).
  • A large number of protozoal pathogens is known, which require during their life cycle in their host, e.g. a human, to attach to and/or enter scavenger receptor expressing cells, in particular hepatic and haematopoietic cells. These diseases are all amenable to the treatment and/or prophylaxis with inhibitors of scavenger receptor class proteins. Accordingly, in a preferred use of the invention the infectious disease is a protozoal infection. Preferably the pathogenic protozoa is selected from the group consisting of Entomoeba histolytica, Trichomonas tenas, Trichomonas hominis, Trichomonas vaginalis, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Toxoplasma gondii, Theileria lawrenci, Theileria parva, Plasmodium vivax, Plasmodium falciparum, and Plasmodium malaria. In a particular preferred use of the invention the protozoa is a member of the family of plasmodiidae, preferably Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi. In the most preferred use of the invention the infectious disease for which treatment and/or prophylaxis is provide is malaria.
  • As set out above a large number of inhibitors of scavenger receptor class proteins, in particular ScarB1 is known from the prior art. In order to identify further compounds suitable for the use of the present invention the present invention relates in another aspect to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
    • (i) contacting a cell comprising a scavenger receptor class protein, in particular ScarB1 or ScarBII, or a functional variant thereof, with a test compound,
    • (ii) measuring cholesterol transport into or out of said cell,
    • (iii) selecting a test compound, which inhibits cholesterol transport into or out of said cells,
    • (iv) contacting liver or hematopoietic cell with the selected test compound prior, during or after infection of said cell with an infectious agent, and
    • (v) selecting a test compound inhibiting proliferation and/or development of the infectious agent by at least 10%.
  • In the context of the present invention the term “contacting” refers to the process of allowing the compound to bind to, preferably to bind to and enter the cell and comprises mixing as well as transfecting, transducing and/or electroporating. A cell “comprising” a scavenger receptor class protein, preferably ScarB1 or ScarBII, may have been stably or transiently transfected with a nucleic acid encoding a scavenger receptor class protein or functional variant thereof, by e.g. viral infection, electroporation, CaCl2 precipitation or the protein may have been directly introduced into the cell by, e.g. electroporation, or liposomal delivery etc. A “functional variant” of a scavenger receptor class protein is a protein, which has been modified by N-terminal, C-terminal and/or internal deletions and/or amino acid additions and or mutations, preferably conservative mutations and which has at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70% or more of the cholesterol transport activity into or out of the cell, if compared to the respective wild type scavenger receptor class protein on which the variant is based. The measuring of the cholesterol transport is preferably carried out by providing some type of labelled cholesterol to the cell, e.g. free cholesterol, LDL or HDL, which might be labelled by any art known label, in particular radioactive, or fluorescent label. The selected test compound preferably inhibits the cholesterol transport into or out of the cells by at least 10%, preferably by at least 20%, preferably by at least 30%, preferably by at least 40%, preferably by at least 50%, preferably by at least 60%, preferably by at least 70%, preferably by at least 80%, preferably by at least 90% or more, if compared to an untreated cell, which is kept under otherwise similar conditions. Methods of propagating/maintaining infectious agents in cell culture systems, in particular in liver and/or haematopoietic cells are known from the prior art and are also described herein. The test compounds are contacted with such cellular systems, which can be in vitro or in vivo, e.g. in animal models of the infectious agent.
  • Test compounds that can be used in the context of the methods of the present invention are not particularly limited and comprise without limitation peptides, proteins, peptidomimetics, small molecules, and/or nucleic acids. Peptides in this sense are chains of naturally and/or non-naturally occurring amino acids with 1 to 50 amino acids connected by peptide bonds. Chains with 50 or more naturally and/or non-naturally occurring amino acids are referred to as proteins. Preferred peptides used in the methods of the present invention are peptides interfering with the interaction of the scavenger receptor class protein(s), in particular ScarB1 and/or ScarBII, with the structure on the respective pathogen, e.g. pasmodiidae, preferably Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi, required for binding to the scavenger receptor class protein(s). Accordingly, in a preferred embodiment peptides are fragments of scavenger receptor type proteins, in particular of ScarB1 and/or ScarBII. Particularly preferred fragments are fragments of the extracellular domain of these receptors. Peptidomimetics are well known in the art and refer to compounds, which are designed based on the primary structure of a given peptide to be modelled, e.g. like one of the peptides mentioned above, and which take on a similar secondary structure. Thus, peptidomimetics can be designed to be, e.g. more protease resistant, have a different half life, improved pharmacokinetics or pharmacodynamics etc. Small molecules within the meaning of the present invention are non peptidly (no peptide bonds), non nucleic acid compounds, of a molecular weight lower than 1.000 g/mol, preferably lower than 500 g/mol. In most cases the small molecules used in the methods of the present invention are hydrocarbons or mixtures thereof, e.g. plant extracts. The term “nucleic acids” comprises without limitation, DNA and RNA, e.g. siRNA etc.
  • The selecting of a test compound inhibiting proliferation or development of the infectious agent is based on its activity in inhibiting proliferation and/or development of the infectious agent. It is expected that any compound showing an activity in step (iii) will also be active in inhibiting the infectious agent. However, in some instances a compound with a high activity in step (iii) will be less active than in step (v) as another drug having the same activity in step (iii) and vice versa. Accordingly, the further step of assessing the activity of the preselected compounds in a further selection step leads to compounds more active in therapy and/or prophylaxis of infectious diseases, in particular malaria. The infectious agents are those, which are outlined above in particular plasmodiidae, preferably Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi.
  • In order to identify further compounds suitable for the use of the present invention the present invention also relates in another aspect to a method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
    • (i) contacting one or more scavenger receptor class protein, in particular ScarB1 and/or ScarBII protein, functional variants, or soluble parts thereof with a test compound,
    • (ii) selecting a test compound, which specifically binds to the scavenger receptor class protein(s), in particular ScarB1 or ScarBII,
    • (iii) contacting liver or hematopoietic cell with the selected test compound prior, during or after infection of said cell with an infectious agent, and
    • (iv) selecting a test compound inhibiting proliferation and/or development of the infectious agent by at least 10%.
  • The term “functional variant” in the context of this method has the same meaning as outlined above. Soluble parts are fragments, which preferably do not comprise the hydrophobic membrane spanning regions of the protein. A test compound is considered to specifically bind to a scavenger receptor class protein, in particular ScarB1 or ScarBII, if it has a binding constant to the respective scavenger receptor class protein of 100 μM or less, preferably 50 μM or less, preferably 30 μM or less, and preferably 20 μM or less.
  • It is preferred that the scavenger receptor class proteins, in particular ScarB1 or ScarBII protein, used in above assay is recombinantly expressed. Various suitable expression systems are known, which include without limitation baculovirus systems using cells like Hi5 or Sf9, bacterial expression systems using E. coli, yeas systems using cells like P. pastori or S. cerevisiae or mammalian systems using cell like CHO, HeLa, NIH 3T3, or Swiss 3T3. It is further preferred that the proteins, the variants or parts thereof are purified prior to their use in above assay.
  • In a further preferred method the present invention comprises the additional step of formulating the test compound selected in step (v) and (iv), respectively, of either method with pharmaceutically acceptable additives and/or auxiliary substances. Auxiliary substances comprise liposomes, virosomes, microsphere, niosomes, dendrimeres, stabilizers, buffers, and carriers. Stabilizers are known in the art and comprise, for example, α-tocopherol and various carbohydrates.
  • In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as saline solutions in water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. A saline solution is a preferred carrier when the composition comprising the scavenger receptor class inhibitor is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, alginates, calcium carbonate, dextrose, fructose, maltose, maltodextrin, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition comprising the scavenger receptor class inhibitor, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition comprising the scavenger receptor class inhibitor can be formulated as a suppository, with traditional binders and carriers such as triglycerides. The compounds usable according to the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include in particular those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
  • Pharmaceutical compositions comprising the scavenger receptor class inhibitor(s) may be adapted for oral administration and can be provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions. Tablets or hard gelatine capsules may comprise lactose, starch or derivatives thereof, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, stearic acid or salts thereof. Soft gelatine capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars.
  • The scavenger receptor class inhibitor usable according to the present invention may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used). Thus, the sustained release of an active agent may be achieved over many hours and, if necessary, the active agent can be protected from being degraded within the stomach. Pharmaceutical compositions for oral administration may be formulated to facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.
  • The scavenger receptor class inhibitor may be adapted for transdermal administration and can be provided as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. They may be adapted for topical administration and can be provided as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For topical administration to the skin, mouth, eye or other external tissues a topical ointment or cream is preferably used. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water base or a water-in-oil base. Pharmaceutical compositions adapted for topical administration to the eye include eye drops. In these compositions, the active ingredient can be dissolved or suspended in a suitable carrier, e.g., in an aqueous solvent. Pharmaceutical compositions adapted for topical administration in the mouth include lozenges, pastilles and mouthwashes.
  • The scavenger receptor class inhibitor may be adapted for nasal administration and can comprise solid carriers such as powders (preferably having a particle size in the range of 20 to 500 microns). Powders can be administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nose from a container of powder held close to the nose. Alternatively, compositions adopted for nasal administration may comprise liquid carriers, e.g., nasal sprays or nasal drops. These compositions may comprise aqueous or oil solutions of the active ingredient. Compositions for administration by inhalation may be supplied in specially adapted devices including, but not limited to, pressurized aerosols, nebulizers or insufflators, which can be constructed so as to provide predetermined dosages of the active ingredient. In a preferred embodiment, pharmaceutical compositions of the invention are administered via the nasal cavity to the lungs.
  • The scavenger receptor class inhibitor may be adapted for rectal administration may be provided as suppositories or enemas. Pharmaceutical compositions adapted for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • The scavenger receptor class inhibitor may be adapted for parenteral administration and can include aqueous and non-aqueous sterile injectable solutions or suspensions, which may contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially isotonic with the blood of an intended recipient. Other components that may be present in such compositions include water, alcohols, polyols, glycerine and vegetable oils, for example. Compositions adapted for parenteral administration may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, e.g., sterile saline solution for injections, immediately prior to use.
  • In a further aspect the present invention relates to the use of a test compound selected in step (v) of the method of the present invention for the production of a medicament for the therapy and/or prophylaxis of infectious diseases, which involve infection of liver and/or hematopoietic cells.
  • The increasing speed of the development of resistance of protozoal pathogens, in particular malaria to the various medicaments used to treat these disease makes it necessary to efficiently eradicate the pathogen without giving it a chance to develop a resistance. To that end it is desirable to interfere with distinct pathways required for the lifecycle of a given pathogen. Since the present inventors have for the first time shown that inhibitors of ScarB1 can interfere with development/proliferation of malaria the compounds present a hitherto unknown route of attack on pathogens, in particular pathogens causing malaria, which can beneficially combined with the known treatments of malaria. Accordingly the present invention in a further aspect relates to pharmaceutical compositions comprising one or more of compound usable according to the present invention and one or more of a known malaria therapeutic including in particular one or more selected from the group consisting of chinine alkaloids, chloroquine (-phosphate, hydroxychloroquinesulfate), mefloquine (Lariam), bi-guanides: proguanil (Paludrine), di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine and suitable carriers. Accordingly, the present invention also relates to the use of the compounds usable according to the present invention and one or more malaria medicament, preferably chinine alkaloids, chloroquine (-phosphate, hydroxychloroquinesulfate), mefloquine (Lariam), bi-guanides: proguanil (Paludrine), di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine for the manufacture of a medicament for the treatment of diseases involving liver and/or hematopoeitc cells, preferably malaria. Preferably, the two medicaments are administered simultaneously, e.g. combined in one administration form or simultaneously or subsequently in separate administration forms.
  • The surprising discovery underlying the present invention that scavenger receptor class proteins, in particular ScarB1 and ScarBII, are involved in mediating entry of pathogens into liver and hematopoietic cells also provides the possibility to identify those structures on the pathogens, which interact with the scavenger receptor class proteins and which are, thus, also potential targets in order to interfere with the live cycle of those pathogens. Therefore, the present invention in a further aspect relates to a method of identifying molecules, which are present in, in particular on the surface, of pathogens capable of infecting liver and hematopoietic cells and which interact with one or more scavenger receptor class protein, in particular ScarB1 and/or ScarBII. The method preferably comprises the following steps:
    • (i) contacting one or more scavenger receptor class proteins, in particular ScarB1 and/or ScarBII protein, functional variants, or soluble parts thereof with one or more molecules present in, in particular on the surface of pathogens, which are involved in the infection of liver and/or hematopoietic cells,
    • (ii) selecting a molecule, which specifically binds to the scavenger receptor class protein, in particular ScarB1 or ScarBII.
  • The terms “functional variants” and “soluble parts thereof” have the above outlined meaning. Preferred molecules of pathogens, which can be tested for their binding to scavenger receptor class proteins comprise proteins, lipids and carbohydrates, preferably proteins. In many cases cell surface receptors of pathogens are involved in a specific interaction with a corresponding receptor on a host cell. Accordingly, it is particularly preferred that the molecules tested for binding to scavenger receptor class proteins are cell surface receptors of the particular pathogen. All pathogens outlined above can be the source for molecules tested in this method of the invention, preferably, however, the pathogens are selected from the group consisting Entomoeba histolytica, Trichomonas tenas, Trichomonas hominis, Trichomonas vaginalis, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Toxoplasma gondii, Theileria lawrenci, Theileria parva, Plasmodium vivax, Plasmodium falciparum, Plasmodium ovale, Plasmodium malariae, Plasmodium semiovale and Plasmodium knowlesi, in particular Plasmodium vivax and Plasmodium falciparum.
  • The contacting between the scavenger receptor class protein and the molecule(s) derived from the pathogen can be carried out in vivo or in vitro. For example, (i) both the scavenger receptor class protein(s), functional variants, or soluble parts thereof and the potentially interacting molecule(s) can be present together in a cell, (ii) either the scavenger receptor class protein(s), functional variants, or soluble parts thereof or the potentially interacting molecule(s) can be expressed in a cell, e.g. on the surface of a cell, which is then contacted with the respective other entity in, e.g. solution or (iii) both scavenger receptor class protein(s), functional variants, or soluble parts thereof and the potentially interacting molecule(s) are contacted in vitro.
  • A molecule comprised in a pathogen is considered to specifically bind to a scavenger receptor class protein, in particular ScarB1 or ScarBII, if it has a binding constant to the respective scavenger receptor class protein of 100 μM or less, preferably 50 μM or less, preferably 30 μM or less, and preferably 20 μM or less.
  • It is preferred that the method comprises the further step of determining the molecule, which specifically binds to the scavenger receptor class protein(s). Various methods of determining the nature of an interaction molecule are known in the prior art, which in part depend on the respective method used to select the specifically binding molecule as discussed below. Preferably the determining of the molecule comprises MS, peptide or nucleic acid sequencing, ELISA etc.
  • Several methods are known in the prior art to determine molecules interacting with a given target molecule. These methods comprise without limitation co-immunoprecipitation, affinity purification, cross-linking, phage display and so called “two-hybrid” assays. In co-immunoprecipitation experiments usually the target, i.e. the scavenger receptor class protein can be immobilized on, e.g. beads or another matrix, and will be contacted with a cellular extract of the respective pathogen or recombinant proteins derived from an expression library. Alternatively, the target is contacted with the molecules derived from the pathogens in a homogenous system, i.e. in solution, and only after binding has occurred the target is bound “pulled down” by interaction with a molecule specifically binding the target, e.g. a scavenger receptor specific antibody, which has been attached to a bead or matrix. To assure specific binding the beads or matrix will be washed to remove unbound and/or unspecifically bound molecules, the specifically bound molecules are then eluted and analyzed by e.g. MS, peptide sequencing or Western blot. The affinity purification is similar to co-immunoprecipitation, however, the binding is carried out by applying the molecules of the pathogens to a column loaded with a matrix to which the scavenger receptor class protein has been attached. Cross-linking typically involves the labelling of the target, which may or may not be further modified to include a cross-linking moiety, the contacting of the labelled target with the molecules of the pathogen, preferably with the intact pathogen and effecting crosslinking between the target and whatever molecule the target has bound to. The complex which is formed between the target and the molecule of the pathogen can then be purified away from the other molecules of the pathogen on the basis of the label and/or analyzed by art known methods, involving MS, peptide sequencing and the like. Phage display is a method wherein proteins or protein fragments are fused to phage coat proteins and, thus, displayed on the surface of the resulting phage. It is possible to express protein libraries derived from the pathogens of interest on phage and then select those phages displaying proteins of the pathogens, which are capable of specifically interacting with the respective scavenger receptor class protein(s). The identity of the interacting molecule can then be determined easily by sequencing of the phage DNA. A further well known method to identify proteins, which interact with a given target molecule is the so called “two-hybrid” assay (first described by Fields S. and Song O. (1989) Nature 340:245-6). This assay has been modified in the past to improve sensitivity and specificity and to adapt the assay to the specific requirements of the target protein (reviewed in, e.g. Piehler J. (2005) Curr. Opin. Struct. Biol. 15(1):4-14 and Fields S. 2005) FEBS J. 272(21):5391-9). For example, LaCount D J, et al. (Nature (2005) 438:103-7) describe a high-throughput version of the yeast two-hybrid assay that circumvents the difficulties in expressing P. falciparum proteins in Saccharomyces cerevisiae. This assay could be adapted to isolate scavenger receptor class protein, in particular ScarB1 and ScarBII, interacting proteins from the pathogens indicated above, in particular from P. falciparum
  • Above indicated assays and variations thereof can be used to identify proteins of pathogens interacting with scavenger receptor class proteins present on liver and hematopoietic cells. The identification will then facilitate the isolation of compounds specifically interfering with the interaction between the molecules of the pathogens and the scavenger receptor class proteins.
    • DESCRIPTION OF THE TABLES AND FIGURES
  • FIG. 1: Inhibition of EEF (Exo-Erythrocytic Forms) development in Huh-7 human hepatoma cells by BLT-1. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 2: Inhibition of EEF development in Huh-7 human hepatoma cells by BLT-2. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 3: Inhibition of EEF development in Huh-7 human hepatoma cells by BLT-4. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 4: Inhibition of EEF development in Huh-7 human hepatoma cells by Ezetimibe. Light grey bars represent EEF number (values on the left side of the graph) and the dark grey line represents percentage of cell confluency (values on the right side of the graph).
  • FIG. 5: Ezetimibe reduces infection rate for liver in mice.
  • FIG. 6: Structures of preferred compounds usable to treat infection by plasmodiidae.
  • FIG. 7: Knock down of ScarB1 by RNAi reduces EEF development in human hepatoma cells.
  • FIG. 8: Inhibitory effect on EEF development correlates with knock down of ScarB1. Dark bars depict the remaining mRNA and light bars depict the numbers of EEF.
  • FIG. 9: siRNAs sequences targeting ScarB1 (SEQ ID NO 3 to SEQ ID NO 8)
  • FIG. 10: Nucleic acid sequence of Homo sapiens scavenger receptor class B, member 1 (SCARB1), NM—005505.3 (SEQ ID NO: 1).
  • FIG. 11: Scavenger receptor class B, member 1 [Homo sapiens], amino acid sequence, NP—005496.3 (SEQ ID NO: 9).
  • FIG. 12: BLT-1 reduces infection rate for liver in mice.
  • FIG. 13: Inhibitory effect on EEF development correlates with knock down of ScarB1 in living mice.
  • FIG. 14: Inhibition of EEF development in Mouse Primary Hepatocytes by BLT-1.
  • FIG. 15: Inhibition of P. Yoelii EEF development in Hepa 1-6 cells by BLT-1. The time period given indicates the length of the presence of 10 μM BLT-1 during infection.
  • FIG. 16: Infection Score for preferred compounds usable in the present invention and for comparative compounds.
    •  EXAMPLES Example 1 Cell Cultivation and Seeding
  • Huh human hepatoma cells, were cultivated in RPMI (Gibco/Invitrogen) medium containing 10% FBS, 1% non-essential amino acid solution (Gibco/Invitrogen), 1% penicillin/streptomycin solution (Gibco/Invitrogen), 1% glutamine (Gibco/Invitrogen) and 1% Hepes pH 8 (Gibco/Invitrogen).
  • Hepa 1-6 cells were cultured in complete DMEM medium (Gibco/Invitrogen) supplemented with 10% fetal calf serum (Gibco/Invitrogen) and 1% penicillin/streptomycin (Gibco/Invitrogen) incubated at 37° C. and 5% CO2.
  • Cells were split twice per week by seeding 106 cells in 15 ml complete medium in 75 ml culture flasks (Nunc). For passaging, cells were detached from the flask by incubation with 3 ml Trypsin solution (Gibco/Invitrogen) for 5 min at 37° C. Trypsin was inactivated by adding 10 ml of complete medium to the flask.
  • Cell based experiments were performed in black, optical 96 well plates (Costar/Coming). 4000-6000 cells per well were seeded in a volume of 100 μl/well.
  • To allow homogenous settling of the cells, the plates were left for 30 min at RT before they were transferred to an incubator with 37° C. and 5% CO2.
    • Example 2 Isolation of Sporozoites of Plasmodium berghei ANKA or Plasmodium yoelii from Mosquitoes
  • Sporozoites were obtained from Anopheles stephensi mosquitoes infected with P. berghei ANKA or P. yoelii. Salivary glands were dissected and collected in RPMI medium (GIBCO) on ice. Collected tissues were gently ground in the medium to release sporozoites. Tissue fragments were removed by centrifugation at 40×g for 3 min, and sporozoites were collected from the supernatant.
    • Example 3 Treatment of Cells with Chemical Compounds Prior to Infection
  • Blt-1, Blt-2, and Blt-4 were purchased from ChemBridge Corporation (San Diego, USA). Ezetimibe (for chemical structure see FIG. 6 and structure (XXVI)) was derived from powdered Ezeterol tablets (Essex Pharma, UK). Each compound was dissolved in DMSO at a final concentration of 50 mM. 48 hours after seeding of 6000 Huh-7 cells per well, growth medium was replaced by fresh complete culture medium, containing the compounds in 4 different concentrations, generated by dilution series of the compound stock solutions in complete growth medium: 8 μM; 1.6 μM; 320 nM; 64 nM. Controls media were prepared according to DMSO concentrations in the 4 compound dilutions, i.e. 0.016%; 0.0032%; 0.00064%; 0.000128%. Huh-7 cells were equilibrated for 1 h with compound/DMSO-containing medium at 37° C. before infection with 10,000 sporozoites per well (FIG. 1 to 4).
    • Example 4 Immuno-Staining of Cells and Fluorescence Microscopy Based Quantification of Infection Rate Cell Staining:
  • For the microscopy based analysis of sporozoite infection, cell proliferation and cell viability, experimental plates were subjected to the following fixation and antibody staining procedure:
  • Culture medium was completely removed by inverting the plates and replaced by 100 μl of 3% PFA in phosphate buffered saline (PBS). After an incubation step of 30 min at RT, experimental plates were washed 3 times with 500 μl of PBS per well.
  • Next, unspecific binding sites were blocked for 45 min at RT in PBS substituted with 0.1% saponin, 3% BSA 100 mM glycine and 10% FCS (blocking buffer).
  • After washing with 500 μl PBS/well, cells were incubated with a 1:500 dilution of a mouse monoclonal antibody, 2E6, targeting the parasite heat shock protein 70 (Tsuji et al., 1994) in blocking buffer for 45 min at RT. Complete removal of non-bound primary antibody was assured by extensive washing with PBS.
  • The secondary antibody solution consisting of blocking buffer, substituted with an alexa-555 labeled goat anti mouse secondary antibody (Molecular Probes/Invitrogen) in a final dilution of 1/1000, Phalloidin coupled to alexa-488 in a final dilution of 1/500 and Hoechst-33342 in a final dilution of 1:2000, was applied to the cells for 45 min at RT followed by extensive washing with PBS.
  • Finally, experimental plates were sealed with each well containing 100 μl of PBS and stored at 4° C. in the dark until image acquisition.
    • Image Acquisition:
  • Cells were imaged using a fully automated fluorescence microscope from MDC (Molecular Devices Corporation, CA, USA). Per experimental well 9 fields with a dimension of approx. 2×1.5 mm were acquired using excitation/emission conditions, optimized to the spectral properties of the three chromophores, alexa-488, alexa-555 and Hoechst-33342.
    • Image Analysis:
  • An automated image analysis routine based on Metamorph (Molecular Devices Corporation, CA, USA) was applied to the image sets from each well, consisting of 3 images, representing the channels for alexa 488, alexa 555 and Hoechst respectively, for each of the 9 fields acquired. Numerical readouts comprised of cell proliferation as measured by the number of nuclei per imaged field (Hoechst staining), cell confluency as measured by the percentage of the imaged field covered by cells (actin/Phalloidin staining), and number of EEFs per imaged field. EEFs were identified as bright, round objects in the 2E6 staining. Objects in a size range of 16-150 pixels were quantified.
  • Furthermore, visual analysis of the cellular and nuclear morphology using the actin/Phalloidin and Hoechst images allowed a manual evaluation of cell toxicity.
    • Data Normalization:
  • EEF numbers were normalized to the cell confluency (see above).
  • Next, EEF numbers, normalized to cell confluency, were averaged between the 9 fields imaged per well and normalized to the corresponding mean value from 3 untreated wells present on the same experimental plate.
  • Finally, for each treatment, mean value and standard deviation were calculated from the normalized average values of 3 replicate wells.
    • Example 5 Treatment of Mice with Ezetimibe or BLT-1 Prior to Infection
  • Ezeterol tablets were used to prepare a 0.3 mg/ml solution of Ezetimibe in water. Experimental C57B1/6 mice were treated by oral gavage with 200 μl of Ezetimibe solution (3 mg/kg) 2 hours prior to infection with sporozoites. To control mice, 200 μl of water were administered by oral gavage. Infection with Plasmodium berghei was performed by i.v. injection of 30 000 sporozoites (see FIG. 5). For BLT-1 treatment of C57B1/6 mice (male, 6-8 weeks old), intra-peritoneal injections of 50 mg/kg of BLT-1 in DMSO were carried out prior to infection. Control mice were treated with DMSO only. Two hours later, mice were infected by intravenous injection with 3×104 P. berghei sporozoites (see FIG. 12).
    • Example 6 Quantification of Liver Infection in Mice Preparation of Liver Homogenates and RNA Extraction:
  • Mice were sacrificed 40-42 hours after infection and their livers collected. Livers were placed in 4 ml cold lysis buffer (4 M guanidine thio-cyanate, 25 mM sodium citrate, pH 7.0 and 0.5% sarcosyl) and homogenised on ice with a tissue tearer. 1 ml aliquots of liver homogenate were kept at −80° C. until RNA extraction. Total RNA was extracted from 50 μl of liver homogenate with Qiagen's RNeasy RNA extraction kit following the instructions of the manufacturer. Prepation of cDNA samples from the extracted RNA was carried out using the First Strand cDNA Synthesis Kit for RT-PCR (Roche) and following the manufacturer's instructions.
  • Quantification of P. berghei ANKA and ScarB1 in the Liver:
  • P. berghei ANKA load and ScarB1 expression in the liver was quantified by Real-Time PCR using the SYBR Green Mix (Applied Biosystems) and primers designed for the 18S RNA of the parasite and primers for ScarB1. The mouse hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1) gene was used as housekeeping control to account for differential efficiencies in RNA extraction between samples (see FIGS. 5 and 13).
    • Example 7 Generation of dsRNA Molecules for RNAi Experiments
  • siRNAs of a given nucleotide sequence were synthesized by Ambion, Inc. (Austin, Tex., USA), using standard methods known to the person skilled in the art of siRNA synthesis. The sequences of the two respective RNAs hybridized to each other are shown in the left and right hand panel of FIG. 9 (From left to right and from top to bottom SEQ ID NO: 3, 4, 5, 6, 7, and 8).
    • Example 8 Transfection of Cells with siRNAs Prior to Infection
  • For RNAi experiments, cells were transfected with siRNAs 24 h after cell seeding of 4000 cells per well of a 96 well plate.
  • Each siRNA was transfected in triplicates; the transfection mix was prepared as follows:
  • 4 μl of a 10 μM stock of siRNA was diluted with 64 μl of Opti-MEM (Invitrogen Inc.), and 1.6 μl Oligofectamine transfection reagent (Invitrogen) were diluted with 9.6 μl of Opti-MEM. For complex formation, both solutions were gently mixed and incubated for 20 min at RT.
  • After replacing the complete culture medium with 80 μl/well of serum free culture medium without antibiotics, 20 μl of transfection mix was added to each of 3 replicate wells.
  • Cells were incubated at 37° C. for 4 hours and then shifted back to initial growth conditions by adding 50 μl of fresh medium, supplemented with 30% fetal calf serum and 3% Penicillin/Streptomycin.
  • Controls: Each 96 well screening plate contained 3 wells transfected with a control siRNA (sharing no complete sequence homology with any coding sequence in the human transcriptome) and 3 untreated wells. (FIGS. 7 and 8)
    • Example 9 Validation of siRNA Efficacy in Human Cells by Real-Time RT-PCR (qRT-PCR)
  • 48 h after transfection total RNA was extracted from the cells using Invisorb 96 well kits (Invitek, Germany), following the protocol provided by the manufacturer. cDNA was synthesized using TaqMan RT reagents (Applied Biosystems, Foster City, Calif.) following the instructions provided by the manufacturer. Real-Time qPCR with gene-specific primers was performed in the following reaction mix
  • 5.5 μl 2× SybrGreen PCR mix (ABgene, Surrey, UK)
  • 3.0 μl cDNA
  • 2.5 μl 2 μM primers
  • =11 μl total
  • in an ABI-7900-HT real-time PCR machine (Applied Biosystems) running the following program:
  • 50° C. 2 min-95° C. 10min-45 cycles (95° C. 15 sec-60° C. 1 min)-95° C. 15 sec-60° C. 15 sec-95° C. 15 sec (melting curve).
  • In addition to expression of the gene of interest, expression level of GAPDH as a housekeeper was determined for each sample in order to account for inter-sample variability. The degree of knockdown was determined by comparing the amplification level for the gene of interest, normalized through the level of GAPDH, between samples transfected with a specific siRNA and samples transfected with unspecific control siRNAs. Dark bars delineate level of mRNA and light bares indicate number of EEFs (see FIG. 8).
    • Example 10 Assays to Determine Cholesterol Transport Lipoproteins and Cells
  • This assay is essentially as described in WO 2004/032716. Briefly: Human HDL are isolated and labelled with either 125I (125I-HDL), 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI, Molecular Probes; DiI-HDL) or [3H]cholesteryl oleyl ether ([3H]CE, [3H]CE-HDL) (Gu, et al. (1998) J. Biol. Chem. 273, 26338-48; Gu, et al. (2000) J. Biol. Chem. 275, 29993-30001; Acton, et al. (1994) J. Biol. Chem. 269, 21003-9; Pitas, et al. (1981) Arteriosclerosis 1, 177-85). LDL receptor deficient Chinese hamster ovary cells that express low levels of endogenous ScarB1, ldlA-7 (Kingsley, et al. (1984) Proc. Nat. Acad. Sci. USA 81, 5454-8), ldlA-7 cells stably transfected to express high levels of murine ScarB1 (termed “ldlA[mSR-BI]”, see Acton, et al., 1996), Y1-BS1 murine adrenocortical cells that express high levels of ScarB1 after induction with ACTH (Rigotti, et al. (1996) J. Biol. Chem. 271, 33545-9), monkey kidney BS-C1 cells (Kapoor, et al. (2000) J. Cell Biol. 150, 975-88) and HeLa cells (Temel, et al. (2002) J. Biol. Chem. 8, 8) are maintained as previously described.
    • High Throughput Screen
  • On day 0, ldlA[mSR-BI] cells are plated at 15,000 cells/well in clear bottom, black wall 384-well black assay plates (Costar) in 50 μl of medium A (Ham's F12 supplemented with 2 mM L-glutamine, 50 units/ml penicillin/50 μg/ml streptomycin, and 0.25 mg/ml G418.) supplemented with 10% fetal bovine serum (medium B). On day 1, cells are washed once with medium C (medium A with 1% (w/v) bovine serum albumin (BSA) and 25 mM HEPES pH 7.4, but no G418) and supplied with 40 μl of medium C.
  • Test compounds are dissolved in 100% DMSO and are added manually or for high throughput screens robotically ‘pin’ transferred (40 nl) to each well to give a nominal concentration of 10 μM (0.01% DMSO). After a 1 hr incubation at 37° C., DiI-HDL (final concentration of 10 μg protein/ml) in 20 μl of medium C are added. Two hours later, fluorescence is measured at room temperature (approximately 2 minutes/plate) using a Analyst plate reader (Rhodamine B dichroic filter, emission 525 nm and excitation 580 nm; LJL Biosystems), both prior to removing the incubation medium (to test for autofluorescence and quenching) and after the medium removal and four washes with 80 μl of PBS/1 mM MgCl2/0.1 mM CaCl2 to determine cellular uptake of DiI. All compounds are sampled in duplicate on different plates, and each screen includes ldlA-7 and ldlA[mSR-BI] cells in the presence and/or absence of a 40-fold excess of unlabeled HDL, but with no added compounds, as controls.
    • Assays
  • For the assays, all media and buffers contain 0.5% DMSO and 0.5% bovine serum albumin to maintain compound solubility. Cells are pre-incubated with BLTs for 1 hr (or 2.5 hrs for transferrin, EGF and cholera toxin uptake experiments) and all the experiments are performed at 37° C. Detailed characterization of the respective test compound and their effects is performed.
  • (i) Lipid Uptake from HDL, Cholesterol Efflux to HDL and HDL Binding Assays.
  • Assays for the uptake of lipids from DiI-HDL and 3CE-HDL, efflux of [3H]cholesterol from labeled cells, and 125I-HDL binding are performed as described by Acton et al. (1996) Science 271:518-20; Gu, et al. (2000) J. Biol. Chem. 275:29993-30001; and Ji, et al. (1997) J. Biol. Chem. 272, 20982-5. In some experiments, values are normalized so that the 100% of control represents activity in the absence of compounds and 0% represents activity determined in the presence of a 40-fold excess of unlabeled HDL or, for Y1-BS1 cells, in the presence of a 1:500 dilution of the KKB-1 blocking antibody (Gu, et al., 2000, supra). The amounts of cell-associated [3H]cholesteryl ether are expressed as the equivalent amount of [3H]CE-HDL protein (ng) to permit direct comparison of the relative amounts of 125I-HDL binding and [3H]CE uptake.
  • The rates of HDL dissociation from cells are determined by incubation of the cells with 125I-HDL (10 μg protein/ml, 2 hrs, 37° C.) with and without BLTs. The medium is then either replaced with the same medium in which the 125I-HDL is substituted by a 40-fold excess of unlabeled HDL or a 40-fold excess of unlabeled HDL is added to the labelled incubation medium. The amounts of cell-associated 125I-HDL are then determined as a function of time. Either of these methods can be used.
    • (ii) Fluorescence Microscopy Analysis of Intracellular Trafficking and Cytoskeletal Organization.
  • Receptor mediated endocytosis of Alexa-594 labelled transferrin or FITC labelled epidermal growth factor (EGF, Molecular Probes) by HeLa cells (Spiro, et al. (1996) Mol. Biol. Cell 7, 355-67) and uptake of Alexa-594-labeled holo-cholera toxin by BSC-1 cells is detected by fluorescent microscopy. The intracellular transport of the temperature sensitive glycoprotein of vesicular stomatitis virus (VSVGts045) fused at its carboxyl terminus to EGFP (VSVGts045-EGFP) from the endoplasmic reticulum to the plasma membrane, after a shift from 40° C. to 32° C. for 2 hrs, is determined by fluorescent microscopy. The effects of the compounds on the distribution of actin using rhodamine labeled phalloidin and tubulin using the FITC labelled DM1 monoclonal antibody (Sigma Co.) in ldlA[mSR-BI] cells is determined as described by Rigotti, et al. (1996) J. Biol. Chem. 271, 33545-9 by fluorescence microscopy using an air 63* objective (Nikon).
    • Example 11 Knockdown of ScarB1 in Mice by RNAi
  • C57B1/6 mice (male, 6-8 weeks old) were treated daily for 10 days with 200 μg/kg of the control siRNA (Negative, Ambion Inc., Texas, USA) or siRNA targeting SR-BI (ID 72593 and 152100, Ambion Inc., Texas, US). Mice were infected by intravenous injection of 2×104 P. berghei sporozoites. (see FIG. 13)
    • Example 12 Treatment of Mouse Primary Hepatocytes with BLT-1 Prior to Infection with P. berghei Sporozoites
  • C57B1/6 freshly isolated mouse primary hepatocytes (1×105 cells per well) were seeded in 700 μl of Williams E medium supplemented with 1× glutamax (Gibco/Invitrogen), 4% fetal calf serum (Gibco/Invitrogen) and 1% penicillin/streptomycin (Gibco/Invitrogen) in 24 well plates incubated at 37° C. 5% CO2.
  • After two days cells were treated with 10 μM BLT-1 for different time points: for the full 24 hours of infection with P. berghei (5×105 sporozoites), only during the first 2 hours of infection, or for the time of 2 hours after infection until evaluation at 24 hours. (see FIG. 14)
    • Example 13 Treatment of Hepa1-6 Cells with BLT-1 Prior to Infection with P. yoelii Sporozoites
  • Cells were treated with 10 μM BLT-1 for different time points: for the full 24 hours of infection with P. yoelii (1×105 sporozoites), only during the first 2 hours of infection, or for the time of 2 hours after infection until evaluation of infection at 24 hours (see FIG. 15).
    • Example 14 Treatment of Huh-7 Cells with Various Compounds of the Invention
  • All compounds tested were synthesized by Tripos UK Ltd. or purchased from chemical suppliers.
  • Huh-7 human hepatoma cells were treated as described in examples 3 and 4. Incubation with the compounds was performed at final concentrations of 1, 2, 5, and 10 μM.
  • Influence of the compounds on proliferation and infection with plasmodium sporozoites was calculated as % of the plate mean for all samples, with the mean set to 100%. To assess its performance, each compound was assigned a score between 0 and 4 for inhibition of infection. A compound would score at 4, if at all 4 tested concentrations it would reduce the number of EEFs by at least 50% (corresponding to an IC50 of 1 μM or lower), it would score at 3, if this was true for the 3 highest concentrations (IC50 between 1 and 2 μM), and so on. (see FIG. 16).

Claims (39)

1-38. (canceled)
39. A method of treating a protozoal infection comprising the administration of an inhibitor of a scavenger receptor class protein to an individual having a protozoal infection.
40. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (I):
Figure US20090324580A1-20091231-C00367
wherein,
R1 is NR5R6;
R2 is hydrogen or alkyl, optionally substituted;
R3 and R4 together form a cycloalkyl, heterocycloalkyl, cycloalkenyl or heterocycloalkenyl, optionally substituted;
R5 is hydrogen or alkyl, optionally substituted;
R6 is hydrogen, hydroxyl, halogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, alkynyl, alkanoyl, alkoxyalkyl; or —CO—R′; optionally substituted;
wherein
R′ is hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; aryl; aralkyl; heteroalkyl; cycloheteroalkyl; heteroaryl; heteroaralkyl; or alkynyl; optionally substituted;
and
Y is S or N,
or a pharmaceutically acceptable salt thereof.
41. The method according to claim 40, wherein R3 and R4 together form a C3 to C10-cycloalkyl or C3 to C10-heterocycloalkyl, optionally substituted.
42. The method according to claim 41, wherein the C3to C10-cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, (C6-10)-spiroalkyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, and adamantyl and the C3 to C10-heterocycloalkyl is selected from the group consisting of piperidinyl; 1,2-diazacyclohexyl; 1,3-diazacyclohexyl; piperazinyl; 1-oxo-2-azacyclohexyl; 1-oxo-3-azacyclohexyl; morpholinyl; (C6-10)-spiroheteroalkyl; tetrahydrofuranyl; tetrahydrothiophenyl; pyrrolidinyl; 1,2-diazacyclopentyl; 1,3-diazacyclopentyl; 1-oxo-2-azacyclopentyl; 1-oxo-3-azacyclopentyl; 1-thio-2-azacyclopentyl; and 1-thio-3-azacyclopentyl.
43. The method according to claim 40, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (II)
Figure US20090324580A1-20091231-C00368
wherein,
R1 is NR5R6;
R2 is hydrogen or alkyl, optionally substituted;
R5 is hydrogen or alkyl, optionally substituted;
R6 is hydrogen, hydroxyl, halogen, alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, alkynyl, alkanoyl, alkoxyalkyl; or —CO—R′ each of which can be optionally substituted,
wherein
R′ is hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; aryl; aralkyl; heteroalkyl; cycloheteroalkyl; heteroaryl; heteroaralkyl; or alkynyl; each of which can be optionally substituted;
R7, R8, R9, and R10 are each independent of each other selected from the group consisting of hydrogen, hydroxyl, halogen, oxo, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, alkenyl, cycloalkenyl, heterocycloalkenyl, alkynyl, heteroaralkynyl, or NR11R12, optionally substituted and/or one or both of R7 and R8 or R9 and R10 are taken together to form an aryl or heteroaryl, optionally substituted;
R11 is hydrogen or alkyl, optionally substituted;
R12 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted;
X is not present, or is CH2, C2H4, N, S or O; and
Y is S or N;
or a pharmaceutically acceptable salt thereof.
44. The method according to claim 40, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (III):
Figure US20090324580A1-20091231-C00369
wherein,
R1 is NR5R6;
R2 is hydrogen or alkyl, optionally substituted;
R5 is hydrogen or alkyl, optionally substituted;
R6 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted;
R7 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl, or NR11R12, optionally substituted;
R8, R9 and R10 are independent of each other hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted;
R11 is hydrogen or alkyl, optionally substituted;
R12 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted; and
Y is S or N;
or a pharmaceutically acceptable salt thereof.
45. The method according to claim 44, wherein
R7 is substituted 1 to 3 times with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl; and/or
R8, R9, and R10 are each independent of each other substituted 1 to 3 times with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; and (C1-6)alkoxy; and/or
R2, R5, R6, R11 and R12 are each independent of each other substituted 1 to 3 times with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; and (C1-6)alkoxy.
46. The method according to claim 44, wherein
R7 is (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkoxy(C1-6)alkyl; (C1-6)aralkyl; or (C1-6)heteroaralkyl; and/or
R2, R3 and R4 are independent of each other selected from the group consisting of hydrogen, Cl, Br, (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkoxy(C1-6)alkyl; (C1-6)aralkyl; (C1-6)heteroaralkyl; and/or
R2 is hydrogen or (C1-6)alkyl; and/or
R5 is hydrogen; and/or
R6 is hydrogen, (C1-6)alkyl or (C2-6)alkenyl.
47. The method according to claim 44, wherein the compound according to formula (III) has a structure selected from the structures according to formulas (IV) to (VII)
Figure US20090324580A1-20091231-C00370
each of which can be optionally substituted or pharmaceutically acceptable salts thereof.
48. The method according to claim 40, wherein the compound according to formula (II) has a structure selected from the structures according to formulas (VIII) to (XXXI)
Figure US20090324580A1-20091231-C00371
Figure US20090324580A1-20091231-C00372
Figure US20090324580A1-20091231-C00373
Figure US20090324580A1-20091231-C00374
Figure US20090324580A1-20091231-C00375
each of which can be optionally substituted or pharmaceutically acceptable salts thereof.
49. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (XXXII):
Figure US20090324580A1-20091231-C00376
wherein,
R1 is NR5R6;
R2 is hydrogen or alkyl, optionally substituted;
R5 is hydrogen, alkyl or alkenyl, optionally substituted;
R6 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, heteroalkenyl, cycloheteroalkenyl or alkynyl, optionally substituted; and
R13, R14, R15, R16, and R17 are independent of each other hydrogen, hydroxyl, halogen, SO2, NO2, CN; alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alicyclic system, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, alkenyl, cycloalkenyl, alkynyl, or NR11R12, optionally substituted;
R11 is hydrogen or alkyl, optionally substituted;
R12 is hydrogen, hydroxyl, halogen, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted; and
X is S or O;
or a pharmaceutically acceptable salt thereof.
50. The method according to claim 49, wherein
R2 and R5 are independent of each other substituted 1 to 3 time with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; and (C1-6)alkoxy;
R6 is substituted 1 to 3 time with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; in particular methoxy, (C1-6)alkoxy(C1-6)alkyl; NR11′R12′; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl, optionally substituted;
wherein R11′ and R12′ are independent of each other selected from hydrogen, hydroxyl; halogen; alkyl; heteroalkyl; (C1-6)alkoxy; (C1-6)alkylsulphonyl; alkenyl; (C2-6)alkenyloxy, cycloalkenyl; (C2-6)alkenylsulphonyl; alkynyl; aryl; aralkyl; heteroaryl; or heteroaralkyl, optionally substituted;
and/or
R13, R14, R15, R16, and R17 are independent of each other substituted 1 to 3 time with a radical selected from the group consisting of halogen; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl.
51. The method according to claim 49, wherein
R2 is hydrogen or (C1-6)alkyl; and/or
R5 is hydrogen, (C1-6)alkyl, or (C2-6)alkenyl; and/or
R6 is phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3,-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; 1,2,4-benzotriazinyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; spiro-[3,3]-heptyl; spiro-[3,4]-octyl; spiro-[4,3]-octyl; spiro-[3,5]-nonyl; spiro-[5,3]-nonyl; spiro-[3,6]-decyl; spiro-[6,3]-decyl; spiro-[4,5]-decyl, spiro-[5,4]-decyl, bicyclo-[2.2.1]-heptyl, bicyclo-[2.2.2]-octyl, adamantyl, piperidinyl; 1,2-diazacyclohexyl; 1,3-diazacyclohexyl; piperazinyl; 1-oxo-2-azacyclohexyl; 1-oxo-3-azacyclohexyl; 1,8-diaza-spiro-[4,5]-decyl; 1,7-diaza-spiro-[4,5]-decyl; 1,6-diaza-spiro-[4,5]-decyl; 2,8-diaza-spiro[4,5]decyl; 2,7-diaza-spiro[4,5]-decyl; 2,6-diaza-spiro[4,5]decyl; 1,8-diaza-spiro-[5,4]decyl; 1,7-diaza-spiro-[5,4]-decyl; 2,8-diaza-spiro-[5,4]-decyl; 2,7-diaza-spiro-[5,4]decyl; 3,8-diaza-spiro-[5,4]-decyl; 3,7-diaza-spiro-[5,4]-decyl; 1,4-diazabicyclo-[2.2.2]-oct-2-yl morpholinyl; tetrahydrofuranyl; tetrahydrothiophenyl; pyrrolidinyl; (C1-6)aralkyl; (C1-C6)heteroaralkyl; (C1-6)alkyl or (C2-6)alkenyl; optionally substituted and/or
R13 is (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkyl-(C1-6)alkoxy; (C1-6)aralkyl; or (C1-6)heteroaralkyl; and/or
R13, R14, R15, R16, and R17 are independent of each other selected from the group consisting of hydrogen, F, Cl, Br, (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; (C1-6)alkoxy(C1-6)alkyl; (C1-6)aralkyl; (C1-6)heteroaralkyl.
52. The method according to claim 49, wherein the compound according to formula (XI) has a structure according to formula (XXXIII) to (XLVIII):
Figure US20090324580A1-20091231-C00377
Figure US20090324580A1-20091231-C00378
Figure US20090324580A1-20091231-C00379
Figure US20090324580A1-20091231-C00380
each of which can be optionally substituted or pharmaceutically acceptable salts thereof.
53. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (IL):
Figure US20090324580A1-20091231-C00381
wherein,
R18 is alkyl, alkenyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, optionally substituted;
R19 and R20 are independently alkyl, alkenyl, aryl or heteroaryl, optionally substituted; and
X is O or S
or is a pharmaceutically acceptable salt thereof.
54. The method according to claim 53, wherein
R18 is substituted 1 to 3 time with a radical selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; in particular methoxy, (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; or two adjacent substituents are taken together to form a 4, 5, 6, or 7 membered cycloalkyl or cycloalkenyl; and/or
R19 and R20 are independent of each other substituted 1 to 3 time with a radical selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C2-6)alkenyl; (C1-6)alkoxy;
55. The method according to claim 53, wherein, R18 is (C1-6)aralkyl, in particular (C1-6)phenylalkyl, (C1-6)heteroaralkyl, phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl; and/or
R19 and R20 are independent of each other phenyl, naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl.
56. The method according to claim 53, wherein the compound according to formula (IL) has a structure according to formula (L):
Figure US20090324580A1-20091231-C00382
that is optionally substituted or is a pharmaceutically acceptable salt thereof.
57. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (LI):
Figure US20090324580A1-20091231-C00383
wherein,
R21 and R22 are independent of each other aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted; and
R23, R24, and R25 are independent of each other hydrogen, hydroxyl, F, Cl, Br, I, CN, SO2, NO2, alkyl, heteroalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, cycloalkenyl, or alkynyl, optionally substituted
or is a pharmaceutically acceptable salt thereof.
58. The method according to claim 57, wherein
R21 and R22 are independent of each other substituted with 1 to 3 radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; in particular methoxy, (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C1-6)alkyl, (C2-6)alkenyloxy, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; and/or
R23, R24, and R25 are independent of each substituted with 1 to 3 radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C2-6)alkenyl; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy.
59. The method according to claim 57, wherein R21 and R22 are independent of each other phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl.
60. The method according to claim 57, wherein the compound according to formula (LI) has a structure according to formula (LEI):
Figure US20090324580A1-20091231-C00384
that is optionally substituted or is a pharmaceutically acceptable salt thereof.
61. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein has a structure according to formula (LIII):
Figure US20090324580A1-20091231-C00385
wherein
R26 is hydrogen, aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted;
R27 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted;
R28 is hydrogen or alkyl, optionally substituted; and
R29 is aryl, aralkyl, heteroaryl or heteroaralkyl, optionally substituted
or is a pharmaceutically acceptable salt thereof.
62. The method according to claim 61, wherein
R27 and R29 are independent of each other substituted with one to three radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; (C2-6)alkenyl; (C1-6)alkoxy; in particular methoxy, (C1-6)alkoxy(C1-6)alkyl; amino, optionally mono- or disubstituted by (C1-6)alkoxy, (C2-6)alkenyloxy, (C1-6)alkyl, (C2-6)alkenyl, (C1-6)alkylsulphonyl, and (C2-6)alkenylsulphonyl; and/or
R26 and R28 are independent of each other substituted with one to three radicals selected from the group consisting of F; Cl; Br; I; hydroxyl; SO2; NO2; CN; (C1-6)alkyl; and (C2-6)alkenyl.
63. The method according to claim 61, wherein
R27 and R29 are independent of each other phenyl; naphthalenyl; anthracenyl; furanyl; thiophenyl; oxazolyl; isoxazolyl; 1,2,5-oxadiazolyl; 1,2,3-oxadiazolyl; pyrrolyl; imidazolyl; pyrazolyl; 1,2,3-triazolyl; thiazolyl; isothiazolyl; 1,2,3-thiadiazolyl; 1,2,5-thiadiazolyl; pyridinyl; pyrimidinyl; pyrazinyl; 1,2,3-triazinyl; 1,2,4-triazinyl; 1,3,5-triazinyl; 1-benzofuranyl; 2-benzofuranyl; indolyl; isoindolyl; benzothiophenyl; 2-benzothiophenyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; indoxazinyl; 2,1-benzisoxazolyl; benzothiazolyl; 1,2-benzisothiazolyl; 2,1-benzisothiazolyl; benzotriazolyl; quinolinyl; isoquinolinyl; 2,3-benzodiazinyl; quinoxalinyl; quinazolinyl; quinolinyl; 1,2,3-benzotriazinyl; or 1,2,4-benzotriazinyl; and/or
R26 and R28 are independent of each other hydrogen, (C1-6)alkyl; (C2-6)alkenyl, (C1-6)aralkyl or (C1-6)heteroaralkyl.
64. The method according to claim 61, wherein the compound according to formula (LIII) has a structure according to formula (LIV):
Figure US20090324580A1-20091231-C00386
that is optionally substituted or is a pharmaceutically acceptable salt thereof.
65. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein is a compound set forth in Table I, each of which can be optionally substituted.
66. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein is an antibody specifically binding to said scavenger receptor class protein.
67. The method according to claim 39, wherein the inhibitor of the scavenger receptor class protein is a small interfering RNA (siRNA) capable of inhibiting expression of said scavenger receptor class protein.
68. The method according to claim 39, wherein the siRNA is designed to inhibit expression of scavenger receptor class B 1 (ScarB1) or scavenger receptor type B 2 (ScarBII).
69. The method according to claim 39 wherein the scavenger receptor class protein is ScarB1 or ScarBII.
70. The method according claim 39, wherein the protozoal infection is a protozoa selected from the group consisting of Entomoeba histolytica, Trichomonas tenas, Trichomonas hominis, Trichomonas vaginalis, Trypanosoma gambiense, Trypanosoma rhodesiense, Trypanosoma cruzi, Leishmania donovani, Leishmania tropica, Leishmania braziliensis, Pneumocystis pneumonia, Toxoplasma gondii, Theileria lawrenci, Theileria parva, Plasmodium vivax, Plasmodium falciparum, and Plasmodium malaria.
71. A method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
(i) contacting a cell expressing a scavenger receptor class protein with a test compound,
(ii) measuring cholesterol transport into or out of said cell,
(iii) selecting a test compound, which inhibits cholesterol transport into or out of said cells,
(iv) contacting liver or hematopoietic cell with the selected test compound prior, during or after infection of said cell with an infectious agent, and
(v) selecting a test compound inhibiting proliferation of the infectious agent by at least 10%.
72. The method according to claim 71, further comprising the step of formulating the test compound selected in step (v) of claim 33 or step (iv) of claim 34 with pharmaceutically acceptable additives and/or auxiliary substances.
73. A method of identifying compounds for treatment and/or prophylaxis of infectious diseases involving liver or hematopoietic cells comprising the steps of:
(i) contacting a scavenger receptor class protein, functional variants, or soluble parts thereof with a test compound,
(ii) selecting a test compound, which specifically binds to ScarB1 or ScarBII,
(iii) contacting liver or hematopoietic cell with the selected test compound prior, during or after infection of said cell with an infectious agent, and
(iv) selecting a test compound inhibiting proliferation and/or development of the infectious agent by at least 10%.
74. The method according to claim 73, further comprising the step of formulating the test compound selected in step (v) of claim 33 or step (iv) of claim 34 with pharmaceutically acceptable additives and/or auxiliary substances.
75. A method for the identification of molecules of pathogens, which are involved in the infection of liver and/or hematopoietic cells, comprising the following steps:
(i) contacting one or more scavenger receptor class proteins, functional variants, or soluble parts thereof with one or more molecules present in pathogens, which are involved in the infection of liver and/or hematopoietic cells,
(ii) selecting a molecule, which specifically binds to the scavenger receptor class protein.
76. A pharmaceutical composition comprising a compound according to any one of Formulae (I), (II), (III), (XXXII), (IL), (LI) or (LIII), an antibody or an siRNA molecule and one or more compound selected from the group consisting of a chinine alkaloid, chloroquine-phosphate, hydroxychloroquinesulfate, mefloquine, proguanil, di-aminopyrimidines: pyrimethamine, atovaquone, doxycycline, artemether, and lumefantrine and pharmaceutically acceptable additives and/or auxiliary substances.
US12/281,438 2006-03-09 2007-03-09 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases Abandoned US20090324580A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/281,438 US20090324580A1 (en) 2006-03-09 2007-03-09 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78056706P 2006-03-09 2006-03-09
EP06004854A EP1832283A1 (en) 2006-03-09 2006-03-09 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
EP06004854.3 2006-03-09
PCT/EP2007/002110 WO2007101710A1 (en) 2006-03-09 2007-03-09 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
US12/281,438 US20090324580A1 (en) 2006-03-09 2007-03-09 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002110 A-371-Of-International WO2007101710A1 (en) 2006-03-09 2007-03-09 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/548,777 Continuation US8507546B2 (en) 2006-03-09 2012-07-13 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases

Publications (1)

Publication Number Publication Date
US20090324580A1 true US20090324580A1 (en) 2009-12-31

Family

ID=38001885

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/281,438 Abandoned US20090324580A1 (en) 2006-03-09 2007-03-09 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
US13/548,777 Expired - Fee Related US8507546B2 (en) 2006-03-09 2012-07-13 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/548,777 Expired - Fee Related US8507546B2 (en) 2006-03-09 2012-07-13 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases

Country Status (4)

Country Link
US (2) US20090324580A1 (en)
EP (1) EP1991215A1 (en)
CA (1) CA2645211A1 (en)
WO (1) WO2007101710A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034539A1 (en) * 2009-12-07 2013-02-07 The Johns Hopkins University Sr-bi as a predictor of human female infertility and responsiveness to treatment
WO2014141110A3 (en) * 2013-03-14 2015-04-23 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107908A4 (en) 2007-02-02 2011-07-20 Redpoint Bio Corp Use of a trpm5 inhibitor to regulate insulin and glp-1 release
US20120100555A1 (en) * 2009-06-29 2012-04-26 Martin James Lear Synthesis And Use Of Fluorophore-Tagged Antimalarials
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2573078B1 (en) * 2010-05-14 2016-11-02 Chinese PLA General Hospital Acrylamide compounds and use thereof for inhibiting apoptosis
JP5752239B2 (en) * 2010-05-14 2015-07-22 チャイニーズ・ピーエルエイ・ゼネラル・ホスピタル Urea compounds and their use to inhibit apoptosis
WO2012088420A1 (en) * 2010-12-22 2012-06-28 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and usese thereof
WO2013118606A1 (en) * 2012-02-08 2013-08-15 独立行政法人産業技術総合研究所 Drug for preventing or treating malaria and method for screening for same
US20150079111A1 (en) 2012-06-05 2015-03-19 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
EP3085690B1 (en) 2013-12-20 2019-09-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China New urea compound, manufacturing method and application thereof
US10292976B2 (en) 2014-01-09 2019-05-21 Riken Anti-malarial agent
US10137119B2 (en) * 2014-01-09 2018-11-27 Riken Anti-malarial agent
WO2017207556A2 (en) * 2016-05-30 2017-12-07 Technische Universität München Urea motif containing compounds and derivatives thereof as antibacterial drugs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057557A (en) * 1975-02-13 1977-11-08 Sandoz Ltd. Certain 5-nitrothiazolylimidazolidine compounds
WO2002095361A2 (en) * 2001-05-22 2002-11-28 President And Fellows Of Harvard College Identification of anti-protozoal agents
US20030186993A1 (en) * 2001-10-23 2003-10-02 Ulrich Peter C. Anti-malarial compounds, compositions and methods
WO2004032716A2 (en) * 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US20040186168A1 (en) * 2002-06-21 2004-09-23 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
WO2005023305A2 (en) * 2003-09-10 2005-03-17 Inpharmatica Limited Modulating cell activity by using an agent that reduces the level of cholesterol within a cell

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2736064A1 (en) * 1977-08-10 1979-02-22 Bayer Ag Synergistic antimalarial compsn. contg. heterocyclic guanyl-hydrazone - and folic acid antagonist or glucose transport inhibitor
CA1217491A (en) * 1982-10-11 1987-02-03 Erhardt Winkelmann 3-aryl-7-chloro-3,4-dihydroacridine-1,9(2h,10h)-dione 1-oximes and 1-hydrazone derivatives, their salts, a process for their preparation, agents containing them and their use
EP1206568A2 (en) * 1999-08-30 2002-05-22 K.U. Leuven Research & Development Target for antiparasitic agents and inhibitors thereof
JP2004513161A (en) * 2000-11-10 2004-04-30 アクテリオン　ファマシューティカルズ　リミテッド Substituted alkyl diamines
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
DE60238633D1 (en) * 2001-11-09 2011-01-27 Angeletti P Ist Richerche Bio SCREENING ON INHIBITORS OF INPUTS OF HEPATITIS C VIRUS
ZA200607582B (en) * 2004-03-05 2009-02-25 Univ California Anti-parasitic compounds and methods of their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057557A (en) * 1975-02-13 1977-11-08 Sandoz Ltd. Certain 5-nitrothiazolylimidazolidine compounds
WO2002095361A2 (en) * 2001-05-22 2002-11-28 President And Fellows Of Harvard College Identification of anti-protozoal agents
US20030186993A1 (en) * 2001-10-23 2003-10-02 Ulrich Peter C. Anti-malarial compounds, compositions and methods
US20040186168A1 (en) * 2002-06-21 2004-09-23 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
WO2004032716A2 (en) * 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
WO2005023305A2 (en) * 2003-09-10 2005-03-17 Inpharmatica Limited Modulating cell activity by using an agent that reduces the level of cholesterol within a cell

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034539A1 (en) * 2009-12-07 2013-02-07 The Johns Hopkins University Sr-bi as a predictor of human female infertility and responsiveness to treatment
US9163240B2 (en) * 2009-12-07 2015-10-20 The Johns Hopkins University SR-BI mutation as a predictor of low progesterone levels and poor fetal viability during pregnancy
WO2014141110A3 (en) * 2013-03-14 2015-04-23 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors

Also Published As

Publication number Publication date
WO2007101710A8 (en) 2009-02-05
US20120276121A1 (en) 2012-11-01
US8507546B2 (en) 2013-08-13
CA2645211A1 (en) 2007-09-13
EP1991215A1 (en) 2008-11-19
WO2007101710A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
US8507546B2 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
US20250120982A1 (en) Covalent targeting of e3 ligases
JP7212781B2 (en) Inhibitors of SARM1 in combination with neuroprotective agents
Song et al. Sphingosine kinase 2 activates autophagy and protects neurons against ischemic injury through interaction with Bcl-2 via its putative BH3 domain
US12121521B2 (en) Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
EP1395261B1 (en) Pyridylpyrimidine derivatives as effective compounds against prion diseases
US9359363B2 (en) Identification of compounds that disperse TDP-43 inclusions
US10207998B2 (en) Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
JP6441219B2 (en) Compounds for treating mTOR pathway related diseases
US20190389904A2 (en) Malt1 inhibitors and uses thereof
CN105026398A (en) Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
Shin et al. Sertindole, a potent antagonist at dopamine D2 receptors, induces autophagy by increasing reactive oxygen species in SH-SY5Y neuroblastoma cells
CN101489542B (en) Application of scavenger receptor protein inhibitors in the treatment of infectious diseases
AU2019204363A1 (en) Icariin derivatives
US20240261378A1 (en) Trim proteins and galectins cooperate and codirect autophagy and are useful in the treatment of autophagy related diseases
CN103764659A (en) Glioblastoma inhibiting compounds and their use
WO2017189553A1 (en) Removal of senescence-associated macrophages
US11364219B2 (en) Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption
US20210188783A1 (en) Substituted benzimidazoles as inhibitors of transforming growth factor-beta kinase
US20160052918A1 (en) Small compounds targeting tacc3
US20240197890A1 (en) Flavone derivatives and uses in targeting ck2-mediated diseases and conditions
US20170369474A1 (en) Compounds, compositions and methods of use
US12194027B2 (en) Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indications
JP7315729B2 (en) Composition for treating degenerative brain disease containing 2-pentylfuran as an active ingredient
US10556889B1 (en) Salvinorin derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOTA, MARIA M.;PRUDENCIO, MIGUEL;RODRIGUES, CHRISTINA DIAS;REEL/FRAME:021956/0628;SIGNING DATES FROM 20081114 TO 20081118

Owner name: CENIX BIOSCIENCE GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HANNUS, MICHAEL;MARTIN, CECILIE;REEL/FRAME:021956/0538

Effective date: 20081124

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION